

Current concepts in the management of *Helicobacter pylori* Consensus Report

Gut

56, 772-781

DOI: [10.1136/gut.2006.101634](https://doi.org/10.1136/gut.2006.101634)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | In vitro induction of resistance to metronidazole, and analysis of mutations in rdxA and frxA genes from <i>Helicobacter pylori</i> isolates. <i>Journal of Infection and Chemotherapy</i> , 2005, 11, 59-63. | 0.8 | 18 |
| 2 | <i>Helicobacter pylori</i> antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations in central and south London during 2000. <i>Journal of Medical Microbiology</i> , 2005, 54, 567-574. | 0.7 | 22 |
| 3 | One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2005, 37, 571-576. | 0.4 | 28 |
| 4 | Reflujo gastroesofágico en el niño. <i>EMC Pediatría</i> , 2005, 40, 1-11. | 0.0 | 0 |
| 5 | Effects of <i>Helicobacter pylori</i> and Nonsteroidal Anti-Inflammatory Drugs on Peptic Ulcer Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 130-142. | 2.4 | 124 |
| 6 | Antibiotic Therapy for <i>Helicobacter pylori</i> . <i>Medical Clinics of North America</i> , 2006, 90, 1125-1140. | 1.1 | 9 |
| 7 | The clinical applications and accuracy of 2 rapid near-patient tests in detecting <i>Helicobacter pylori</i> infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 241-246. | 0.8 | 11 |
| 9 | Protective immunization against <i>Candidatus Helicobacter suis</i> with heterologous antigens of <i>H. pylori</i> and <i>H. felis</i> . <i>Vaccine</i> , 2006, 24, 2469-2476. | 1.7 | 2 |
| 11 | Evidence-based gastroenterology and hepatology, second edition. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1123. | 0.8 | 0 |
| 12 | <i>Helicobacter pylori</i> Eradication for the Prevention of Gastric Cancer. <i>Helicobacter</i> , 2006, 11, 52-57. | 1.6 | 35 |
| 13 | Comparison of a new office-based stool immunoassay and ¹³ C-UBT in the diagnosis of current <i>Helicobacter pylori</i> infection. <i>Translational Research</i> , 2006, 147, 145-149. | 2.4 | 14 |
| 14 | Triple Levofloxacin-Based Rescue Therapy is an Accepted Empirical Third-Line Treatment. <i>American Journal of Gastroenterology</i> , 2006, 101, 1938-1938. | 0.2 | 5 |
| 15 | Proton pump inhibitors and gastric neoplasia. <i>Gut</i> , 2006, 55, 1217-1221. | 6.1 | 85 |
| 16 | Should triple therapy for <i>Helicobacter pylori</i> eradication be prescribed for 1 week or 2 weeks?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 596-597. | 1.7 | 1 |
| 17 | Where have all the <i>Helicobacters</i> gone?. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 727-728. | 1.1 | 6 |
| 18 | How to Proceed in <i>Helicobacter pylori</i> -Positive Chronic Gastritis Refractory to First- and Second-Line Eradication Therapy. <i>Digestive Diseases</i> , 2007, 25, 203-205. | 0.8 | 6 |
| 19 | <i>Helicobacter pylori</i> testing and treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 71-79. | 1.4 | 9 |
| 20 | The presence of dental disease can be a risk factor for recurrent <i>Helicobacter pylori</i> infection after eradication therapy: A 3-year follow-up. <i>Endoscopy</i> , 2007, 39, 942-947. | 1.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 21 | One- or two-week triple therapy for <i>Helicobacter pylori</i> : questions of efficacy and inclusion of a dual therapy treatment arm * Authors' response. <i>Gut</i> , 2007, 56, 1021-1023. | 6.1 | 4 |
| 22 | Comparison of the Effectiveness of Geranylgeranylacetone with Cimetidine in Gastritis Patients with Dyspeptic Symptoms and Gastric Lesions: A Randomized, Double-Blind Trial in Japan. <i>Digestion</i> , 2007, 75, 215-224. | 1.2 | 18 |
| 23 | How accurate are fecal tests for determination of cure after <i>Helicobacter pylori</i> eradication therapy?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 248-249. | 1.7 | 0 |
| 24 | Meta-analysis: Duration of First-Line Proton-Pump Inhibitor-Based Triple Therapy for <i>Helicobacter pylori</i> Eradication. <i>Annals of Internal Medicine</i> , 2007, 147, 553. | 2.0 | 220 |
| 25 | Progress in developing accurate tests for the diagnosis of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 531-540. | 1.6 | 0 |
| 26 | Personalized medicine for eradication of <i>Helicobacter pylori</i> . <i>Personalized Medicine</i> , 2007, 4, 321-328. | 0.8 | 1 |
| 28 | Should patients with pH-documented laryngopharyngeal reflux routinely undergo oesophagogastroduodenoscopy? A retrospective analysis. <i>Journal of Laryngology and Otology</i> , 2007, 121, 1165-1169. | 0.4 | 15 |
| 30 | Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. <i>European Journal of Internal Medicine</i> , 2007, 18, 496-500. | 1.0 | 11 |
| 31 | Sequential regimens for <i>Helicobacter pylori</i> eradication. <i>Lancet, The</i> , 2007, 370, 1010-1012. | 6.3 | 58 |
| 32 | <i>Helicobacter pylori</i> Detection and Antimicrobial Susceptibility Testing. <i>Clinical Microbiology Reviews</i> , 2007, 20, 280-322. | 5.7 | 595 |
| 33 | The sequential therapy regimen for <i>Helicobacter pylori</i> eradication: a pooled-data analysis. <i>Gut</i> , 2007, 56, 1353-1357. | 6.1 | 254 |
| 34 | Treatment strategy to eradicate <i>Helicobacter pylori</i> infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2701-2717. | 0.9 | 27 |
| 35 | Eradication Therapy for <i>Helicobacter pylori</i> . <i>Gastroenterology</i> , 2007, 133, 985-1001. | 0.6 | 217 |
| 36 | â€œCervia II Working Group Report 2006â€ Guidelines on diagnosis and treatment of <i>Helicobacter pylori</i> infection in Italy. <i>Digestive and Liver Disease</i> , 2007, 39, 782-789. | 0.4 | 88 |
| 37 | <i>Helicobacter pylori</i> eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: A multicentre study. <i>Digestive and Liver Disease</i> , 2007, 39, 806-810. | 0.4 | 30 |
| 38 | Levofloxacin-based triple therapy for <i>Helicobacter pylori</i> re-treatment: Role of bacterial resistance. <i>Digestive and Liver Disease</i> , 2007, 39, 1001-1005. | 0.4 | 92 |
| 39 | <i>Helicobacter pylori</i> as a class I carcinogen: Physiopathology and management strategies. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 264-273. | 1.2 | 39 |
| 40 | Diagnosis of <i>Helicobacter pylori</i> : Invasive and non-invasive tests. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 299-313. | 1.0 | 178 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 41 | Evaluation of the monoclonal stool antigen test for <i>Helicobacter pylori</i> in an Asian population with dyspepsia. <i>Journal of Digestive Diseases</i> , 2007, 8, 207-210. | 0.7 | 9 |
| 42 | Inhibitory effect of nordihydroguaiaretic acid, a plant lignan, on <i>Helicobacter pylori</i> -associated gastric carcinogenesis in Mongolian gerbils. <i>Cancer Science</i> , 2007, 98, 1689-1695. | 1.7 | 20 |
| 43 | First-line triple therapy with levofloxacin for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 495-500. | 1.9 | 49 |
| 44 | The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate <i>Helicobacter pylori</i> in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1537-1542. | 1.9 | 58 |
| 45 | Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 346-354. | 1.9 | 77 |
| 46 | A systematic evaluation of payback of publicly funded health and health services research in Hong Kong. <i>BMC Health Services Research</i> , 2007, 7, 121. | 0.9 | 32 |
| 47 | Routine use of real-time PCR for detection of <i>Helicobacter pylori</i> and of clarithromycin resistance mutations. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 792-795. | 0.9 | 14 |
| 49 | Efficacy and Safety of <i>Saccharomyces boulardii</i> in the 14-day Triple Anti- <i>Helicobacter pylori</i> Therapy: A Prospective Randomized Placebo-Controlled Double-Blind Study. <i>Helicobacter</i> , 2007, 12, 309-316. | 1.6 | 124 |
| 50 | Levofloxacin in First-line Treatment of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2007, 12, 364-365. | 1.6 | 23 |
| 51 | Treatment of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2007, 12, 31-37. | 1.6 | 125 |
| 52 | <i>Helicobacter</i> and Gastric Malignancies. <i>Helicobacter</i> , 2007, 12, 23-30. | 1.6 | 84 |
| 53 | Diagnosis of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2007, 12, 4-9. | 1.6 | 67 |
| 54 | Eradication of <i>Helicobacter pylori</i> Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long-term NSAID Treatment: Double-Blind, Randomized, Placebo-Controlled Trial. <i>Helicobacter</i> , 2007, 12, 477-485. | 1.6 | 61 |
| 55 | Second-Line Treatment for <i>Helicobacter pylori</i> Infection: 10-day Moxifloxacin-Based Triple Therapy versus 2-week Quadruple Therapy. <i>Helicobacter</i> , 2007, 12, 623-628. | 1.6 | 41 |
| 56 | Rabeprazole versus Esomeprazole-Based Eradication Regimens for <i>H. pylori</i> Infection. <i>Helicobacter</i> , 2007, 12, 633-637. | 1.6 | 24 |
| 57 | Methods to Detect <i>Helicobacter pylori</i> : From Culture to Molecular Biology. <i>Helicobacter</i> , 2007, 12, 6-11. | 1.6 | 62 |
| 58 | Epidemiology of Premalignant Gastric Lesions: Implications for the Development of Screening and Surveillance Strategies. <i>Helicobacter</i> , 2007, 12, 22-31. | 1.6 | 77 |
| 59 | Early Influences and Childhood Development. Does <i>Helicobacter</i> Play a Role?. <i>Helicobacter</i> , 2007, 12, 69-74. | 1.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 60 | <i>Helicobacter pylori</i> – a Timeless Source of Lessons and Research Initiatives. <i>Helicobacter</i> , 2007, 12, 85-89. | 1.6 | 7 |
| 62 | <i>Helicobacter pylori</i> et nœoplasies gastriques. <i>Journal Africain D'Hepato-Gastroenterologie</i> , 2007, 1, 1-4. | 0.0 | 1 |
| 64 | Clarithromycin Resistance, Tumor Necrosis Factor Alpha Gene Polymorphism and Mucosal Inflammation Affect <i>H. pylori</i> Eradication Success. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1506-1514. | 0.9 | 12 |
| 65 | A historical perspective of <i>Helicobacter gastroduodenitis</i> and its complications. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 335-346. | 1.0 | 14 |
| 66 | <i>Helicobacter pylori</i> infection and gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 281-297. | 1.0 | 95 |
| 67 | <i>Helicobacter pylori</i> Recurrence and Infection Rate in Israeli Adults. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1211-1214. | 1.1 | 10 |
| 68 | <i>Candida albicans</i> Infection Delays Duodenal Ulcer Healing in Cysteamine-Induced Duodenal Ulcers in Rats. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2878-2885. | 1.1 | 6 |
| 69 | Proton pump inhibitors: an update of their clinical use and pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 935-951. | 0.8 | 266 |
| 70 | Prevalence of <i>Helicobacter pylori</i> Seropositivity Among Patients Undergoing Bariatric Surgery: A Preliminary Study. <i>World Journal of Surgery</i> , 2008, 32, 2021-2025. | 0.8 | 59 |
| 71 | Prevalence of <i>Helicobacter pylori</i> Infection Among Patients Undergoing Bariatric Surgery: A Preliminary Study. <i>World Journal of Surgery</i> , 2008, 32, 2026-2027. | 0.8 | 8 |
| 75 | What is new in the management of <i>Helicobacter pylori</i> ?. <i>Irish Journal of Medical Science</i> , 2008, 177, 185-188. | 0.8 | 9 |
| 76 | Could the simplified 14C urea breath test be a new standard in noninvasive diagnosis of <i>Helicobacter pylori</i> infection?. <i>Annals of Nuclear Medicine</i> , 2008, 22, 611-616. | 1.2 | 15 |
| 77 | The role of <i>Helicobacter pylori</i> in the pathogenesis of gastric malignancies. <i>Oncology Reviews</i> , 2008, 2, 131-140. | 0.8 | 5 |
| 78 | Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology</i> , 2008, 43, 108-114. | 2.3 | 8 |
| 79 | Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology</i> , 2008, 43, 429-433. | 2.3 | 23 |
| 80 | <i>Helicobacter pylori</i> infection: effect on malnutrition and growth failure in dyspeptic children. <i>European Journal of Pediatrics</i> , 2008, 167, 557-562. | 1.3 | 34 |
| 81 | Diagnostic de l'infection Å <i>Helicobacter pylori</i> . <i>Revue Francophone Des Laboratoires</i> , 2008, 2008, 36-38. | 0.0 | 0 |
| 82 | Diagnosis of <i>Helicobacter pylori</i> infection with the ¹³ C-urea breath test by means of GC-MS analysis. <i>Journal of Separation Science</i> , 2008, 31, 329-335. | 1.3 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 83 | The role of viral and bacterial pathogens in gastrointestinal cancer. <i>Journal of Cellular Physiology</i> , 2008, 216, 378-388. | 2.0 | 46 |
| 84 | Oneâ€Week Onceâ€Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent <i>Helicobacter pylori</i> Resistant to Both Metronidazole and Clarithromycin. <i>Helicobacter</i> , 2008, 13, 69-74. | 1.6 | 62 |
| 85 | An Evaluation of a Serologic Test with a Current Infection Marker of <i>Helicobacter pylori</i> Before and After Eradication Therapy in Chinese. <i>Helicobacter</i> , 2008, 13, 49-55. | 1.6 | 17 |
| 86 | Inhibition of <i>Helicobacter pylori</i> Infection in Humans by <i>Lactobacillus reuteri</i> ATCC 55730 and Effect on Eradication Therapy: A Pilot Study. <i>Helicobacter</i> , 2008, 13, 127-134. | 1.6 | 135 |
| 87 | Equipoise, <i>H. pylori</i> , and Musketeers â€ Choosing an Appropriate Standard Clinical Care Regimen. <i>Helicobacter</i> , 2008, 13, 79-80. | 1.6 | 5 |
| 88 | Evaluation of a Novel Monoclonalâ€Based Antigenâ€inâ€Stool Enzyme Immunoassay (Premier Platinum HpSA) Tj ETQq1 1 0.784314 13, 269-273. | 1.6 | 29 |
| 89 | The Effects of Probiotics on PPIâ€Triple Therapy for <i>Helicobacter pylori</i> Eradication. <i>Helicobacter</i> , 2008, 13, 261-268. | 1.6 | 108 |
| 90 | Eradicating <i>Helicobacter pylori</i> in Peptic Ulcer Disease Reduces Medical Costs in the Community. <i>Helicobacter</i> , 2008, 13, 346-351. | 1.6 | 3 |
| 91 | Evaluation of Two Tripleâ€Therapy Regimens with Metronidazole or Clarithromycin for the Eradication of <i>H. Pylori</i> Infection in Vietnamese Children: a Randomized, Doubleâ€Blind Clinical Trial. <i>Helicobacter</i> , 2008, 13, 550-556. | 1.6 | 18 |
| 92 | Epidemiology of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2008, 13, 1-6. | 1.6 | 170 |
| 93 | <i>Helicobacter pylori</i> Infection in Children. <i>Helicobacter</i> , 2008, 13, 41-46. | 1.6 | 25 |
| 94 | <i>Helicobacter pylori</i> and Nonâ€malignant Diseases. <i>Helicobacter</i> , 2008, 13, 23-27. | 1.6 | 3 |
| 95 | Treatment of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2008, 13, 35-40. | 1.6 | 100 |
| 96 | Failure of <i>Helicobacter pylori</i> Treatment After Regimes Containing Clarithromycin: New Practical Therapeutic Options. <i>Helicobacter</i> , 2008, 13, 572-576. | 1.6 | 34 |
| 97 | <i>Helicobacter pylori</i> Stool Antigen (HpSA) Tests in Children Before and After Eradication Therapy: Comparison of Rapid Immunochromatographic Assay and HpSA ELISA. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2053-2058. | 1.1 | 37 |
| 98 | Third Chinese National Consensus Report on the management of <i>Helicobacter pylori</i> infection¹â€(August 2007, Lushan, Jiangxi Province, China). <i>Journal of Digestive Diseases</i> , 2008, 9, 178-184. | 0.7 | 75 |
| 99 | Asiaâ€Pacific consensus guidelines on gastric cancer prevention. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 351-365. | 1.4 | 291 |
| 100 | Kinetics of ¹⁴carbon dioxide excretion from ¹⁴Câ€urea by oral commensal flora. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1603-1607. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 101 | Tailored eradication therapy based on fecal <i>Helicobacter pylori</i> clarithromycin sensitivities. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, S171-4. | 1.4 | 60 |
| 102 | CYP2C19 genotypes and <i>Helicobacter pylori</i> eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1163-1163. | 1.4 | 8 |
| 103 | Proteomic identification of biomarkers related to <i>Helicobacter pylori</i> -associated gastroduodenal disease: Challenges and opportunities. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1657-1661. | 1.4 | 28 |
| 104 | Gastroesophageal reflux disease: An Asian perspective. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1785-1793. | 1.4 | 87 |
| 105 | Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 868-877. | 1.9 | 110 |
| 106 | Quadruple rescue therapy for <i>Helicobacter pylori</i> infection after two treatment failures. <i>European Journal of Clinical Investigation</i> , 2008, 38, 404-409. | 1.7 | 48 |
| 107 | Do urea breath test (UBT) referrals for <i>Helicobacter pylori</i> testing match the clinical guidelines in primary care practice? A prospective observational study. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 799-802. | 0.9 | 4 |
| 108 | Evidence-based healthcare, clinical knowledge and the rise of personalised medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2008, 14, 621-649. | 0.9 | 109 |
| 109 | Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. <i>Neurogastroenterology and Motility</i> , 2008, 20, 884-890. | 1.6 | 25 |
| 110 | Effect of Specific Colostral Antibodies and Selected Lactobacilli on the Adhesion of <i>Helicobacter pylori</i> on AGS Cells and the <i>Helicobacter</i> -induced IL-8 Production. <i>Scandinavian Journal of Immunology</i> , 2008, 68, 280-286. | 1.3 | 34 |
| 111 | Gastric Cancer Consensus Conference Recommends <i>Helicobacter pylori</i> Screening and Treatment in Asymptomatic Persons From High-Risk Populations to Prevent Gastric Cancer. <i>American Journal of Gastroenterology</i> , 2008, 103, 510-514. | 0.2 | 92 |
| 112 | Patients with duodenal ulcer have lower levels of serum cholesterol compared to other dyspeptic patients independently of <i>Helicobacter pylori</i> status. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 922-928. | 0.6 | 7 |
| 113 | Therapy for <i>Helicobacter pylori</i> Infection Can be Improved. <i>Drugs</i> , 2008, 68, 725-736. | 4.9 | 79 |
| 114 | Esomeprazole. <i>Drugs</i> , 2008, 68, 1571-1607. | 4.9 | 62 |
| 117 | Gastric Cancer Risk in Patients With Premalignant Gastric Lesions: A Nationwide Cohort Study in the Netherlands. <i>Gastroenterology</i> , 2008, 134, 945-952. | 0.6 | 649 |
| 118 | Safety and Immunogenicity of an Intramuscular <i>Helicobacter pylori</i> Vaccine in Noninfected Volunteers: A Phase I Study. <i>Gastroenterology</i> , 2008, 135, 787-795. | 0.6 | 152 |
| 119 | Causal Relationship of <i>Helicobacter pylori</i> With Iron-Deficiency Anemia or Failure of Iron Supplementation in Children. <i>Gastroenterology</i> , 2008, 135, 1534-1542. | 0.6 | 69 |
| 120 | <i>Helicobacter Pylori</i> Infection in the Elderly. <i>International Journal of Gerontology</i> , 2008, 2, 145-153. | 0.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 121 | The management of common gastrointestinal disorders in general practice. <i>Digestive and Liver Disease</i> , 2008, 40, 659-666. | 0.4 | 39 |
| 122 | <i>Helicobacter pylori</i> infection: A clinical overview. <i>Digestive and Liver Disease</i> , 2008, 40, 619-626. | 0.4 | 105 |
| 123 | Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for <i>Helicobacter pylori</i> Infection in Patients Naive to Treatment. <i>Annals of Internal Medicine</i> , 2008, 148, 923. | 2.0 | 254 |
| 124 | New concepts of resistance in the treatment of <i>Helicobacter pylori</i> infections. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 321-331. | 1.7 | 298 |
| 129 | New Aspects of <i>Helicobacter pylori</i> Infection Involvement in Gastric Oncogenesis. <i>Journal of Surgical Research</i> , 2008, 146, 149-158. | 0.8 | 62 |
| 130 | The long-term effect of <i>Helicobacter pylori</i> eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype – A link to gastric carcinogenesis. <i>Cancer Letters</i> , 2008, 270, 218-228. | 3.2 | 8 |
| 131 | Comparison of sequential and standard triple-drug regimen for <i>Helicobacter pylori</i> eradication: A 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. <i>Clinical Therapeutics</i> , 2008, 30, 528-534. | 1.1 | 39 |
| 132 | New strategies for <i>Helicobacter pylori</i> eradication. <i>Current Opinion in Pharmacology</i> , 2008, 8, 593-597. | 1.7 | 37 |
| 133 | Comparison of stool antigen immunoassay methods for detecting <i>Helicobacter pylori</i> infection before and after eradication treatment. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 150-155. | 0.8 | 23 |
| 134 | A rapid lateral flow stool antigen immunoassay and 14C-urea breath test for the diagnosis and eradication of <i>Helicobacter pylori</i> infection in children. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 351-356. | 0.8 | 27 |
| 138 | <i>Helicobacter pylori</i> test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). <i>BMJ: British Medical Journal</i> , 2008, 336, 651-654. | 2.4 | 81 |
| 139 | Ten-Day Sequential Treatment for <i>Helicobacter pylori</i> Eradication in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2008, 103, 2220-2223. | 0.2 | 67 |
| 140 | Is Eradication of <i>Helicobacter pylori</i> the Feasible Way to Prevent Gastric Cancer? New Evidence and Progress, but Still a Long Way to Go. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 591-599. | 0.8 | 9 |
| 141 | Prevalence of <i>Helicobacter pylori</i> infection and value of preoperative testing and treatment in patients undergoing laparoscopic Roux-en-Y gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2008, 4, 383-388. | 1.0 | 80 |
| 142 | Persistent <i>Helicobacter pylori</i> Infection After a Course of Antimicrobial Therapy – What's Next?. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1086-1090. | 2.4 | 8 |
| 143 | Cure of <i>Helicobacter pylori</i> infection in all compliant patients: report on 644 subjects. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1149-1150. | 0.6 | 6 |
| 144 | Symptoms, endoscopic findings and histology predicting symptomatic benefit of <i>Helicobacter pylori</i> eradication. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 810-816. | 0.6 | 7 |
| 145 | Does the eradication of <i>Helicobacter pylori</i> delay the diagnosis of gastric cancer?. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1456-1460. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 146 | Short-term/low-dose aspirin-induced duodenal erosions are not dependent on <i>Helicobacter pylori</i> infection, cyclooxygenase expression and prostaglandin E2 levels. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 801-809. | 0.6 | 7 |
| 147 | What is the best first-line therapy for <i>Helicobacter pylori</i> infection?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 606-607. | 1.7 | 1 |
| 148 | <i>Helicobacter pylori</i> infection and short-term intake of low-dose aspirin have different effects on alpha-1 antitrypsin/alpha-1 peptidase inhibitor (I±1-PI) levels in antral mucosa and peripheral blood. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1194-1201. | 0.6 | 7 |
| 149 | Migrant communities constitute a possible target population for primary prevention of <i>Helicobacter pylori</i> -related complications in low incidence countries. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 403-409. | 0.6 | 45 |
| 150 | Pantoprazole: from drug metabolism to clinical relevance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 471-483. | 1.5 | 13 |
| 151 | Review: Eradication of <i>Helicobacter pylori</i> to prevent gastroduodenal diseases: Hitting more than one bird with the same stone. <i>Therapeutic Advances in Gastroenterology</i> , 2008, 1, 111-120. | 1.4 | 16 |
| 152 | Sequential Therapy for <i>Helicobacter pylori</i> . <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1346. | 3.8 | 26 |
| 153 | Accuracy of <i>Helicobacter pylori</i> serology in two peptic ulcer populations and in healthy controls. <i>World Journal of Gastroenterology</i> , 2008, 14, 5039. | 1.4 | 11 |
| 154 | <i>Helicobacter pylori</i> Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice. <i>Cancer Research</i> , 2008, 68, 3540-3548. | 0.4 | 112 |
| 155 | Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. <i>Gut</i> , 2008, 57, 1207-1213. | 6.1 | 159 |
| 156 | Factors Affecting Physicians' Practices Related to <i>Helicobacter pylori</i> Infection: Effect of Experience and Mode of Practice. <i>Digestion</i> , 2008, 78, 77-81. | 1.2 | 2 |
| 157 | An Alternative Salvage Regimen for <i>Helicobacter pylori</i> -Resistant Patients with Heart Failure. <i>Cardiology</i> , 2008, 110, 112-115. | 0.6 | 3 |
| 158 | Dyspepsia and <i>Helicobacter pylori</i> . <i>Digestive Diseases</i> , 2008, 26, 210-214. | 0.8 | 16 |
| 159 | <i>Helicobacter pylori</i> eradication therapy: indications, efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 271-281. | 1.0 | 22 |
| 160 | Quadruplex Real-Time PCR Assay Using Allele-Specific Scorpion Primers for Detection of Mutations Conferring Clarithromycin Resistance to <i>Helicobacter pylori</i> . <i>Journal of Clinical Microbiology</i> , 2008, 46, 2320-2326. | 1.8 | 63 |
| 161 | Second-Line Rescue Therapy With Levofloxacin After <i>H. pylori</i> Treatment Failure: A Spanish Multicenter Study of 300 Patients. <i>American Journal of Gastroenterology</i> , 2008, 103, 71-76. | 0.2 | 79 |
| 162 | What is the best salvage therapy for patients with <i>Helicobacter pylori</i> infection?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 608-609. | 1.7 | 3 |
| 163 | The occupational risk of <i>Helicobacter pylori</i> infection among workers in institutions for people with intellectual disability. <i>Occupational and Environmental Medicine</i> , 2008, 65, 587-591. | 1.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 164 | Use of NSAIDs and infection with <i>Helicobacter pylori</i> —what does the rheumatologist need to know?. <i>Rheumatology</i> , 2008, 47, 1342-1347. | 0.9 | 16 |
| 165 | Evaluation of a Commercial Immunoblot, Helicoblot 2.1, for Diagnosis of <i>Helicobacter pylori</i> Infection. <i>Vaccine Journal</i> , 2008, 15, 1705-1710. | 3.2 | 25 |
| 166 | Cost-effectiveness of and satisfaction with a <i>Helicobacter pylori</i> "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia. <i>Gut</i> , 2008, 57, 1214-1220. | 6.1 | 46 |
| 167 | Evaluation of a Rapid New Stool Antigen Test for Diagnosis of <i>Helicobacter pylori</i> Infection in Adult Patients. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2062-2065. | 1.8 | 22 |
| 168 | Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant <i>Helicobacter pylori</i> clinical isolates. <i>Journal of Clinical Pathology</i> , 2008, 61, 1112-1115. | 1.0 | 61 |
| 169 | <i>Helicobacter pylori</i> Antigen in Stool Is Associated With SIDS and Sudden Infant Deaths due to Infectious Disease. <i>Pediatric Research</i> , 2008, 64, 405-410. | 1.1 | 20 |
| 170 | <i>Helicobacter pylori</i> infection in children: management and pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 577-585. | 0.9 | 12 |
| 171 | A critical evaluation of the evidence on a causal relationship between <i>Helicobacter pylori</i> and otitis media with effusion. <i>Journal of Laryngology and Otology</i> , 2008, 122, 905-911. | 0.4 | 22 |
| 173 | Treatment of <i>Helicobacter pylori</i> infection. <i>BMJ: British Medical Journal</i> , 2008, 337, a1454-a1454. | 2.4 | 36 |
| 174 | Is There a Dark Side to Long-term Proton Pump Inhibitor Therapy?. <i>American Journal of Therapeutics</i> , 2008, 15, 536-542. | 0.5 | 35 |
| 175 | Composite marginal zone B cell lymphoma and enteropathy-type T cell lymphoma of the stomach: a case report. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 791-795. | 0.8 | 11 |
| 177 | Effect of esomeprazole triple therapy on eradication rates of <i>Helicobacter pylori</i> , gastric ulcer healing and prevention of relapse in gastric ulcer patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 526-536. | 0.8 | 29 |
| 178 | Diagnosis of <i>Helicobacter pylori</i> Infection in a High-prevalence Pediatric Population: A Comparison of 2 Fecal Antigen Testing Methods and Serology. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2008, 47, 130-135. | 0.9 | 18 |
| 179 | Errors in a Meta-analysis of Treatments for <i>Helicobacter pylori</i> Infection. <i>Annals of Internal Medicine</i> , 2008, 149, 686. | 2.0 | 6 |
| 180 | Could Increasing the Duration of Triple Therapy Be a Clinically Useful Strategy?. <i>Annals of Internal Medicine</i> , 2008, 148, 624. | 2.0 | 6 |
| 182 | Prevention of Indomethacin-Induced Gastric Mucosal Injury in <i>Helicobacter pylori</i> -Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2008, 43, 34-40. | 0.6 | 20 |
| 183 | An Insight into the Relationships between Hcpidin, Anemia, Infections and Inflammatory Cytokines in Pediatric Refugees: A Cross-Sectional Study. <i>PLoS ONE</i> , 2008, 3, e4030. | 1.1 | 73 |
| 184 | <i>Helicobacter pylori</i> Infection and Peptic Ulcer Disease in Patients with Liver Cirrhosis. <i>Korean Journal of Internal Medicine</i> , 2008, 23, 16. | 0.7 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 185 | Furazolidone, tetracycline and omeprazole: a low-cost alternative for <i>Helicobacter pylori</i> eradication in children. <i>Jornal De Pediatria</i> , 2008, 84, 160-165. | 0.9 | 17 |
| 186 | <i>Helicobacter pylori</i> genotypes in Lithuanian patients with chronic gastritis and duodenal ulcer. <i>Medicina (Lithuania)</i> , 2008, 44, 449. | 0.8 | 18 |
| 187 | The epidemiology of <i>Helicobacter pylori</i> infection in African refugee children resettled in Australia. <i>Medical Journal of Australia</i> , 2008, 189, 438-441. | 0.8 | 30 |
| 188 | Risks of proton pump inhibitors: what every doctor should know. <i>Medical Journal of Australia</i> , 2009, 190, 109-110. | 0.8 | 11 |
| 189 | Effect of Eradication of <i>Helicobacter pylori</i> on Incidence of Metachronous Gastric Carcinoma after Endoscopic Resection of Early Gastric Cancer: An Open-label, Randomised Controlled Trial. <i>Lancet</i> 2008;372:392-397. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2009, 54, 60. | 0.2 | 1 |
| 190 | Validade de instrumento epidemiol3gico para rastrear <i>H. pylori</i> entre pacientes disp4pticos. <i>Revista De Saude Publica</i> , 2009, 43, 639-646. | 0.7 | 2 |
| 191 | Azithromycin-containing versus standard triple therapy for <i>Helicobacter pylori</i> eradication: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2009, 15, 6102. | 1.4 | 13 |
| 192 | Inflammatory Disorders of the Stomach. , 2009, , 269-320. | | 8 |
| 193 | <i>Helicobacter Pylori</i> associated global gastric cancer burden. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 1490. | 3.0 | 84 |
| 194 | Gastroenterology in developing countries: Issues and advances. <i>World Journal of Gastroenterology</i> , 2009, 15, 2839. | 1.4 | 88 |
| 196 | Identification and molecular characterization of triple- and quadruple-resistant <i>Helicobacter pylori</i> clinical isolates in Germany. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 648-653. | 1.3 | 61 |
| 197 | Review: Improving compliance with <i>Helicobacter pylori</i> eradication therapy: when and how?. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 273-279. | 1.4 | 73 |
| 198 | <i>H. pylori</i> Eradication Prevents the Progression of Gastric Intestinal Metaplasia in Reflux Esophagitis Patients Using Long-Term Esomeprazole. <i>American Journal of Gastroenterology</i> , 2009, 104, 1642-1649. | 0.2 | 44 |
| 199 | Was It Really an "Ugly" Meta-Analysis?. <i>American Journal of Gastroenterology</i> , 2009, 104, 2853-2853. | 0.2 | 2 |
| 200 | <i>Helicobacter pylori</i> Eradication and Gastric Cancer: When Is the Horse Out of the Barn?. <i>American Journal of Gastroenterology</i> , 2009, 104, 1342-1345. | 0.2 | 72 |
| 201 | Sequential Therapy or Triple Therapy for <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 3069-3079. | 0.2 | 254 |
| 202 | Sequential Therapy for Eradication of <i>Helicobacter pylori</i> : A New Guiding Light or a False Dawn?. <i>American Journal of Gastroenterology</i> , 2009, 104, 3081-3083. | 0.2 | 21 |
| 203 | Eradication Therapy for <i>Helicobacter pylori</i> in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1932-1937. | 0.2 | 84 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 204 | Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen. American Journal of Gastroenterology, 2009, 104, 21-25. | 0.2 | 135 |
| 205 | Stepwise Diagnosis and Treatment from Uninvestigated Dyspepsia to Functional Dyspepsia in Clinical Practice in Japan: Proposal of a 4-Step Algorithm. Digestion, 2009, 79, 19-25. | 1.2 | 3 |
| 206 | Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. Journal of Medical Microbiology, 2009, 58, 930-935. | 0.7 | 50 |
| 207 | Helicobacter pylori infection in children. Saudi Journal of Gastroenterology, 2009, 15, 86. | 0.5 | 37 |
| 209 | Helicobacter pylori is not associated with anaemia in Latin America: results from Argentina, Brazil, Bolivia, Cuba, Mexico and Venezuela. Public Health Nutrition, 2009, 12, 1862-1870. | 1.1 | 42 |
| 210 | Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance in Helicobacter pylori. Journal of Clinical Microbiology, 2009, 47, 3600-3607. | 1.8 | 151 |
| 211 | Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World Journal of Gastroenterology, 2009, 15, 860. | 1.4 | 36 |
| 212 | A Questionnaire-Based Survey on the Prescription of Non-Steroidal Anti-Inflammatory Drugs by Physicians in East Asian Countries in 2007. Digestion, 2009, 79, 177-185. | 1.2 | 28 |
| 213 | Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group. Digestion, 2009, 80, 74-88. | 1.2 | 131 |
| 214 | Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines. Digestion, 2009, 80, 226-234. | 1.2 | 26 |
| 215 | Iron Deficiency, & Helicobacter & Infection and Gastritis. Acta Haematologica, 2009, 122, 97-102. | 0.7 | 31 |
| 216 | Hepatitis E, Helicobacter pylori and peptic ulcers in workers exposed to sewage: a prospective cohort study. Occupational and Environmental Medicine, 2009, 66, 45-50. | 1.3 | 15 |
| 217 | Increasing Prevalence of Primary Clarithromycin Resistance in Helicobacter pylori Strains in Split, Croatia. Journal of Chemotherapy, 2009, 21, 598-599. | 0.7 | 2 |
| 218 | Helicobacter Pylori, Zinc and Iron in Oxidative Stress-Induced Injury of Gastric Mucosa. Mini-Reviews in Medicinal Chemistry, 2009, 9, 26-30. | 1.1 | 10 |
| 219 | Gastroesophageal Reflux Disease. New England Journal of Medicine, 2009, 360, 729-730. | 13.9 | 4 |
| 221 | Association between polymorphisms in glutathione S-transferase Mu3 and IgG titer levels in serum against Helicobacter pylori. Journal of Human Genetics, 2009, 54, 557-563. | 1.1 | 5 |
| 223 | Helicobacter pylori's Unconventional Role in Health and Disease. PLoS Pathogens, 2009, 5, e1000544. | 2.1 | 89 |
| 224 | Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK. Journal of Medical Microbiology, 2009, 58, 1322-1328. | 0.7 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 225 | A new approach for the prevention and treatment of <i>Helicobacter pylori</i> infection via upregulation of autophagy and downregulation of apoptosis. <i>Autophagy</i> , 2009, 5, 413-414. | 4.3 | 21 |
| 226 | In Vitro Antibacterial Activity of Acyl-Lysyl Oligomers against <i>Helicobacter pylori</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4231-4239. | 1.4 | 20 |
| 227 | Combination of Sulindac and Antimicrobial Eradication of <i>Helicobacter pylori</i> Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice. <i>Cancer Research</i> , 2009, 69, 8166-8174. | 0.4 | 55 |
| 228 | Assessing the risks and benefits of treating <i>Helicobacter pylori</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 141-147. | 1.4 | 19 |
| 229 | Review: Eradication of <i>H. pylori</i> infection: the challenge is on if standard therapy fails. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 59-66. | 1.4 | 8 |
| 230 | Cost-Effectiveness of a Potential Prophylactic <i>Helicobacter pylori</i> Vaccine in the United States. <i>Journal of Infectious Diseases</i> , 2009, 200, 1311-1317. | 1.9 | 47 |
| 231 | Sitafloxacin Activity against <i>Helicobacter pylori</i> Isolates, Including Those with <i>gyrA</i> Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3097-3099. | 1.4 | 38 |
| 232 | Gastric cancer mortality trends in Spain, 1976-2005, differences by autonomous region and sex. <i>BMC Cancer</i> , 2009, 9, 346. | 1.1 | 24 |
| 233 | <i>Helicobacter pylori</i> , helminth infections and growth: a cross-sectional study in a high prevalence population. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2009, 98, 860-864. | 0.7 | 33 |
| 235 | Exploring the cost-effectiveness of <i>Helicobacter pylori</i> screening to prevent gastric cancer in China in anticipation of clinical trial results. <i>International Journal of Cancer</i> , 2009, 124, 157-166. | 2.3 | 84 |
| 236 | Increased risk of esophageal squamous cell carcinoma in patients with gastric atrophy: Independent of the severity of atrophic changes. <i>International Journal of Cancer</i> , 2009, 124, 2135-2138. | 2.3 | 26 |
| 237 | Anti-inflammatory effects of caffeic acid phenethyl ester (CAPE), a nuclear factor- κ B inhibitor, on <i>Helicobacter pylori</i> -induced gastritis in Mongolian gerbils. <i>International Journal of Cancer</i> , 2009, 125, 1786-1795. | 2.3 | 80 |
| 238 | Second-line treatment for <i>Helicobacter pylori</i> infection based on moxifloxacin triple therapy: a randomized controlled trial. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 47-52. | 1.0 | 21 |
| 239 | Efficiency of Antianxiety Preparation Tenoten Used in Complex Therapy of Patients with <i>Helicobacter pylori</i> -Associated Ulcer Disease of the Duodenum. <i>Bulletin of Experimental Biology and Medicine</i> , 2009, 148, 351-352. | 0.3 | 0 |
| 240 | Effects of <i>Helicobacter pylori</i> infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. <i>Cancer Causes and Control</i> , 2009, 20, 2021-2029. | 0.8 | 30 |
| 241 | The Relationship Between Virulence Factors of <i>Helicobacter pylori</i> and Severity of Gastritis in Infected Patients. <i>Digestive Diseases and Sciences</i> , 2009, 54, 103-110. | 1.1 | 35 |
| 242 | <i>Helicobacter pylori vacA</i> Arrangement and Related Diseases: A Retrospective Study Over a Period of 15 Years. <i>Digestive Diseases and Sciences</i> , 2009, 54, 97-102. | 1.1 | 9 |
| 243 | Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole for Patients Who Failed to Eradicate <i>Helicobacter pylori</i> with Triple Therapy. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1953-1957. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 244 | Gastric infection by <i>Helicobacter pylori</i> . <i>Current Gastroenterology Reports</i> , 2009, 11, 455-461. | 1.1 | 21 |
| 246 | <i>H. pylori</i> eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study. <i>Annals of Hematology</i> , 2009, 88, 769-773. | 0.8 | 5 |
| 247 | Antimicrobial Susceptibility Testing of <i>Helicobacter pylori</i> Determined by Microdilution Method Using a New Medium. <i>Current Microbiology</i> , 2009, 58, 559-563. | 1.0 | 22 |
| 248 | <i>Helicobacter pylori</i> related dyspepsia: prevalence and treatment outcomes at University Kebangsaan Malaysia-Primary Care Centre. <i>Asia Pacific Family Medicine</i> , 2009, 8, 4. | 0.4 | 5 |
| 249 | Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed <i>Helicobacter pylori</i> eradication. <i>BMC Gastroenterology</i> , 2009, 9, 38. | 0.8 | 27 |
| 250 | Urticaria and infections. <i>Allergy, Asthma and Clinical Immunology</i> , 2009, 5, 10. | 0.9 | 150 |
| 251 | Review article: "Reinfection of <i>Helicobacter pylori</i> after successful eradication" worldwide annual rates, risk factors and clinical implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 145-160. | 1.9 | 35 |
| 252 | Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis" results from the EXPO study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 959-966. | 1.9 | 13 |
| 253 | Influence of gastric mucosal status on success of stepwise acid suppressive therapy for dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 82-89. | 1.9 | 0 |
| 254 | Clinical trial: long-term use of proton pump inhibitors in primary care patients" a cross sectional analysis of 901 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 725-732. | 1.9 | 33 |
| 255 | Analysis of drug resistance and virulence factor genotype of Irish <i>Helicobacter pylori</i> strains: is there any relationship between resistance to metronidazole and <i>cagA</i> status?. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 784-790. | 1.9 | 37 |
| 256 | Accuracy of a new ultrafast rapid urease test to diagnose <i>Helicobacter pylori</i> infection in 1000 consecutive dyspeptic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 331-338. | 1.9 | 31 |
| 257 | Sequential therapy vs. standard triple therapies for <i>Helicobacter pylori</i> infection: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 41-53. | 0.7 | 107 |
| 258 | Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of <i>Helicobacter pylori</i> after failure of first-line therapy (KDOG0201 Study). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 303-307. | 0.7 | 10 |
| 259 | Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. <i>British Journal of Cancer</i> , 2009, 100, 1503-1507. | 2.9 | 137 |
| 260 | Infections of the esophagus and the stomach. <i>Periodontology 2000</i> , 2009, 49, 166-178. | 6.3 | 3 |
| 261 | Biopsy site for detecting <i>Helicobacter pylori</i> infection in patients with gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 469-474. | 1.4 | 49 |
| 262 | Resistance to metronidazole, clarithromycin and levofloxacin of <i>Helicobacter pylori</i> before and after clarithromycin-based therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1230-1235. | 1.4 | 67 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 263 | <i>Helicobacter pylori</i> Antibiotic resistance and treatment options. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1155-1157. | 1.4 | 16 |
| 264 | Second Asiaâ€‘Pacific Consensus Guidelines for <i>Helicobacter pylori</i> infection. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1587-1600. | 1.4 | 493 |
| 265 | Influence of <i>Helicobacter pylori</i> eradication on reflux esophagitis in Japanese patients. Ecological Management and Restoration, 2009, 22, 361-367. | 0.2 | 9 |
| 266 | <i>Helicobacter pylori</i> eradication: role of individual therapy constituents and therapy duration. Fundamental and Clinical Pharmacology, 2009, 23, 43-52. | 1.0 | 10 |
| 267 | Prevalence of Primary Fluoroquinolone Resistance Among Clinical Isolates of <i>Helicobacter pylori</i> at a University Hospital in Southern Taiwan. Helicobacter, 2009, 14, 61-65. | 1.6 | 71 |
| 268 | <i>Helicobacter pylori</i> Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Tripleâ€‘Therapy Regimens. Helicobacter, 2009, 14, 29-35. | 1.6 | 40 |
| 269 | Impact of Quadruple Regimen of Clarithromycin Added to Metronidazoleâ€‘Containing Triple Therapy Against <i>Helicobacter pylori</i> Infection Following Clarithromycinâ€‘Containing Tripleâ€‘Therapy Failure. Helicobacter, 2009, 14, 91-99. | 1.6 | 46 |
| 270 | A Randomized Clinical Trial to Determine the Efficacy of Regimens Containing Clarithromycin, Metronidazole, and Amoxicillin Among Histologic Subgroups for <i>Helicobacter pylori</i> Eradication in a Developing Country. Helicobacter, 2009, 14, 100-108. | 1.6 | 16 |
| 271 | Metaâ€‘analysis: Fourâ€‘Drug, Threeâ€‘Antibiotic, Nonâ€‘bismuthâ€‘Containing â€‘Concomitant Therapyâ€‘Versus Triple Therapy for <i>Helicobacter pylori</i> Eradication. Helicobacter, 2009, 14, 109-118. | 1.6 | 209 |
| 272 | Effect of <i>Helicobacter pylori</i> Eradication on Incidence of Gastric Cancer in Human and Animal Models: Underlying Biochemical and Molecular Events. Helicobacter, 2009, 14, 159-171. | 1.6 | 52 |
| 273 | Clinical Significance of IgG Antibody Titer against <i> Helicobacter pylori</i>. Helicobacter, 2009, 14, 231-236. | 1.6 | 34 |
| 274 | Helicobacters and Extragastric Diseases. Helicobacter, 2009, 14, 58-68. | 1.6 | 65 |
| 275 | Treatment of <i>Helicobacter pylori</i> Infection. Helicobacter, 2009, 14, 46-51. | 1.6 | 94 |
| 276 | Moxifloxacinâ€‘Containing Triple Therapy as Secondâ€‘Line Treatment for <i>Helicobacter pylori</i> Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate. Helicobacter, 2009, 14, 429-437. | 1.6 | 48 |
| 277 | Annual Change of Primary Resistance to Clarithromycin among <i>Helicobacter pylori</i> Isolates from 1996 through 2008 in Japan. Helicobacter, 2009, 14, 438-442. | 1.6 | 94 |
| 278 | Variables Influencing Outcome of <i>Helicobacter pylori</i> Eradication Therapy in South China. Helicobacter, 2009, 14, 443-448. | 1.6 | 23 |
| 279 | Clarithromycinâ€‘Amoxicillinâ€‘Containing Triple Therapy: A Valid Empirical Firstâ€‘Line Treatment for <i>Helicobacter pylori</i> Eradication in Hong Kong?. Helicobacter, 2009, 14, 505-511. | 1.6 | 41 |
| 280 | Insights into the future of gastric acid suppression. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 524-532. | 8.2 | 66 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 281 | Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic β -cell function. <i>Diabetes Research and Clinical Practice</i> , 2009, 86, 89-95. | 1.1 | 34 |
| 282 | Evaluation of a latex agglutination test (PYLOGEN) for the detection of Helicobacter pylori in stool specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 349-353. | 0.8 | 8 |
| 283 | The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. <i>European Journal of Internal Medicine</i> , 2009, 20, 53-57. | 1.0 | 20 |
| 284 | Idiopathic thrombocytopenic purpura: Helicobacter pylori infection should be considered. <i>European Journal of Internal Medicine</i> , 2009, 20, e127. | 1.0 | 0 |
| 285 | The prevalence of Helicobacter pylori in obese subjects. <i>European Journal of Internal Medicine</i> , 2009, 20, 695-697. | 1.0 | 118 |
| 287 | Protective immunization with homologous and heterologous antigens against Helicobacter suis challenge in a mouse model. <i>Vaccine</i> , 2009, 27, 1416-1421. | 1.7 | 6 |
| 290 | Peptic ulcer disease. <i>Lancet</i> , The, 2009, 374, 1449-1461. | 6.3 | 896 |
| 291 | Diagnostic value of rapid urease test and urea breath test for Helicobacter pylori detection in patients with Billroth II gastrectomy: A prospective controlled trial. <i>Digestive and Liver Disease</i> , 2009, 41, 4-8. | 0.4 | 27 |
| 292 | The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. <i>Digestive and Liver Disease</i> , 2009, 41, 644-647. | 0.4 | 42 |
| 293 | Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study. <i>Digestive and Liver Disease</i> , 2009, 41, 467-473. | 0.4 | 35 |
| 294 | Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. <i>Digestive and Liver Disease</i> , 2009, 41, 480-485. | 0.4 | 53 |
| 295 | High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pancreatitis. <i>Digestive and Liver Disease</i> , 2009, 41, 555-558. | 0.4 | 10 |
| 296 | The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 18-25. | 0.5 | 42 |
| 297 | Novel Helicobacter pylori therapeutic targets: the unusual suspects. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 835-867. | 2.0 | 11 |
| 298 | Acid peptic diseases: pharmacological approach to treatment. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 295-314. | 1.3 | 83 |
| 299 | Rabeprazole. <i>Drugs</i> , 2009, 69, 1373-1401. | 4.9 | 24 |
| 300 | Illustrating Economic Evaluation of Diagnostic Technologies: Comparing Helicobacter pylori Screening Strategies in Prevention of Gastric Cancer in Canada. <i>Journal of the American College of Radiology</i> , 2009, 6, 317-323. | 0.9 | 25 |
| 301 | Sequential therapy for Helicobacter pylori eradication: the time is now!. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 317-322. | 1.4 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 302 | Pylera [®] for the eradication of <i>Helicobacter pylori</i> infection. Expert Review of Anti-Infective Therapy, 2009, 7, 793-799. | 2.0 | 23 |
| 303 | Periodontal Therapy Improves Gastric <i>Helicobacter pylori</i> Eradication. Journal of Dental Research, 2009, 88, 946-950. | 2.5 | 62 |
| 304 | Meta-analysis: Can <i>Helicobacter pylori</i> Eradication Treatment Reduce the Risk for Gastric Cancer?. Annals of Internal Medicine, 2009, 151, 121. | 2.0 | 315 |
| 305 | Ordonnance pour r cidive d mulc re duod nal. Pharmacien Hospitalier, 2009, 44, 200-204. | 0.1 | 0 |
| 306 | Development of vaccines against <i>Helicobacter pylori</i> . Expert Review of Vaccines, 2009, 8, 1037-1049. | 2.0 | 81 |
| 307 | Editorial: H. pylori Treatment: New Wine in Old Bottles?. American Journal of Gastroenterology, 2009, 104, 26-30. | 0.2 | 54 |
| 308 | Esomeprazole: a proton pump inhibitor. Expert Review of Gastroenterology and Hepatology, 2009, 3, 15-27. | 1.4 | 18 |
| 309 | Is sequential therapy superior to standard triple therapy for the treatment of <i>Helicobacter pylori</i> infection?. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 8-9. | 1.7 | 9 |
| 310 | Enhanced systemic matrix metalloproteinase response in <i>Helicobacter pylori</i> gastritis. Annals of Medicine, 2009, 41, 208-215. | 1.5 | 69 |
| 311 | Early-stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. Oncologist, 2009, 14, 148-154. | 1.9 | 13 |
| 312 | In vitro Antagonism of Rabeprazole and Metronidazole upon Clinical Isolates of <i>Helicobacter pylori</i> . Chemotherapy, 2009, 55, 308-311. | 0.8 | 4 |
| 313 | Pathogenesis and Management of Iron Deficiency Anemia: Emerging Role of Celiac Disease, <i>Helicobacter pylori</i> , and Autoimmune Gastritis. Seminars in Hematology, 2009, 46, 339-350. | 1.8 | 61 |
| 314 | Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncology, The, 2009, 10, 400-408. | 5.1 | 180 |
| 315 | Spontaneous Clearance of <i>Helicobacter pylori</i> Colonization in Patients with Partial Gastrectomy: Correlates with Operative Procedures and Duration After Operation. Journal of the Formosan Medical Association, 2009, 108, 13-19. | 0.8 | 26 |
| 316 | Gastric cancer. Lancet, The, 2009, 374, 1594. | 6.3 | 14 |
| 317 | Fluorescence In Situ Hybridization Confirms Clearance of Visible <i>Helicobacter</i> spp. Associated with Gastritis in Dogs and Cats. Journal of Veterinary Internal Medicine, 2009, 23, 16-23. | 0.6 | 39 |
| 318 | Refractory Peptic Ulcer Disease. Gastroenterology Clinics of North America, 2009, 38, 267-288. | 1.0 | 22 |
| 319 | Review: Second-line rescue therapy of <i>Helicobacter pylori</i> infection. Therapeutic Advances in Gastroenterology, 2009, 2, 331-356. | 1.4 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 320 | Helicobacter pylori Eradication in Patients on Long-term Treatment With NSAIDs Reduces the Severity of Gastritis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 140-146. | 1.1 | 15 |
| 321 | Levofloxacin, Amoxicillin, and Omeprazole as First-line Triple Therapy for Helicobacter pylori Eradication. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 384-385. | 1.1 | 19 |
| 322 | Helicobacter pylori: diagnosis and treatment. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 549-556. | 1.0 | 36 |
| 323 | Results of a prospective comparison pilot validation study of a low-dose tablet formulation 13C urea and citric acid breath test employing a novel automated nondispersive isotope selective infrared spectroscopy analyser for the diagnosis of Helicobacter pylori infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1321-1322. | 0.8 | 2 |
| 324 | Accuracy of Urea Breath Tests Tablets After 10 Minutes Compared With Standard 30 Minutes to Diagnose and Monitoring Helicobacter pylori Infection: A Randomized Controlled Trial. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 693-694. | 1.1 | 8 |
| 325 | A Novel Association Between Polycystic Ovary Syndrome and Helicobacter pylori. <i>American Journal of the Medical Sciences</i> , 2009, 338, 174-177. | 0.4 | 21 |
| 326 | Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. <i>Blood</i> , 2009, 113, 1231-1240. | 0.6 | 273 |
| 327 | Evidence of an inverse relationship between cytotoxin-associated gene A-positive Helicobacter pylori infection and oesophageal adenocarcinoma and possible geographical implications. <i>The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2009, 24, 50-50. | 0.2 | 0 |
| 328 | Helicobacter pylori Infection: To Eradicate or Not to Eradicate. <i>Frontiers of Gastrointestinal Research</i> , 2009, , 186-198. | 0.1 | 0 |
| 330 | H. pylori Eradication Prevents the Progression of Gastric Intestinal Metaplasia in Reflux Esophagitis Patients Using Long-Term Esomeprazole. <i>Yearbook of Gastroenterology</i> , 2010, 2010, 24-25. | 0.1 | 0 |
| 331 | 14C-Urea breath test is safe for pediatric patients. <i>Nuclear Medicine Communications</i> , 2010, 31, 830-835. | 0.5 | 14 |
| 332 | Helicobacter pylori-negative Gastritis in Erosive Esophagitis, Nonerosive Reflux Disease or Functional Dyspepsia Patients. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 180-185. | 1.1 | 14 |
| 333 | Stomach Cancer Risk in Gastric Cancer Relatives. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e34-e39. | 1.1 | 125 |
| 334 | Ten and Eight-day Sequential Therapy in Comparison to Standard Triple Therapy for Eradicating Helicobacter pylori Infection. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 261-266. | 1.1 | 65 |
| 335 | Clinical Practice: Diagnosis and Evaluation of Dyspepsia. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 167-172. | 1.1 | 25 |
| 336 | Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1128-1133. | 0.8 | 90 |
| 337 | Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1123-1127. | 0.8 | 36 |
| 338 | Helicobacter pylori Eradication Regimens: Is there a Difference?. <i>Journal of Pharmacy Practice and Research</i> , 2010, 40, 194-198. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 340 | 2. Iron-deficiency Anemia in Childhood and Adolescence.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1201-1206. | 0.0 | 0 |
| 341 | Changes in 12-Year First-Line Eradication Rate of <i>Helicobacter pylori</i> Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. Journal of Clinical Biochemistry and Nutrition, 2010, 47, 53-58. | 0.6 | 90 |
| 342 | Effect of Sequential Treatment as a First-Line Therapy for <i>Helicobacter pylori</i> Eradication in Patients with Diabetes Mellitus. Southern Medical Journal, 2010, 103, 988-992. | 0.3 | 23 |
| 343 | Primary Low-grade and High-grade Gastric MALT-lymphoma Presentation. Journal of Clinical Gastroenterology, 2010, 44, 340-344. | 1.1 | 54 |
| 344 | Sequential Therapy for <i>Helicobacter pylori</i> Eradication. Journal of Clinical Gastroenterology, 2010, 44, 313-325. | 1.1 | 194 |
| 346 | Comparison of the Diagnostic Values of the 3 Different Stool Antigen Tests for the Noninvasive Diagnosis of <i>Helicobacter pylori</i> Infection. Journal of Investigative Medicine, 2010, 58, 982-986. | 0.7 | 26 |
| 347 | Is Antimicrobial Susceptibility Testing Necessary Before First-line Treatment for <i>Helicobacter pylori</i> Infection? -Meta-analysis of Randomized Controlled Trials-. Internal Medicine, 2010, 49, 1103-1109. | 0.3 | 88 |
| 348 | Prevention of Gastric Cancer by <i>Helicobacter pylori</i> Eradication. Internal Medicine, 2010, 49, 633-636. | 0.3 | 54 |
| 350 | A "Screen-and-Treat" Approach for <i>Helicobacter pylori</i> Infection: A Population-Based Study in Vammala, Finland. Helicobacter, 2010, 15, 28-37. | 1.6 | 13 |
| 351 | Bismuth-Containing Quadruple Therapy as Second-Line Treatment for <i>Helicobacter pylori</i> Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea. Helicobacter, 2010, 15, 38-45. | 1.6 | 109 |
| 352 | High Level of Antimicrobial Resistance in French <i>Helicobacter pylori</i> Isolates. Helicobacter, 2010, 15, 21-27. | 1.6 | 102 |
| 353 | Guidelines for the Management of <i>Helicobacter pylori</i> Infection in Japan: 2009 Revised Edition. Helicobacter, 2010, 15, 1-20. | 1.6 | 416 |
| 354 | Role of Probiotics in Pediatric Patients with <i>Helicobacter pylori</i> Infection: A Comprehensive Review of the Literature. Helicobacter, 2010, 15, 79-87. | 1.6 | 70 |
| 355 | Comparison of the Efficacy of the Two Tetracycline-Containing Sequential Therapy Regimens for the Eradication of <i>Helicobacter Pylori</i> : 5-days Versus 14-days Amoxicillin. Helicobacter, 2010, 15, 143-147. | 1.6 | 20 |
| 356 | Ten-Day Sequential Therapy as First-Line Treatment for <i>Helicobacter pylori</i> Infection in Korea: A Retrospective Study. Helicobacter, 2010, 15, 148-153. | 1.6 | 41 |
| 357 | The Effect of Probiotics and Mucoprotective Agents on PPI-Based Triple Therapy for Eradication of <i>Helicobacter pylori</i> . Helicobacter, 2010, 15, 206-213. | 1.6 | 83 |
| 358 | Time Trends of <i>Helicobacter pylori</i> Resistance to Antibiotics in Children Living in Vienna, Austria. Helicobacter, 2010, 15, 214-220. | 1.6 | 27 |
| 359 | Accuracy of Monoclonal Stool Tests for Determining Cure of <i>Helicobacter pylori</i> Infection After Treatment. Helicobacter, 2010, 15, 201-205. | 1.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 360 | High Efficacy of 14-Day Triple Therapy-Based, Bismuth-Containing Quadruple Therapy for Initial <i>Helicobacter pylori</i> Eradication. <i>Helicobacter</i> , 2010, 15, 233-238. | 1.6 | 108 |
| 361 | Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy. <i>Helicobacter</i> , 2010, 15, 265-272. | 1.6 | 40 |
| 362 | Interaction of <i>Helicobacter pylori</i> Infection and Nonsteroidal Anti-Inflammatory Drugs in Gastric and Duodenal Ulcers. <i>Helicobacter</i> , 2010, 15, 239-250. | 1.6 | 24 |
| 363 | Treatment of <i>Helicobacter pylori</i> Infection 2010. <i>Helicobacter</i> , 2010, 15, 46-52. | 1.6 | 61 |
| 364 | <i>Helicobacter pylori</i> infection and Nonmalignant Diseases. <i>Helicobacter</i> , 2010, 15, 29-33. | 1.6 | 13 |
| 365 | <i>Helicobacter pylori</i> Infection and Childhood. <i>Helicobacter</i> , 2010, 15, 53-59. | 1.6 | 38 |
| 366 | The Evolution of <i>Helicobacter pylori</i> Antibiotics Resistance Over 10 Years in Beijing, China. <i>Helicobacter</i> , 2010, 15, 460-466. | 1.6 | 122 |
| 367 | Is the Association Between <i>Helicobacter pylori</i> Infection and Anemia Age Dependent?. <i>Helicobacter</i> , 2010, 15, 467-472. | 1.6 | 36 |
| 368 | Sequential Metronidazole-Furazolidone or Clarithromycin-Furazolidone Compared to Clarithromycin-Based Quadruple Regimens for the Eradication of <i>Helicobacter pylori</i> in Peptic Ulcer Disease: A Double-Blind Randomized Controlled Trial. <i>Helicobacter</i> , 2010, 15, 497-504. | 1.6 | 24 |
| 369 | Identification of a Correlation between <i>Helicobacter pylori</i> Infection and Graves™ Disease. <i>Helicobacter</i> , 2010, 15, 558-562. | 1.6 | 35 |
| 373 | Appropriateness of treatment recommendations for PPI in hospital discharge letters. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1265-1271. | 0.8 | 70 |
| 374 | In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against <i>Helicobacter pylori</i> isolates in Taiwan, 1998-2007. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 1369-1375. | 1.3 | 15 |
| 375 | <i>Helicobacter pylori</i> eradication with a 7-day low-dose triple therapy in hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2010, 14, 469-473. | 0.7 | 15 |
| 376 | Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent <i>Helicobacter pylori</i> infection: a meta analysis. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 413-422. | 1.0 | 54 |
| 379 | Treatment of low-grade gastric MALT-lymphoma unresponsive to <i>Helicobacter pylori</i> therapy. <i>Medical Oncology</i> , 2010, 27, 291-295. | 1.2 | 42 |
| 380 | Clinical Trial Report: Eradication of <i>Helicobacter pylori</i> Reduces the Risk for Subsequent Gastric Cancer. <i>Current Gastroenterology Reports</i> , 2010, 12, 427-430. | 1.1 | 1 |
| 382 | A comparison amongst three rapid urease tests to diagnose <i>Helicobacter pylori</i> infection in 375 consecutive dyspeptic. <i>Internal and Emergency Medicine</i> , 2010, 5, 41-47. | 1.0 | 21 |
| 383 | Non-invasive Testing for <i>Helicobacter pylori</i> in Patients Hospitalized with Peptic Ulcer Hemorrhage: A Cost-Effectiveness Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1356-1363. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 384 | Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait. Digestive Diseases and Sciences, 2010, 55, 3120-3123. | 1.1 | 6 |
| 386 | Clarithromycin-Resistant Genotypes and Eradication of Helicobacter Pylori. Journal of Pediatrics, 2010, 157, 228-232. | 0.9 | 147 |
| 387 | The effect of mastic gum on Helicobacter pylori: A randomized pilot study. Phytomedicine, 2010, 17, 296-299. | 2.3 | 65 |
| 388 | Non-steroidal anti-inflammatory drug use in the elderly. Surgical Oncology, 2010, 19, 167-172. | 0.8 | 45 |
| 389 | Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. BMC Health Services Research, 2010, 10, 344. | 0.9 | 18 |
| 390 | Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clinical Therapeutics, 2010, 32, 667-677. | 1.1 | 87 |
| 391 | Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in Chinese adults. Clinical Therapeutics, 2010, 32, 2003-2011. | 1.1 | 29 |
| 392 | Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: From risk factor identification to risk factor intervention. Joint Bone Spine, 2010, 77, 6-12. | 0.8 | 32 |
| 393 | Prévention des complications digestives des anti-inflammatoires non stéroïdiens: de la connaissance des facteurs de risque à leur prise en compte. Revue Du Rhumatisme (Edition Française), 2010, 77, 7-13. | 0.0 | 0 |
| 394 | Test-and-treat strategy for Helicobacter pylori (HP) infection in older patients. Archives of Gerontology and Geriatrics, 2010, 51, 237-240. | 1.4 | 2 |
| 395 | Adverse effects of proton pump inhibitors. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 193-201. | 1.0 | 72 |
| 396 | Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Annals of Clinical Microbiology and Antimicrobials, 2010, 9, 13. | 1.7 | 17 |
| 397 | Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Annals of Clinical Microbiology and Antimicrobials, 2010, 9, 22. | 1.7 | 46 |
| 398 | Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2010, 31, 1077-1084. | 1.9 | 98 |
| 399 | Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary Pharmacology and Therapeutics, 2010, 32, 1069-1079. | 1.9 | 191 |
| 400 | The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 713-722. | 0.7 | 22 |
| 401 | Role of Helicobacter pylori infection in gastric cancer pathogenesis: A chance for prevention. Journal of Digestive Diseases, 2010, 11, 2-11. | 0.7 | 28 |
| 402 | Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia. Journal of Digestive Diseases, 2010, 11, 101-105. | 0.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 403 | Efficacy of one-week proton pump inhibitor triple therapy as first-line <i>Helicobacter Pylori</i> eradication regime in Asian patients: Is it still effective 10 years on?. <i>Journal of Digestive Diseases</i> , 2010, 11, no-no. | 0.7 | 22 |
| 404 | Controversy of proton pump inhibitor and clopidogrel interaction: A review. <i>Journal of Digestive Diseases</i> , 2010, 11, 334-342. | 0.7 | 1 |
| 405 | Marshall and Warren Lecture 2009: Peptic Ulcer Bleeding: An expedition of 20 years from 1989 to 2009. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 229-233. | 1.4 | 14 |
| 406 | Changes in the prevalence of <i>Helicobacter pylori</i> infection and gastrointestinal diseases in the past 17 years. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, S99-S110. | 1.4 | 55 |
| 407 | Safety of the long-term use of proton pump inhibitors. <i>World Journal of Gastroenterology</i> , 2010, 16, 2323. | 1.4 | 241 |
| 408 | <i>Helicobacter pylori</i> Eradication in Diabetic Patients: Still Far Off the Treatment Targets. <i>Southern Medical Journal</i> , 2010, 103, 975-976. | 0.3 | 4 |
| 409 | Evaluation of Bio M <i>pylori</i> serologic test and C-13 urea breath test for <i>H. pylori</i> infection in children with recurrent abdominal pain: a pilot study. <i>Paediatrica Indonesiana</i> , 2010, 50, 101. | 0.0 | 0 |
| 410 | Infections of the gastrointestinal tract. , 2010, , 593-607. | | 0 |
| 411 | Indications to Upper Gastrointestinal Endoscopy in Children With Dyspepsia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 50, 493-499. | 0.9 | 23 |
| 413 | Validation of a rapid stool antigen test for diagnosis of <i>Helicobacter pylori</i> infection. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2010, 52, 125-128. | 0.5 | 20 |
| 415 | Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomy. <i>The Korean Journal of Hematology</i> , 2010, 45, 197. | 0.7 | 8 |
| 416 | In vitro Antibacterial and Morphological Effects of the Urushiol Component of the Sap of the Korean lacquer tree (<i>Rhus vernicifera</i> Stokes) on <i>Helicobacter pylori</i> . <i>Journal of Korean Medical Science</i> , 2010, 25, 399. | 1.1 | 20 |
| 417 | Nuclear Imaging. , 2010, , 527-536. | | 0 |
| 418 | Gastric cancer, <i>Helicobacter pylori</i> infection and other risk factors. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 342. | 0.8 | 69 |
| 419 | Clarithromycin-resistant <i>Helicobacter pylori</i> in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction. <i>Arquivos De Gastroenterologia</i> , 2010, 47, 379-382. | 0.3 | 19 |
| 420 | Seroprevalence of <i>Helicobacter pylori</i> infection among children of low socioeconomic level in São Paulo. <i>Sao Paulo Medical Journal</i> , 2010, 128, 187-191. | 0.4 | 21 |
| 421 | Association Between <i>Helicobacter pylori</i> and Gastrointestinal Symptoms in Children. <i>Pediatrics</i> , 2010, 125, e651-e669. | 1.0 | 101 |
| 422 | <i>Helicobacter pylori</i> infection and current clinical areas of contention. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 618-623. | 1.0 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 423 | Comparative Accuracy of 3 Monoclonal Stool Tests for Diagnosis of <i>Helicobacter pylori</i> Infection among Patients with Dyspepsia. <i>Clinical Infectious Diseases</i> , 2010, 50, 323-328. | 2.9 | 39 |
| 424 | Bismuth-Based First-Line Therapy for <i>Helicobacter pylori</i> Eradication in Type 2 Diabetes Mellitus Patients. <i>Digestion</i> , 2010, 82, 47-53. | 1.2 | 16 |
| 425 | A new 24 h ELISA culture based method for <i>Helicobacter pylori</i> chemosusceptibility. <i>Journal of Clinical Pathology</i> , 2010, 63, 648-651. | 1.0 | 4 |
| 426 | High Prevalence of Clarithromycin-Resistant <i>Helicobacter pylori</i> Strains and Risk Factors Associated with Resistance in Madrid, Spain. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3703-3707. | 1.8 | 110 |
| 427 | Comparative study of <i>Nigella Sativa</i> and triple therapy in eradication of <i>Helicobacter Pylori</i> in patients with non-ulcer dyspepsia. <i>Saudi Journal of Gastroenterology</i> , 2010, 16, 207. | 0.5 | 98 |
| 428 | Considerable use of furazolidone in Iran. <i>Saudi Journal of Gastroenterology</i> , 2010, 16, 308. | 0.5 | 2 |
| 429 | Iron, Zinc, and Copper Nutritional Status in Children Infected With <i>Helicobacter pylori</i> . <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 51, 85-89. | 0.9 | 30 |
| 430 | Empiric Quadruple vs. Triple Therapy for Primary Treatment of <i>Helicobacter pylori</i> Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability. <i>American Journal of Gastroenterology</i> , 2010, 105, 65-73. | 0.2 | 188 |
| 431 | Esomeprazole for the treatment of peptic ulcer bleeding. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 679-695. | 1.4 | 1 |
| 432 | Comment and reply on "Helicobacter pylori seroprevalence in patients with chronic prostatitis: A pilot study" Scandinavian Journal of Urology and Nephrology, 2010, 44, 345-346. | 1.4 | 1 |
| 433 | Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of <i>Helicobacter pylori</i> infection and upper gastrointestinal malignancy: an endoscopic database review of 102 665 patients from 1996 to 2006. <i>Gut</i> , 2010, 59, 722-728. | 6.1 | 63 |
| 434 | Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for <i>Helicobacter pylori</i> eradication: a prospective, double-blind, randomized, placebo-controlled study. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 677-683. | 0.6 | 6 |
| 435 | Dyspeptic Symptoms and Endoscopic Findings in the Community: The Loiano "Monghidoro Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 565-571. | 0.2 | 54 |
| 436 | Bismuth improves PPI-based triple therapy for <i>H. pylori</i> eradication. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 538-539. | 8.2 | 49 |
| 437 | Appropriateness Guidelines and Predictive Rules to Select Patients for Upper Endoscopy: A Nationwide Multicenter Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 1327-1337. | 0.2 | 23 |
| 438 | Efficacy of Three Different Dosages of Esomeprazole in the Long-Term Management of Reflux Disease: A Prospective, Randomized Study, Using the Wireless Bravo pH System. <i>American Journal of Gastroenterology</i> , 2010, 105, 308-313. | 0.2 | 13 |
| 439 | Geographic map and evolution of primary <i>Helicobacter pylori</i> resistance to antibacterial agents. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 59-70. | 2.0 | 105 |
| 440 | CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 29-41. | 1.5 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 441 | Ureasas as a target for the treatment of gastric and urinary infections. Journal of Clinical Pathology, 2010, 63, 424-430. | 1.0 | 142 |
| 442 | Assessment of systemic matrix metalloproteinase and their regulator response in children with Helicobacter pylorigastritis. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 492-496. | 0.6 | 18 |
| 443 | The sequential therapy regimen for Helicobacter pylori eradication. Expert Opinion on Pharmacotherapy, 2010, 11, 905-918. | 0.9 | 12 |
| 444 | Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice. Gastroenterology Research and Practice, 2010, 2010, 1-7. | 0.7 | 10 |
| 446 | Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgraduate Medical Journal, 2010, 86, 272-278. | 0.9 | 81 |
| 447 | Helicobacter pylori and Iron deficiency Anemia in Adolescents in Brazil. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 477-480. | 0.9 | 18 |
| 448 | Helicobacter pylori Infection. New England Journal of Medicine, 2010, 363, 595-596. | 13.9 | 28 |
| 449 | Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole. Acta Pharmacologica Sinica, 2010, 31, 501-508. | 2.8 | 9 |
| 450 | To treat or not to treat Helicobacter pylori to benefit asthma patients. Expert Review of Respiratory Medicine, 2010, 4, 147-150. | 1.0 | 11 |
| 451 | Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Review of Gastroenterology and Hepatology, 2010, 4, 149-156. | 1.4 | 40 |
| 452 | Stool Polymerase Chain Reaction for Helicobacter pylori Detection and Clarithromycin Susceptibility Testing in Children. Clinical Gastroenterology and Hepatology, 2010, 8, 309-312. | 2.4 | 50 |
| 453 | Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa-associated Lymphoid Tissue Lymphoma. Clinical Gastroenterology and Hepatology, 2010, 8, 105-110. | 2.4 | 256 |
| 454 | Il linfoma gastrico: una neoplasia che si puo' eradicare?. Italian Journal of Medicine, 2010, 4, 154-158. | 0.2 | 0 |
| 456 | Patient factors affecting culture of Helicobacter pylori isolated from gastric mucosal specimens. Advances in Medical Sciences, 2010, 55, 161-166. | 0.9 | 17 |
| 457 | Bioavailability of Vitamins E and C: Does Helicobacter pylori Infection Play a Role?. Annals of Nutrition and Metabolism, 2010, 56, 253-259. | 1.0 | 5 |
| 458 | Helicobacter pylori Infection. New England Journal of Medicine, 2010, 362, 1597-1604. | 13.9 | 682 |
| 459 | Helicobacter pylori eradication therapy. Future Microbiology, 2010, 5, 639-648. | 1.0 | 94 |
| 462 | Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scandinavian Journal of Gastroenterology, 2010, 45, 1036-1041. | 0.6 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 463 | Efficacy of four different moxifloxacin-based triple therapies for first-line <i>H. pylori</i> treatment. <i>Digestive and Liver Disease</i> , 2010, 42, 110-114. | 0.4 | 26 |
| 464 | <i>Helicobacter pylori</i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , 2010, 42, 287-290. | 0.4 | 53 |
| 465 | Efficacy of <i>H. pylori</i> eradication with a sequential regimen followed by rescue therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2010, 42, 541-543. | 0.4 | 36 |
| 466 | Low prevalence of idiopathic peptic ulcer disease: An Italian endoscopic survey. <i>Digestive and Liver Disease</i> , 2010, 42, 773-776. | 0.4 | 30 |
| 467 | Perforated Peptic Ulcer Disease: A Review of History and Treatment. <i>Digestive Surgery</i> , 2010, 27, 161-169. | 0.6 | 197 |
| 469 | Ten-Day Sequential Therapy of <i>Helicobacter pylori</i> Infection in Thailand. <i>American Journal of Gastroenterology</i> , 2010, 105, 1071-1075. | 0.2 | 43 |
| 471 | Diagnosis, management and treatment of chronic Chagasâ€™ gastrointestinal disease in areas where <i>Trypanosoma cruzi</i> infection is not endemic. <i>Gastroenterology and Hepatology</i> , 2010, 33, 191-200. | 0.2 | 71 |
| 472 | Detection of <i>Helicobacter pylori</i> and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 213-219. | 0.8 | 32 |
| 473 | Two-decade trends in primary <i>Helicobacter pylori</i> resistance to antibiotics in Bulgaria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 319-326. | 0.8 | 26 |
| 474 | Comparative evaluation of 3 selective media for primary isolation of <i>Helicobacter pylori</i> from gastric biopsies under routine conditions. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 474-476. | 0.8 | 12 |
| 475 | Co-infection with two emergent old pathogens: <i>Trypanosoma cruzi</i> and <i>Helicobacter pylori</i> . <i>Enfermedades Infecciosas y Microbiología Clínica</i> , 2010, 28, 751-752. | 0.3 | 7 |
| 476 | Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for <i>Helicobacter pylori</i> eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. <i>European Journal of Internal Medicine</i> , 2010, 21, 310-314. | 1.0 | 26 |
| 477 | Treatment of <i>Helicobacter pylori</i> infection: The past and the future. <i>European Journal of Internal Medicine</i> , 2010, 21, 357-359. | 1.0 | 28 |
| 478 | Quadruple versus common triple-treatment regimens for <i>Helicobacter pylori</i> eradication in the Iranian population: A randomised study. <i>Arab Journal of Gastroenterology</i> , 2010, 11, 187-191. | 0.4 | 2 |
| 479 | Anti-adhesive effect of an acidic polysaccharide from <i>Aloe vera</i> L. var. <i>chinensis</i> (Haw.) Berger on the binding of <i>Helicobacter pylori</i> to the MKN-45 cell line. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 1753-1759. | 1.2 | 25 |
| 480 | <i>Helicobacter pylori</i> treatment in the era of increasing antibiotic resistance. <i>Gut</i> , 2010, 59, 1143-1153. | 6.1 | 821 |
| 481 | A Randomized Controlled Trial: Efficacy and Safety of Azithromycin, Ofloxacin, Bismuth, and Omeprazole Compared With Amoxicillin, Clarithromycin, Bismuth, and Omeprazole as Second-Line Therapy in Patients With <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2010, 15, 154-159. | 1.6 | 34 |
| 482 | Immunoglobulin G Antibody Against <i>Helicobacter pylori</i> Is an Accurate Test for Atrophic Gastritis. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 355-359. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 485 | Barrett esophagus: an update. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 369-378. | 8.2 | 28 |
| 487 | Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for <i>Helicobacter pylori</i> eradication: a randomised trial. <i>Gut</i> , 2010, 59, 1465-1470. | 6.1 | 132 |
| 488 | Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for <i>Helicobacter pylori</i> infection: a randomised comparative trial with crossover design. <i>Gut</i> , 2010, 59, 572-578. | 6.1 | 100 |
| 489 | Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of <i>H. pylori</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 36-41.e1. | 2.4 | 225 |
| 490 | Probiotics and <i>H. pylori</i> Infection. , 2010, , 259-265. | | 0 |
| 491 | Management of <i>Helicobacter pylori</i> infection. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 887-892. | 2.0 | 8 |
| 492 | Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 481-493. | 1.0 | 36 |
| 493 | Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant <i>Helicobacter pylori</i> : A Clinical Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 817-820.e3. | 2.4 | 79 |
| 494 | Optimal Management of Peptic Ulcer Disease in the Elderly. <i>Drugs and Aging</i> , 2010, 27, 545-558. | 1.3 | 47 |
| 495 | Antibiotic resistance of <i>Helicobacter pylori</i> in Israeli children. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 550-555. | 0.6 | 26 |
| 496 | Treatment of gastric marginal zone lymphoma of MALT type. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2141-2152. | 0.9 | 16 |
| 497 | Pathogenesis, Laboratory, and Clinical Characteristics of <i>Helicobacter pylori</i> -Associated Immune Thrombocytopenic Purpura. <i>Advances in Clinical Chemistry</i> , 2010, 52, 131-144. | 1.8 | 4 |
| 498 | Effect of <i>Helicobacter pylori</i> Infection and Its Eradication on Reflux Esophagitis and Reflux Symptoms. <i>American Journal of Gastroenterology</i> , 2010, 105, 2153-2162. | 0.2 | 62 |
| 499 | Therapeutic strategies for the treatment of dyspepsia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2517-2525. | 0.9 | 4 |
| 500 | Manage peptic ulcer disease in the elderly with proton pump inhibitors and additional measures as needed. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 9-11. | 0.3 | 0 |
| 502 | The Prevalence and Incidence of <i>Helicobacter pylori</i> -Associated Peptic Ulcer Disease and Upper Gastrointestinal Bleeding Throughout the World. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 613-635. | 0.6 | 73 |
| 503 | Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to <i>Helicobacter pylori</i> in southern Poland. <i>Pharmacological Reports</i> , 2011, 63, 799-807. | 1.5 | 22 |
| 504 | Recent trends in primary antimicrobial resistance of <i>Helicobacter pylori</i> in Finland. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 22-25. | 1.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 506 | <i>Helicobacter pylori</i> molecular diagnosis. Expert Review of Molecular Diagnostics, 2011, 11, 351-355. | 1.5 | 21 |
| 507 | Guidelines for treatment of <i>Helicobacter pylori</i> in the East and West. Expert Review of Anti-Infective Therapy, 2011, 9, 581-588. | 2.0 | 21 |
| 508 | Peptic Ulcer Disease. Primary Care - Clinics in Office Practice, 2011, 38, 383-394. | 0.7 | 89 |
| 509 | Correlation between creatinine clearance and <i>Helicobacter pylori</i> infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. Arab Journal of Gastroenterology, 2011, 12, 150-153. | 0.4 | 11 |
| 510 | Suspicion of macrolide allergy after treatment of infectious diseases including <i>Helicobacter pylori</i> : Results of allergological testing. Allergologia Et Immunopathologia, 2011, 39, 193-199. | 1.0 | 32 |
| 511 | Practical use of GenoType [®] HelicoDR, a molecular test for <i>Helicobacter pylori</i> detection and susceptibility testing. Diagnostic Microbiology and Infectious Disease, 2011, 70, 557-560. | 0.8 | 39 |
| 513 | Role of <i>Helicobacter pylori</i> virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiology, 2011, 6, 843-846. | 1.0 | 27 |
| 514 | Treatment of <i>Helicobacter pylori</i> infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microbial Pathogenesis, 2011, 51, 366-372. | 1.3 | 41 |
| 516 | Gastric lymphoma: The histology report. Digestive and Liver Disease, 2011, 43, S310-S318. | 0.4 | 25 |
| 518 | <i>Helicobacter pylori</i> eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet, The, 2011, 377, 905-913. | 6.3 | 458 |
| 519 | 14-day triple, 5-day concomitant, and 10-day sequential therapies for <i>Helicobacter pylori</i> infection in seven Latin American sites: a randomised trial. Lancet, The, 2011, 378, 507-514. | 6.3 | 239 |
| 520 | <i>Helicobacter pylori</i> eradication – Author's reply. Lancet, The, 2011, 378, 314. | 6.3 | 1 |
| 521 | Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in <i>Helicobacter pylori</i> Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial. Journal of Korean Medical Science, 2011, 26, 785. | 1.1 | 28 |
| 523 | Prevalence of <i>Helicobacter pylori</i> among Nigerian patients with dyspepsia in Ibadan. Pan African Medical Journal, 2011, 6, . | 0.3 | 37 |
| 524 | Stomach cancer screening and preventive behaviors in relatives of gastric cancer patients. World Journal of Gastroenterology, 2011, 17, 3518. | 1.4 | 19 |
| 525 | <i>Helicobacter pylori</i> Infection and Extraintestinal Manifestations in Children. Korean Journal of Pediatric Gastroenterology and Nutrition, 2011, 14, S1. | 0.2 | 1 |
| 526 | Approach to Role of Capsaicin - Sensitive Afferent Nerves in the Development and Healing in Patients with Chronic Gastritis. , 0, , . | | 3 |
| 527 | Oxidative Stress Involved Autophagy and Apoptosis in <i>Helicobacter pylori</i> Related Gastritis. , 0, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 528 | Inhibitory and Bactericidal Potential of Crude Acetone Extracts of <i>Combretum molle</i> (Combretaceae) on Drug-resistant Strains of <i>Helicobacter pylori</i> . Journal of Health, Population and Nutrition, 2011, 29, 438-45. | 0.7 | 22 |
| 529 | Efficacy, Tolerability, and Factors Affecting the Efficacy of the Sequential Therapy in Curing <i>Helicobacter Pylori</i> Infection in Clinical Setting. Journal of Investigative Medicine, 2011, 59, 917-920. | 0.7 | 16 |
| 530 | <i>Helicobacter pylori</i> antibiotic resistance in Brazil: clarithromycin is still a good option. Arquivos De Gastroenterologia, 2011, 48, 261-264. | 0.3 | 42 |
| 531 | Mechanisms of <i>Helicobacter pylori</i> antibiotic resistance: An updated appraisal. World Journal of Gastrointestinal Pathophysiology, 2011, 2, 35. | 0.5 | 113 |
| 532 | <i>Helicobacter pylori</i> Has an Inverse Relationship With Severity of Reflux Esophagitis. Journal of Neurogastroenterology and Motility, 2011, 17, 209-210. | 0.8 | 6 |
| 533 | Antimicrobial susceptibility of <i>Helicobacter pylori</i> with chronic gastritis. Biomedica, 2011, 32, . | 0.3 | 6 |
| 535 | The Human Gastric Pathogen <i>Helicobacter pylori</i> and Its Association with Gastric Cancer and Ulcer Disease. Ulcers, 2011, 2011, 1-23. | 1.0 | 90 |
| 536 | <i>Helicobacter pylori</i> Infection: Is Sequential Therapy Superior to Standard Triple Therapy? A Single-Centre Italian Study in Treatment-Naive and Non-Treatment-Naive Patients. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 315-318. | 1.8 | 19 |
| 537 | Bovine Antibody-Based Oral Immunotherapy for Reduction of Intra-gastric <i>Helicobacter pylori</i> Colonization: A Randomized Clinical Trial. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 207-213. | 1.8 | 11 |
| 538 | <i>Helicobacter Pylori</i> Infection in Peptic Ulcer Disease. , 2011, , . | | 2 |
| 539 | Second-Line Levofloxacin-Based Triple Therapy's Efficiency for <i>Helicobacter pylori</i> Eradication in Patients With Peptic Ulcer. Southern Medical Journal, 2011, 104, 579-583. | 0.3 | 12 |
| 540 | Evidence-based Guidelines From ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> Infection in Children. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 230-243. | 0.9 | 269 |
| 541 | <i>Helicobacter pylori</i> Infection. Medicine (United States), 2011, 90, 180-185. | 0.4 | 41 |
| 542 | Is Culture Necessary before First-Line Treatment for <i>Helicobacter pylori</i> Infection?. Internal Medicine, 2011, 50, 2719-2720. | 0.3 | 2 |
| 543 | Pharmacogenomics Associated with Therapy for Acid-Related Disorders. , 0, , 175-187. | | 0 |
| 544 | Is Culture Necessary before First-line Treatment for <i>Helicobacter pylori</i> Infection?. Internal Medicine, 2011, 50, 2717-2717. | 0.3 | 17 |
| 546 | Randomized Comparison of Two Nonbismuth-Containing Rescue Therapies for <i>Helicobacter pylori</i> . American Journal of the Medical Sciences, 2011, 342, 177-181. | 0.4 | 16 |
| 547 | Comparison of Two Different Treatment Protocols in <i>Helicobacter pylori</i> Eradication. Southern Medical Journal, 2011, 104, 102-105. | 0.3 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 548 | Aspirin: Old drug, new uses and challenges*. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 426-431. | 1.4 | 42 |
| 549 | Sequential therapy in clarithromycin-sensitive and -resistant <i>Helicobacter pylori</i> based on polymerase chain reaction molecular test. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 825-828. | 1.4 | 43 |
| 550 | <i>Helicobacter pylori</i> infection and histological changes in siblings of young gastric cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1157-1163. | 1.4 | 22 |
| 551 | Resistance of <i>Helicobacter pylori</i> to quinolones and clarithromycin assessed by genetic testing in Japan. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1457-1461. | 1.4 | 36 |
| 552 | Remission of high-grade B-cell lymphoma in a pediatric patient following <i>Helicobacter pylori</i> eradication. Pediatrics International, 2011, 53, 105-107. | 0.2 | 10 |
| 553 | Review article: non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . Alimentary Pharmacology and Therapeutics, 2011, 34, 604-617. | 1.9 | 145 |
| 554 | Review article: common misconceptions in the management of <i>Helicobacter pylori</i> -associated gastric MALT-lymphoma. Alimentary Pharmacology and Therapeutics, 2011, 34, 1047-1062. | 1.9 | 59 |
| 555 | Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for <i>Helicobacter pylori</i> in Korea. Alimentary Pharmacology and Therapeutics, 2011, 34, 1098-1105. | 1.9 | 61 |
| 556 | Review article: the effectiveness of standard triple therapy for <i>Helicobacter pylori</i> has not changed over the last decade, but it is not good enough. Alimentary Pharmacology and Therapeutics, 2011, 34, 1255-1268. | 1.9 | 114 |
| 557 | Age and gender differences in urea breath test results. European Journal of Clinical Investigation, 2011, 41, 767-772. | 1.7 | 13 |
| 558 | <i>Helicobacter pylori</i> and autoimmune diseases. Oral Diseases, 2011, 17, 621-627. | 1.5 | 57 |
| 559 | <i>Helicobacter pylori</i> infection and peptic ulcers. Medicine, 2011, 39, 154-161. | 0.2 | 9 |
| 560 | <i>Helicobacter pylori</i> Chronic Gastritis in Children: To Eradicate or Not to Eradicate?. Journal of Pediatrics, 2011, 159, 50-56. | 0.9 | 19 |
| 561 | Sequential therapy in childhood <i>Helicobacter pylori</i> eradication: emphasis on drug compliance. Journal of Pediatrics, 2011, 159, 700. | 0.9 | 8 |
| 563 | Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy for <i>Helicobacter pylori</i> Eradication. Pharmacotherapy, 2011, 31, 227-238. | 1.2 | 41 |
| 564 | <i>Helicobacter pylori</i> infection and systemic sclerosis—is there a link?. Joint Bone Spine, 2011, 78, 337-340. | 0.8 | 29 |
| 565 | <i>Helicobacter pylori</i> in Childhood. , 2011, , 293-308.e10. | | 3 |
| 566 | Frequency of antibiotic resistance in <i>Helicobacter pylori</i> strains isolated from the northern population of Iran. Journal of Microbiology, 2011, 49, 987-993. | 1.3 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 567 | Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Internal and Emergency Medicine, 2011, 6, 35-39. | 1.0 | 11 |
| 568 | Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter, 2011, 16, 47-51. | 1.6 | 31 |
| 569 | Moxifloxacin-Tetracycline-Lansoprazole Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Prospective Study. Helicobacter, 2011, 16, 52-54. | 1.6 | 5 |
| 570 | An Alternative, Sensitive Method to Detect <i>Helicobacter pylori</i> DNA in Feces. Helicobacter, 2011, 16, 113-118. | 1.6 | 4 |
| 571 | Levofloxacin Susceptibility Testing for <i>Helicobacter pylori</i> in China: Comparison of E-test and Disk Diffusion Method. Helicobacter, 2011, 16, 119-123. | 1.6 | 18 |
| 572 | The Association Between <i>Helicobacter pylori</i> Infection and Insulin Resistance: A Systematic Review. Helicobacter, 2011, 16, 79-88. | 1.6 | 175 |
| 573 | A New Modified Concomitant Therapy for Helicobacter pylori Eradication in Turkey. Helicobacter, 2011, 16, 225-228. | 1.6 | 28 |
| 574 | Moxifloxacin-Containing Triple Therapy versus Bismuth-Containing Quadruple Therapy for Second-Line Treatment of <i>Helicobacter pylori</i> Infection: A Meta-Analysis. Helicobacter, 2011, 16, 131-138. | 1.6 | 33 |
| 575 | Modified Sequential <i>Helicobacter pylori</i> Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days. Helicobacter, 2011, 16, 139-145. | 1.6 | 160 |
| 576 | Is There a Benefit to Extending the Duration of <i>Helicobacter pylori</i> Sequential Therapy to 14 Days?. Helicobacter, 2011, 16, 146-152. | 1.6 | 50 |
| 577 | The Role of <i>Helicobacter pylori</i> in Patients with Hypothyroidism in Whom Could Not be Achieved Normal Thyrotropin Levels Despite Treatment with High Doses of Thyroxine. Helicobacter, 2011, 16, 124-130. | 1.6 | 30 |
| 578 | High Eradication Rates of Helicobacter pylori Infection Following Sequential Therapy: The Israeli Experience Treating Naïve Patients. Helicobacter, 2011, 16, 229-233. | 1.6 | 18 |
| 579 | Mutations of Helicobacter pylori Associated with Fluoroquinolone Resistance in Korea. Helicobacter, 2011, 16, 301-310. | 1.6 | 43 |
| 580 | Efficacy of 2-Week, Second-Line Helicobacter pylori Eradication Therapy Using Rabeprazole, Amoxicillin, and Metronidazole for the Japanese Population. Helicobacter, 2011, 16, 234-240. | 1.6 | 26 |
| 581 | Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy. Helicobacter, 2011, 16, 289-294. | 1.6 | 50 |
| 582 | Effects of Helicobacter pylori Eradication on Gastroesophageal Reflux Disease. Helicobacter, 2011, 16, 255-265. | 1.6 | 59 |
| 583 | Quadruple Therapy with Medications Containing Either Rifaximin or Furazolidone as a Rescue regimen in the Treatment of Helicobacter pylori-Infected Dyspepsia Patients: A Randomized Pilot Study. Helicobacter, 2011, 16, 284-288. | 1.6 | 17 |
| 584 | Primary Antibiotic Resistance of Helicobacter pylori Isolated from Beijing Children. Helicobacter, 2011, 16, 356-362. | 1.6 | 65 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 585 | Twice-a-Day Bismuth-Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14 Days. <i>Helicobacter</i> , 2011, 16, 295-300. | 1.6 | 60 |
| 586 | Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection. <i>Helicobacter</i> , 2011, 16, 420-426. | 1.6 | 49 |
| 587 | Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple Therapy. <i>Helicobacter</i> , 2011, 16, 410-414. | 1.6 | 18 |
| 588 | First-time Urea Breath Tests Performed at Home by 36,629 Patients: A Study of Helicobacter pylori Prevalence in Primary Care. <i>Helicobacter</i> , 2011, 16, 468-474. | 1.6 | 17 |
| 589 | <i>Helicobacter pylori</i> and Nonmalignant Diseases. <i>Helicobacter</i> , 2011, 16, 33-37. | 1.6 | 41 |
| 590 | Treatment of <i>Helicobacter pylori</i> Infection 2011. <i>Helicobacter</i> , 2011, 16, 53-58. | 1.6 | 45 |
| 591 | Helicobacter, peptic ulcers and men's health. <i>Trends in Urology & Men's Health</i> , 2011, 2, 23-26. | 0.2 | 0 |
| 592 | Adverse Effects of Long-Term Proton Pump Inhibitor Therapy. <i>Digestive Diseases and Sciences</i> , 2011, 56, 931-950. | 1.1 | 255 |
| 593 | Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. <i>Journal of Gastroenterology</i> , 2011, 46, 991-997. | 2.3 | 20 |
| 594 | Gastric carcinogenesis. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 729-742. | 0.8 | 41 |
| 595 | Efficacy of serology driven test and treat strategy for eradication of H. pylori in patients with rheumatic disease in the Netherlands. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 903-908. | 1.3 | 0 |
| 598 | Proton pump inhibitors: use, misuse and concerns about long-term therapy. <i>Clinical Journal of Gastroenterology</i> , 2011, 4, 53-59. | 0.4 | 5 |
| 600 | Helicobacter pylori negative, non-steroidal anti-inflammatory drug-negative peptic ulcers in India. <i>Indian Journal of Gastroenterology</i> , 2011, 30, 33-37. | 0.7 | 18 |
| 601 | Helicobacter pylori Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery: Fourteen Days Superior to Seven Days?. <i>Obesity Surgery</i> , 2011, 21, 1377-1381. | 1.1 | 12 |
| 602 | Gastric Infection by Helicobacter pylori. <i>Current Gastroenterology Reports</i> , 2011, 13, 540-546. | 1.1 | 87 |
| 603 | Enfermedades relacionadas con Helicobacter pylori: dispepsia, Úlcera y Cáncer gástrico. <i>Gastroenterología Y Hepatología</i> , 2011, 34, 16-27. | 0.2 | 7 |
| 604 | DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. <i>BMC Gastroenterology</i> , 2011, 11, 112. | 0.8 | 69 |
| 605 | The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. <i>BMC Gastroenterology</i> , 2011, 11, 37. | 0.8 | 92 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 606 | Effect of eradication of <i>Helicobacter pylori</i> in children with chronic immune thrombocytopenia: A prospective, controlled, multicenter study. <i>Pediatric Blood and Cancer</i> , 2011, 56, 273-278. | 0.8 | 57 |
| 607 | <i>H. pylori</i> cagL amino acid sequence polymorphism Y58E59 induces a corpus shift of gastric integrin $\alpha 5\beta 1$ related with gastric carcinogenesis. <i>Molecular Carcinogenesis</i> , 2011, 50, 751-759. | 1.3 | 42 |
| 608 | 5-Nitroimidazole-based 1,3,4-thiadiazoles: Heterocyclic Analogs of Metronidazole as Anti- <i>Helicobacter pylori</i> Agents. <i>Archiv Der Pharmazie</i> , 2011, 344, 178-183. | 2.1 | 29 |
| 609 | A Clinician's Guide to Salvage Therapy for Persistent <i>Helicobacter pylori</i> Infection. <i>Hospital Practice (1995)</i> , 2011, 39, 133-140. | 0.5 | 5 |
| 610 | Crude Ethanolic Extracts of <i>Garcinia kola</i> Seeds Heckel (Guttiferae) Prolong the Lag Phase of <i>Helicobacter pylori</i> : Inhibitory and Bactericidal Potential. <i>Journal of Medicinal Food</i> , 2011, 14, 822-827. | 0.8 | 15 |
| 611 | Genotypic Resistance in <i>Helicobacter pylori</i> Strains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1123-1129. | 1.4 | 61 |
| 612 | Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with <i>Helicobacter pylori</i> . <i>Gut</i> , 2011, 60, 624-630. | 6.1 | 76 |
| 613 | Multicenter Survey of Routine Determinations of Resistance of <i>Helicobacter pylori</i> to Antimicrobials over the Last 20 Years (1990 to 2009) in Belgium. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2200-2209. | 1.8 | 70 |
| 614 | The Intriguing Relationship of <i>Helicobacter pylori</i> Infection and Acid Secretion in Peptic Ulcer Disease and Gastric Cancer. <i>Digestive Diseases</i> , 2011, 29, 459-464. | 0.8 | 76 |
| 615 | Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for <i>Helicobacter pylori</i> infection: a multicentre clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1847-1852. | 1.3 | 46 |
| 616 | Eradication of <i>Helicobacter pylori</i> Infection Aids with the Outcome of Motion Sickness Adaptation. <i>Audiology and Neuro-Otology</i> , 2011, 16, 164-167. | 0.6 | 2 |
| 617 | Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of <i>Helicobacter pylori</i> in Turkey. <i>Libyan Journal of Medicine</i> , 2011, 6, 8412. | 0.8 | 8 |
| 618 | Gastric Atrophy Reversible or Irreversible after <i>Helicobacter pylori</i> Eradication – An Open Question. <i>Digestion</i> , 2011, 83, 250-252. | 1.2 | 9 |
| 619 | <i>Helicobacter pylori</i> Therapy in Children: A Focus on Proton Pump Inhibitors. <i>Chemotherapy</i> , 2011, 57, 85-93. | 0.8 | 4 |
| 620 | <i>Helicobacter pylori</i> Eradication by Sitafloxacin-Lansoprazole Combination and Sitafloxacin Pharmacokinetics in Mongolian Gerbils and Its <i>In Vitro</i> Activity and Resistance Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4261-4266. | 1.4 | 5 |
| 621 | Treatment of <i>Helicobacter pylori</i> . <i>Current Opinion in Gastroenterology</i> , 2011, 27, 565-570. | 1.0 | 51 |
| 622 | EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. <i>Gut</i> , 2011, 60, 747-758. | 6.1 | 305 |
| 623 | Reliability of Diagnostic Tests for <i>Helicobacter pylori</i> Infection. <i>Gastroenterology Research and Practice</i> , 2011, 2011, 1-6. | 0.7 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 624 | Helicobacter pylori Eradication in Functional Dyspepsia. Archives of Internal Medicine, 2011, 171, 1929. | 4.3 | 137 |
| 625 | Esophageal Adenocarcinoma Developing after Eradication of Helicobacter pylori. Case Reports in Gastroenterology, 2011, 5, 355-360. | 0.3 | 10 |
| 626 | High frequency of ulcers, not associated with Helicobacter pylori, in the stomach in the first year after kidney transplantation. Nephrology Dialysis Transplantation, 2011, 26, 727-732. | 0.4 | 20 |
| 627 | Does Long-Term Aspirin Use Have Any Effect On Helicobacter pylori Eradication?. American Journal of the Medical Sciences, 2011, 342, 15-19. | 0.4 | 9 |
| 628 | New Effective Treatment Regimen for Children Infected With a Double-Resistant Helicobacter pylori Strain. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 424-428. | 0.9 | 36 |
| 629 | A new, single-capsule bismuth-containing quadruple therapy. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 307-309. | 8.2 | 26 |
| 630 | A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline versus Triple Therapy for the Eradication of Helicobacter pylori. American Journal of Gastroenterology, 2011, 106, 1970-1975. | 0.2 | 89 |
| 631 | Consensus Guidelines: Method or Madness?. American Journal of Gastroenterology, 2011, 106, 225-227. | 0.2 | 13 |
| 632 | Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication?. Expert Review of Clinical Pharmacology, 2011, 4, 579-582. | 1.3 | 3 |
| 633 | Should quinolones come first in Helicobacter pylori therapy?. Therapeutic Advances in Gastroenterology, 2011, 4, 103-114. | 1.4 | 51 |
| 634 | Aqueous and Organic Solvent-Extracts of Selected South African Medicinal Plants Possess Antimicrobial Activity against Drug-Resistant Strains of Helicobacter pylori: Inhibitory and Bactericidal Potential. International Journal of Molecular Sciences, 2011, 12, 5652-5665. | 1.8 | 32 |
| 635 | Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Gut, 2011, 60, 567-568. | 6.1 | 20 |
| 636 | Helicobacter pylori Perturbs Iron Trafficking in the Epithelium to Grow on the Cell Surface. PLoS Pathogens, 2011, 7, e1002050. | 2.1 | 143 |
| 637 | In vitro activity of DX-619, a des-F(6)-quinolone, against Helicobacter pylori. Journal of Antimicrobial Chemotherapy, 2011, 66, 220-222. | 1.3 | 0 |
| 638 | Synthesis and biological activity of 5-nitrofuranyl-containing (1,3,4-thiadiazol-2-yl)piperazine moieties as a new type of anti-Helicobacter pylori heterocycles. Journal of the Serbian Chemical Society, 2011, 76, 201-210. | 0.4 | 2 |
| 639 | Bacterial Load and Degree of Gastric Mucosal Inflammation in Helicobacter pylori Infection. Digestive Diseases, 2011, 29, 592-599. | 0.8 | 17 |
| 640 | Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterology Research and Practice, 2012, 2012, 1-6. | 0.7 | 64 |
| 641 | Morphologic and Pharmacological Investigations in the Epicatechin Gastroprotective Effect. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-8. | 0.5 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 642 | Efficacy of a "Rescue" Ciprofloxacin-Based Regimen for Eradication of <i>Helicobacter pylori</i> Infection after Treatment Failures. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-5. | 0.7 | 11 |
| 643 | Rescue Therapy for <i>Helicobacter pylori</i> Infection 2012. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-12. | 0.7 | 34 |
| 644 | 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for <i>Helicobacter pylori</i> in Taiwan. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6. | 0.7 | 10 |
| 645 | Variability in Prevalence of <i>Helicobacter pylori</i> Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-7. | 0.7 | 19 |
| 646 | Comparing Multiplex PCR and Rapid Urease Test in the Detection of <i>H. pylori</i> in Patients on Proton Pump Inhibitors. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-5. | 0.7 | 16 |
| 647 | <i>Helicobacter pylori</i> Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-9. | 0.7 | 32 |
| 648 | PLATELET COUNT RESPONSE TO HELICOBACTER PYLORI ERADICATION IN IRANIAN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012056. | 0.5 | 20 |
| 649 | Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). <i>Endoscopy</i> , 2012, 44, 74-94. | 1.0 | 594 |
| 652 | The importance of <i>Helicobacter pylori</i> 's genetic variability for the construction of an efficient vaccine. , 2012, , . | | 0 |
| 653 | Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 136-147. | 0.6 | 136 |
| 654 | Gastroduodenal Lesions in Peritoneal Dialysis Patients: The Role of <i>Helicobacter Pylon</i> Infection. <i>Nephrology Research & Reviews</i> , 2012, 4, 12-17. | 0.2 | 1 |
| 655 | <i>Helicobacter pylori</i> Eradication Therapy: Current Availabilities. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-8. | 1.5 | 25 |
| 656 | Eradication Treatment of <i>Helicobacter pylori</i> Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-9. | 1.5 | 18 |
| 657 | The Optimal First-Line Therapy of <i>Helicobacter pylori</i> Infection in Year 2012. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8. | 0.7 | 34 |
| 658 | Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for <i>Helicobacter pylori</i> Eradication in Taiwanese Population. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-5. | 0.7 | 1 |
| 659 | Distribution of Spontaneous <i>gyrA</i> Mutations in 97 Fluoroquinolone-Resistant <i>Helicobacter pylori</i> Isolates Collected in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 550-551. | 1.4 | 44 |
| 660 | Antimicrobial susceptibility of <i>Helicobacter pylori</i> to six antibiotics currently used in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 170-173. | 1.3 | 66 |
| 661 | Prevalencia de <i>Helicobacter pylori</i> en escolares: factores nutricionales y socio-culturales en Bogotá. <i>Pediatría</i> , 2012, 45, 81-93. | 0.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 662 | Time trends of primary antibiotic resistance of <i>Helicobacter pylori</i> isolates in Southern Croatia. <i>Journal of Chemotherapy</i> , 2012, 24, 182-184. | 0.7 | 6 |
| 663 | <i>Helicobacter pylori</i> -associated gastroenterological diseases: genetic features and probiotic treatment. <i>Beneficial Microbes</i> , 2012, 3, 157-161. | 1.0 | 6 |
| 664 | Comparison of Sequential and Standard Therapy for <i>Helicobacter pylori</i> Eradication in Children and Investigation of Clarithromycin Resistance. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 530-533. | 0.9 | 11 |
| 669 | Gastric intraepithelial neoplasia in a Western population. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 48-54. | 0.8 | 21 |
| 670 | A Rapid Continuous-real-time ¹³ C-Urea Breath Test for the Detection of <i>Helicobacter pylori</i> in Patients After Partial Gastrectomy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 293-296. | 1.1 | 13 |
| 671 | Dyspepsia. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 175-190. | 1.1 | 108 |
| 672 | Diagnostic Performance of Urea Breath Test, Rapid Urea Test, and Histology for <i>Helicobacter pylori</i> Infection in Patients With Partial Gastrectomy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 285-292. | 1.1 | 46 |
| 673 | Predicting <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 259-261. | 1.1 | 28 |
| 674 | Efficacy of a therapeutic strategy for eradication of <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2012, 18, 4542. | 1.4 | 10 |
| 675 | Comparison of sequential and 7-, 10-, 14-d triple therapy for <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2012, 18, 2377. | 1.4 | 55 |
| 676 | A Multicenter Prospective Observational Study of Triple Therapy with Rabeprazole, Amoxicillin and Metronidazole for <i>Helicobacter pylori</i> in Japan. <i>Internal Medicine</i> , 2012, 51, 3103-3108. | 0.3 | 7 |
| 677 | <i>Helicobacter pylori</i> eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. <i>Blood</i> , 2012, 119, 4838-4844. | 0.6 | 123 |
| 678 | Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 1029-1039. | 1.4 | 39 |
| 681 | Protocolo de seguimiento de la infección por <i>Helicobacter pylori</i> . <i>Medicine</i> , 2012, 11, 131-134. | 0.0 | 0 |
| 682 | <i>Helicobacter pylori</i> and Nonmalignant Diseases. <i>Helicobacter</i> , 2012, 17, 22-25. | 1.6 | 9 |
| 683 | Eradication of <i>Helicobacter pylori</i> Infection by the Probiotic Strains <i>Lactobacillus johnsonii</i> MH68 and <i>Salivarius</i> ssp. <i>salicinius</i> AP32. <i>Helicobacter</i> , 2012, 17, 466-477. | 1.6 | 61 |
| 684 | Levofloxacin-containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment for <i>Helicobacter pylori</i> Eradication in China. <i>Helicobacter</i> , 2012, 17, 478-485. | 1.6 | 34 |
| 685 | Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 959-971. | 1.9 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 686 | In Vivo Measurement of Helicobacter pylori Infection. <i>Methods in Molecular Biology</i> , 2012, 921, 239-256. | 0.4 | 11 |
| 688 | Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2254-2259. | 1.3 | 20 |
| 689 | Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible <i>Helicobacter pylori</i> and versus Sequential Therapy for Clarithromycin-Resistant Strains. <i>Helicobacter</i> , 2012, 17, 269-276. | 1.6 | 79 |
| 690 | Einem Leib- und Magenfeind zum Abschied. <i>Chemie in Unserer Zeit</i> , 2012, 46, 378-387. | 0.1 | 1 |
| 691 | The Stomach. , 2012, , 1791-1797. | | 0 |
| 692 | Clinically Significant Endoscopic Findings in a Multi-Ethnic Population With Uninvestigated Dyspepsia. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3205-3212. | 1.1 | 19 |
| 693 | Ten-day sequential versus triple therapy for <i>Helicobacter pylori</i> eradication: a prospective, open-label, randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1675-1680. | 1.4 | 61 |
| 694 | High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for <i>Helicobacter pylori</i> treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1097-1102. | 1.9 | 28 |
| 695 | <i>Helicobacter pylori</i> Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy. <i>Helicobacter</i> , 2012, 17, 254-263. | 1.6 | 49 |
| 696 | Antibiotic resistance of Helicobacter pylori in pediatric patients - 10 years' experience. <i>European Journal of Pediatrics</i> , 2012, 171, 1325-1330. | 1.3 | 22 |
| 697 | Helicobacter pylori Infection and Nonsteroidal Anti-inflammatory Drug Use: Eradication, Acid-Reducing Therapy, or Both?. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 831-836. | 2.4 | 7 |
| 698 | 33-Year-Old Woman With Epigastric Pain and Hematemesis. <i>Mayo Clinic Proceedings</i> , 2012, 87, 194-197. | 1.4 | 0 |
| 699 | Su1735 Effects of Melatonin and Tryptophan on Healing of Gastric and Duodenal Ulcers With Helicobacter pylori Infection in Humans. <i>Gastroenterology</i> , 2012, 142, S-491. | 0.6 | 3 |
| 700 | Endoscopic Reflux Esophagitis and Helicobacter pylori Infection in Young Healthy Japanese Volunteers. <i>Digestion</i> , 2012, 86, 55-58. | 1.2 | 31 |
| 702 | Helicobacter pylori infection in patients with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2012, 21, 21-23. | 0.9 | 10 |
| 703 | Reply to comment on: The seroprevalence of Helicobacter pylori and its relationship to malaria in Ugandan children. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 330. | 0.7 | 0 |
| 704 | A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for <i>Helicobacter pylori</i> Eradication After Sequential Therapy Failure. <i>Helicobacter</i> , 2012, 17, 264-268. | 1.6 | 21 |
| 705 | Eradiation of <i>Helicobacter pylori</i> in Children in Vietnam in Relation to Antibiotic Resistance. <i>Helicobacter</i> , 2012, 17, 319-325. | 1.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 706 | Pilot Studies to Identify the Optimum Duration of Concomitant <i>Helicobacter pylori</i> Eradication Therapy in Thailand. <i>Helicobacter</i> , 2012, 17, 282-285. | 1.6 | 41 |
| 707 | The Efficacy of Second-Line Anti- <i>Helicobacter pylori</i> Therapy Using an Extended 14-Day Levofloxacin/Amoxicillin/Proton Pump Inhibitor Treatment – A Pilot Study. <i>Helicobacter</i> , 2012, 17, 374-381. | 1.6 | 68 |
| 708 | <i>Helicobacter Pylori</i> Breath Testing in an Open Access System has a High Rate of Potentially False Negative Results due to Protocol Violations. <i>Helicobacter</i> , 2012, 17, 391-395. | 1.6 | 5 |
| 709 | <i>Helicobacter pylori</i> Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. <i>Helicobacter</i> , 2012, 17, 458-465. | 1.6 | 15 |
| 710 | Optimal Biopsy Site for <i>Helicobacter pylori</i> Detection during Endoscopic Mucosectomy in Patients with Extensive Gastric Atrophy. <i>Helicobacter</i> , 2012, 17, 405-410. | 1.6 | 23 |
| 711 | Interaction of <i>Helicobacter pylori</i> infection and low-dose aspirin in the upper gastrointestinal tract: Implications for clinical practice. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 163-172. | 1.0 | 19 |
| 712 | Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of <i>Helicobacter pylori</i> . <i>European Journal of Internal Medicine</i> , 2012, 23, 165-168. | 1.0 | 28 |
| 713 | Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding. <i>European Journal of Internal Medicine</i> , 2012, 23, 227-230. | 1.0 | 6 |
| 714 | The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. <i>Dalton Transactions</i> , 2012, 41, 13239. | 1.6 | 100 |
| 715 | Absence of <i>Helicobacter pylori</i> high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. <i>BMC Gastroenterology</i> , 2012, 12, 49. | 0.8 | 4 |
| 716 | Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm?. <i>Infectious Agents and Cancer</i> , 2012, 7, 18. | 1.2 | 12 |
| 717 | Evaluation of <i>Helicobacter Pylori</i> eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. <i>Italian Journal of Pediatrics</i> , 2012, 38, 63. | 1.0 | 48 |
| 718 | Rabeprazole for the treatment of acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 423-435. | 1.4 | 23 |
| 719 | Recent Insights into Antibiotic Resistance in <i>Helicobacter pylori</i> Eradication. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8. | 0.7 | 88 |
| 720 | Randomized Comparison of Two Non-Bismuth-Containing Second-Line Rescue Therapies for <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2012, 17, 216-223. | 1.6 | 39 |
| 721 | Comparison of Lafutidine and Rabeprazole in 7-day Second-Line Amoxicillin and Metronidazole-Containing Triple Therapy for <i>Helicobacter pylori</i> : A Pilot Study. <i>Helicobacter</i> , 2012, 17, 277-281. | 1.6 | 13 |
| 722 | <i>Helicobacter pylori</i> Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate. <i>Helicobacter</i> , 2012, 17, 246-253. | 1.6 | 36 |
| 723 | Therapeutic Management of Recurrent Peptic Ulcer Disease. <i>Drugs</i> , 2012, 72, 1605-1616. | 4.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-------|-----------|
| 724 | Cancer-related risk factors and preventive measures in US Hispanics/Latinos. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 353-363. | 157.7 | 46 |
| 726 | Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2012, 143, 55-61.e1. | 0.6 | 81 |
| 728 | Lymphocytic duodenitis: Aetiology and long-term response to specific treatment. <i>Digestive and Liver Disease</i> , 2012, 44, 643-648. | 0.4 | 37 |
| 729 | Different Antibiotic No Culture Eradicating (DANCE) strategy: An easy way to manage <i>H. pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2012, 44, 889-892. | 0.4 | 10 |
| 730 | Anti- <i>Helicobacter pylori</i> antibodies and polycystic ovary syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 163, 243. | 0.5 | 4 |
| 732 | Diagnosis of <i>Helicobacter pylori</i> infection. <i>BMJ: British Medical Journal</i> , 2012, 344, e828-e828. | 2.4 | 27 |
| 733 | <i>Helicobacter pylori</i> therapy: Present and future. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2012, 3, 68. | 0.6 | 49 |
| 734 | <i>Helicobacter pylori</i> management in non-steroidal anti-inflammatory drug therapy patients in primary care. <i>Internal and Emergency Medicine</i> , 2012, 7, 331-335. | 1.0 | 7 |
| 735 | <i>Helicobacter pylori</i> management in primary care. <i>Internal and Emergency Medicine</i> , 2012, 7, 297-298. | 1.0 | 3 |
| 736 | Role of gastritis pattern on <i>Helicobacter pylori</i> eradication. <i>Internal and Emergency Medicine</i> , 2012, 7, 517-522. | 1.0 | 8 |
| 737 | Is <i>Helicobacter pylori</i> infection associated with Henoch-Schonlein purpura in Chinese children? a meta-analysis. <i>World Journal of Pediatrics</i> , 2012, 8, 301-308. | 0.8 | 33 |
| 739 | Management of <i>Helicobacter pylori</i> infection—the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012, 61, 646-664. | 6.1 | 2,023 |
| 740 | Additional corpus biopsy enhances the detection of <i>Helicobacter pylori</i> infection in a background of gastritis with atrophy. <i>BMC Gastroenterology</i> , 2012, 12, 182. | 0.8 | 42 |
| 741 | Determination of efficacy, adverse drug reactions and cost effectiveness of three triple drug regimens for the treatment of <i>Helicobacter pylori</i> infected acid peptic disease patients. <i>Asian Pacific Journal of Tropical Disease</i> , 2012, 2, S783-S789. | 0.5 | 17 |
| 742 | Update on non-bismuth quadruple (concomitant) therapy for eradication of <i>Helicobacter pylori</i> . <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 23. | 1.0 | 114 |
| 743 | Chromoendoscopy with red phenol in the diagnosis of <i>Helicobacter pylori</i> infection. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 04-09. | 0.1 | 7 |
| 744 | Predictive value of neutrophil infiltration as a marker of <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2012, 18, 5101. | 1.4 | 17 |
| 745 | Eradication of <i>Helicobacter pylori</i> increases childhood growth and serum acylated ghrelin levels. <i>World Journal of Gastroenterology</i> , 2012, 18, 2674. | 1.4 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 746 | Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for <i>Helicobacter pylori</i> Eradication. <i>Gut and Liver</i> , 2012, 6, 434-439. | 1.4 | 25 |
| 747 | Unusual Manifestation of Gastric <i>Helicobacter pylori</i> Infection. <i>Case Reports in Gastroenterology</i> , 2012, 6, 465-471. | 0.3 | 1 |
| 748 | Anti- <i>Helicobacter Pylori</i> Activities of Natural Isopentenylloxycinnamyl Derivatives from <i>Boronia Pinnata</i> . <i>Natural Product Communications</i> , 2012, 7, 1934578X1200701. | 0.2 | 3 |
| 749 | Newer agents for <i>Helicobacter pylori</i> eradication. <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 109. | 1.0 | 14 |
| 750 | Is <i>Helicobacter pylori</i> Eradication Effective in Managing Functional Dyspepsia?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2012, 59, 200. | 0.2 | 1 |
| 751 | The many faces of marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 426-432. | 0.9 | 69 |
| 752 | <i>Helicobacter pylori</i> eradication: A randomised comparative trial of 7-day versus 14-day triple therapy. <i>South African Medical Journal</i> , 2012, 102, 368. | 0.2 | 14 |
| 753 | Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 304-308. | 0.8 | 5 |
| 754 | <i>Helicobacter pylori</i> eradication: Sequential therapy and <i>Lactobacillus reuteri</i> supplementation. <i>World Journal of Gastroenterology</i> , 2012, 18, 6250. | 1.4 | 25 |
| 755 | Adjuvant probiotics improve the eradication effect of triple therapy for <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2012, 18, 6302. | 1.4 | 76 |
| 757 | Update on triple therapy for eradication of <i>Helicobacter pylori</i> : current status of the art. <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 151. | 1.0 | 25 |
| 758 | Metal organic frameworks for drug delivery and environmental remediation: A molecular docking approach. <i>International Journal of Quantum Chemistry</i> , 2012, 112, 3346-3355. | 1.0 | 47 |
| 759 | Micronutrients (Other than iron) and <i>Helicobacter pylori</i> Infection: A Systematic Review. <i>Helicobacter</i> , 2012, 17, 1-15. | 1.6 | 77 |
| 760 | Inverse Association Between <i>Helicobacter pylori</i> and Pediatric Asthma in a High Prevalence Population. <i>Helicobacter</i> , 2012, 17, 30-35. | 1.6 | 61 |
| 761 | A Comparison between Sequential Therapy and a Modified Bismuth-based Quadruple Therapy for <i>Helicobacter pylori</i> Eradication in Iran: A Randomized Clinical Trial. <i>Helicobacter</i> , 2012, 17, 43-48. | 1.6 | 30 |
| 762 | Evaluation of a Four-drug, Three-antibiotic, Nonbismuth-containing Concomitant Therapy as First-line <i>Helicobacter pylori</i> Eradication Regimen in Greece. <i>Helicobacter</i> , 2012, 17, 49-53. | 1.6 | 38 |
| 763 | Fluoroquinolone Resistance in <i>Helicobacter pylori</i> : Role of Mutations at Position 87 and 91 of GyrA on the Level of Resistance and Identification of a Resistance Conferring Mutation in GyrB. <i>Helicobacter</i> , 2012, 17, 36-42. | 1.6 | 76 |
| 764 | Maintenance of <i>Helicobacter pylori</i> Eradication Rates with Triple Therapy Over 12 Years in a Spanish hospital. <i>Helicobacter</i> , 2012, 17, 160-161. | 1.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 765 | Systematic Review and Meta-Analysis: <i>Helicobacter pylori</i> Eradication Therapy After Simple Closure of Perforated Duodenal Ulcer. <i>Helicobacter</i> , 2012, 17, 148-152. | 1.6 | 23 |
| 766 | Bismuth compounds in medicinal chemistry. <i>Future Medicinal Chemistry</i> , 2012, 4, 1495-1523. | 1.1 | 89 |
| 767 | Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. <i>Cancer</i> , 2012, 118, 4953-4960. | 2.0 | 50 |
| 768 | Impact of <i>Helicobacter pylori</i> Infection and Microscopic Duodenal Histopathological Changes on Clinical Symptoms of Patients with Functional Dyspepsia. <i>Digestive Diseases and Sciences</i> , 2012, 57, 967-972. | 1.1 | 31 |
| 769 | Accuracy of Urea Breath Test Performed Immediately After Emergency Endoscopy in Peptic Ulcer Bleeding. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1880-1886. | 1.1 | 14 |
| 770 | Inhibition of <i>H. pylori</i> colonization and prevention of gastritis in murine model. <i>World Journal of Microbiology and Biotechnology</i> , 2012, 28, 2513-2519. | 1.7 | 1 |
| 771 | <i>Helicobacter Pylori</i> Persistence in Children: Distinguishing Inadequate Treatment, Resistant Organisms, and Reinfection. <i>Current Gastroenterology Reports</i> , 2012, 14, 236-242. | 1.1 | 14 |
| 773 | A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for <i>Helicobacter pylori</i> eradication in Japan. <i>Journal of Gastroenterology</i> , 2012, 47, 276-283. | 2.3 | 24 |
| 774 | Detection of clarithromycin resistance in <i>Helicobacter pylori</i> following noncryogenic storage of rapid urease tests for 30 days. <i>Journal of Digestive Diseases</i> , 2012, 13, 54-59. | 0.7 | 25 |
| 775 | Seeking an optimal eradication therapy for <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 7-9. | 1.4 | 7 |
| 776 | Future candidates for indications of <i>Helicobacter pylori</i> eradication: Do the indications need to be revised?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 200-211. | 1.4 | 24 |
| 777 | Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for <i>Helicobacter pylori</i> infection in Korea. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 140-143. | 1.1 | 37 |
| 778 | Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for <i>Helicobacter pylori</i> infection in naïve patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 56-65. | 1.9 | 73 |
| 779 | Review article: rifabutin in the treatment of refractory <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 209-221. | 1.9 | 161 |
| 780 | Letter: the ethics of using inferior regimens in <i>H. pylori</i> randomised trials – invited comment. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 854-856. | 1.9 | 1 |
| 781 | Letter: the ethics of using inferior regimens in <i>H. pylori</i> randomised trials – invited comment. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 856-857. | 1.9 | 1 |
| 782 | Fourth-line rescue therapy with rifabutin in patients with three <i>Helicobacter pylori</i> eradication failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 941-947. | 1.9 | 57 |
| 783 | Review article: bismuth-based therapy for <i>Helicobacter pylori</i> eradication in children. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1010-1026. | 1.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 784 | Performance of individual <i>Helicobacter pylori</i> antigens in the immunoblot-based detection of <i>H. pylori</i> infection. <i>FEMS Immunology and Medical Microbiology</i> , 2012, 64, 352-363. | 2.7 | 9 |
| 785 | Anti- <i>Helicobacter pylori</i> activity of <i>Terminalia macroptera</i> root. <i>FIToterap</i> , 2012, 83, 872-876. | 1.1 | 30 |
| 786 | Supplementing Vitamins C and E to standard triple therapy for the eradication of <i>Helicobacter pylori</i> . <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 282-285. | 0.7 | 25 |
| 787 | Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. <i>International Journal of Clinical Practice</i> , 2012, 66, 767-773. | 0.8 | 76 |
| 788 | Lansoprazole-based sequential and concomitant therapy for the first-line <i>Helicobacter pylori</i> eradication. <i>Journal of Digestive Diseases</i> , 2012, 13, 232-238. | 0.7 | 64 |
| 789 | Extragastrintestinal manifestations of <i>Helicobacter pylori</i> infection: Facts or myth? A critical review. <i>Journal of Digestive Diseases</i> , 2012, 13, 342-349. | 0.7 | 81 |
| 790 | Laser-induced fluorescence integrated in a microfluidic immunosensor for quantification of human serum IgG antibodies to <i>Helicobacter pylori</i> . <i>Sensors and Actuators B: Chemical</i> , 2012, 168, 297-302. | 4.0 | 39 |
| 791 | Virulence genotypes and drug resistance of <i>Helicobacter pylori</i> from Vladivostok, Russia: another feature in the Far East. <i>Microbiology and Immunology</i> , 2012, 56, 198-202. | 0.7 | 5 |
| 792 | Is <i>Helicobacter pylori</i> antibiotic resistance surveillance needed and how can it be delivered?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1221-1230. | 1.9 | 66 |
| 793 | Meta-analysis: probiotics in antibiotic-associated diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1355-1369. | 1.9 | 125 |
| 794 | Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 37-47. | 1.9 | 46 |
| 795 | High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high <i>Helicobacter pylori</i> eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 190-196. | 1.9 | 26 |
| 796 | Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the <i>Helicobacter pylori</i> eradication rate in a placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 231-238. | 1.9 | 44 |
| 797 | Review article: biofilm formation by <i>Helicobacter pylori</i> as a target for eradication of resistant infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 222-230. | 1.9 | 84 |
| 798 | Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 414-425. | 1.9 | 165 |
| 799 | Resistance of <i>Helicobacter pylori</i> strains to antibiotics in Korea with a focus on fluoroquinolone resistance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 493-497. | 1.4 | 46 |
| 800 | Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 498-503. | 1.4 | 21 |
| 801 | Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: A prospective, randomized study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 504-509. | 1.4 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 802 | Characterization and usefulness of stool antigen tests using a monoclonal antibody to <i>Helicobacter pylori</i> catalase. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 23-28. | 1.4 | 31 |
| 803 | Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go. <i>International Journal of Cancer</i> , 2012, 130, 745-753. | 2.3 | 130 |
| 804 | Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 19-46. | 1.4 | 111 |
| 805 | Fourth Chinese National Consensus Report on the management of <i>Helicobacter pylori</i> infection. <i>Journal of Digestive Diseases</i> , 2013, 14, 211-221. | 0.7 | 104 |
| 806 | Trends of Second-Line Eradication Therapy for <i>Helicobacter pylori</i> in Japan: A Multicenter Study in the Tokyo Metropolitan Area. <i>Helicobacter</i> , 2013, 18, 468-472. | 1.6 | 22 |
| 807 | Narrow band imaging versus white light gastroscopy in detecting potentially premalignant gastric lesions: a randomized prospective crossover study. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 37-42. | 0.7 | 30 |
| 808 | Improved Flavodoxin Inhibitors with Potential Therapeutic Effects against <i>Helicobacter pylori</i> Infection. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6248-6258. | 2.9 | 26 |
| 809 | Clinical Practice: <i>Helicobacter pylori</i> infection in childhood. <i>European Journal of Pediatrics</i> , 2013, 172, 1427-1434. | 1.3 | 33 |
| 810 | Detection of primary clarithromycin resistance of <i>Helicobacter pylori</i> and association between <i>cagA</i> + status and clinical outcome. <i>Folia Microbiologica</i> , 2013, 58, 141-146. | 1.1 | 20 |
| 813 | Phenotypic and genotypic analysis of clarithromycin-resistant <i>Helicobacter pylori</i> from Bogotá D.C., Colombia. <i>Journal of Microbiology</i> , 2013, 51, 448-452. | 1.3 | 17 |
| 814 | Cumulative <i>Helicobacter pylori</i> Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2013, 23, 145-149. | 1.1 | 14 |
| 815 | Prevalence of virulent <i>Helicobacter pylori</i> strains in patients affected by idiopathic dysrhythmias. <i>Internal and Emergency Medicine</i> , 2013, 8, 333-337. | 1.0 | 14 |
| 816 | Efficacy of PPI, levofloxacin and amoxicillin in the eradication of <i>Helicobacter pylori</i> compared to conventional triple therapy at a Venezuelan hospital. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 123-125. | 0.4 | 12 |
| 817 | Prise en charge de l'ulcère gastroduodéal perforant: revue de littérature. <i>Journal De Chirurgie Viscérale</i> , 2013, 150, 356-364. | 0.0 | 3 |
| 818 | Penbactam for <i>Helicobacter pylori</i> eradication: A randomised comparison of quadruple and triple treatment schedules in an Iranian population. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 1-5. | 0.4 | 15 |
| 819 | Resistance rates of metronidazole and other antibacterials in <i>Helicobacter pylori</i> from previously untreated patients in Norway. <i>Apmis</i> , 2013, 121, 353-358. | 0.9 | 22 |
| 820 | Efficacy of Two Levofloxacin-Containing Second-Line Therapies for <i>Helicobacter pylori</i> : A Pilot Study. <i>Helicobacter</i> , 2013, 18, 378-383. | 1.6 | 16 |
| 821 | The Role of <i>Helicobacter pylori</i> Outer Membrane Proteins in Adherence and Pathogenesis. <i>Biology</i> , 2013, 2, 1110-1134. | 1.3 | 128 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 822 | Optimized Nonbismuth Quadruple Therapies Cure Most Patients With <i>Helicobacter pylori</i> Infection in Populations With High Rates of Antibiotic Resistance. <i>Gastroenterology</i> , 2013, 145, 121-128.e1. | 0.6 | 177 |
| 823 | Bioengineered surfaces promote specific protein-glycan mediated binding of the gastric pathogen <i>Helicobacter pylori</i> . <i>Acta Biomaterialia</i> , 2013, 9, 8885-8893. | 4.1 | 19 |
| 824 | Detection of Clarithromycin-Resistant <i>Helicobacter pylori</i> by Stool PCR in Children: A Comprehensive Review of Literature. <i>Helicobacter</i> , 2013, 18, 89-101. | 1.6 | 25 |
| 825 | Therapeutic management of perforated gastro-duodenal ulcer: Literature review. <i>Journal of Visceral Surgery</i> , 2013, 150, 333-340. | 0.4 | 38 |
| 826 | GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 726-735. | 2.4 | 950 |
| 827 | Low <i>Helicobacter pylori</i> primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. <i>BMC Gastroenterology</i> , 2013, 13, 164. | 0.8 | 19 |
| 828 | Remarkable prevalence of coeliac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study. <i>Arthritis Research and Therapy</i> , 2013, 15, R201. | 1.6 | 27 |
| 829 | Sequential therapy versus standard triple-drug therapy for <i>Helicobacter pylori</i> eradication: A randomized study. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 392-396. | 0.7 | 22 |
| 830 | <i>Helicobacter pylori</i> inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , 2013, 68, 284-290. | 2.6 | 17 |
| 831 | <i>Helicobacter pylori</i> resistance to antibiotics in Europe and its relationship to antibiotic consumption. <i>Gut</i> , 2013, 62, 34-42. | 6.1 | 743 |
| 832 | Breath Tests for Detection of <i>Helicobacter pylori</i> and <i>Aspergillus fumigatus</i> . , 2013, , 13-30. | | 0 |
| 834 | Genotypic and phenotypic patterns of antimicrobial susceptibility of <i>Helicobacter pylori</i> strains among Egyptian patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2013, 14, 235-246. | 0.5 | 7 |
| 836 | Interaction between gene A-positive <i>Helicobacter pylori</i> and human leukocyte antigen II alleles increase the risk of Graves disease in Chinese Han population: An association study. <i>Gene</i> , 2013, 531, 84-89. | 1.0 | 7 |
| 837 | Bacterial-binding chitosan microspheres for gastric infection treatment and prevention. <i>Acta Biomaterialia</i> , 2013, 9, 9370-9378. | 4.1 | 29 |
| 838 | Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of <i>H. pylori</i> : A prospective study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 527-529. | 0.7 | 8 |
| 839 | Effect of <i>Helicobacter pylori</i> eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 55-58. | 0.4 | 25 |
| 840 | Diagnostic testing for <i>Helicobacter Pylori</i> in patients with atrophic gastritis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, e115-e116. | 0.7 | 1 |
| 841 | Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for <i>Helicobacter pylori</i> infection in Singapore? Results of a time trend analysis. <i>Journal of Digestive Diseases</i> , 2013, 14, 100-104. | 0.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 842 | Quadruple therapy for eradication of <i>Helicobacter pylori</i> . World Journal of Gastroenterology, 2013, 19, 931. | 1.4 | 16 |
| 843 | Randomized trial comparing rabeprazole versus lansoprazole based <i>Helicobacter pylori</i> eradication regimens. Kaohsiung Journal of Medical Sciences, 2013, 29, 379-384. | 0.8 | 5 |
| 844 | Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2013, 108, 308-328. | 0.2 | 1,375 |
| 845 | A novel nanobody against urease activity of <i>Helicobacter pylori</i> . International Journal of Infectious Diseases, 2013, 17, e723-e728. | 1.5 | 40 |
| 846 | Prevalence of Primary and Secondary Antimicrobial Resistance of <i>Helicobacter pylori</i> in Korea from 2003 through 2012. Helicobacter, 2013, 18, 206-214. | 1.6 | 214 |
| 847 | Current options for the treatment of <i>Helicobacter pylori</i> . Expert Opinion on Pharmacotherapy, 2013, 14, 211-223. | 0.9 | 50 |
| 848 | Gastritis. , 2013, , 129-190. | | 0 |
| 849 | Erosionen und Ulzera des Magens und Bulbus duodeni. , 2013, , 191-199. | | 0 |
| 850 | Comparison of the Diagnostic Accuracy of Five Different Stool Antigen Tests for the Diagnosis of <i>Helicobacter pylori</i> Infection. Helicobacter, 2013, 18, 384-391. | 1.6 | 63 |
| 851 | <i>H. pylori</i> infection and gastric cancer: State of the art. International Journal of Oncology, 2013, 42, 5-18. | 1.4 | 178 |
| 852 | An update on current pharmacotherapy options for dyspepsia. Expert Opinion on Pharmacotherapy, 2013, 14, 1737-1753. | 0.9 | 15 |
| 853 | Sequential therapy versus standard triple-drug therapy for <i>Helicobacter pylori</i> eradication: a prospective randomized study. European Journal of Clinical Pharmacology, 2013, 69, 1709-1715. | 0.8 | 27 |
| 854 | <i>Helicobacter pylori</i> Infection. , 2013, , 437-441. | | 1 |
| 855 | <i>Helicobacter pylori</i> resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Irish Journal of Medical Science, 2013, 182, 693-695. | 0.8 | 26 |
| 856 | Treatment of gastric MALT lymphoma with a focus on <i>Helicobacter pylori</i> eradication. International Journal of Hematology, 2013, 97, 735-742. | 0.7 | 14 |
| 857 | Upper GI endoscopy in elderly patients: predictive factors of relevant endoscopic findings. Internal and Emergency Medicine, 2013, 8, 141-146. | 1.0 | 17 |
| 858 | Sequential therapy versus standard triple-drug therapy for <i>Helicobacter pylori</i> eradication: Result of the HPFEZ randomised study. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 416-421. | 0.7 | 23 |
| 859 | Non-steroidal anti-inflammatory drugs and gastroprotection gap among Family Physicians: Results from a survey. GE Jornal Português De Gastrenterologia, 2013, 20, 243-249. | 0.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 860 | Comparison of Hybrid and Sequential Therapies for <i>Helicobacter pylori</i> Eradication in Iran: A Prospective Randomized Trial. <i>Helicobacter</i> , 2013, 18, 129-134. | 1.6 | 95 |
| 861 | Usefulness of antimicrobial susceptibility in the eradication of <i>Helicobacter pylori</i> . <i>Clinical Microbiology and Infection</i> , 2013, 19, 379-383. | 2.8 | 48 |
| 862 | PRIMARY ANTIMICROBIAL RESISTANCE OF <i>HELICOBACTER PYLORI</i> IN BELGIUM. <i>Acta Clinica Belgica</i> , 2013, 68, 183-187. | 0.5 | 15 |
| 863 | High <i>Helicobacter pylori</i> Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, 645-648. | 0.9 | 43 |
| 864 | Complete Genome Sequences of <i>Helicobacter pylori</i> Clarithromycin-Resistant Strains. <i>Genome Announcements</i> , 2013, 1, . | 0.8 | 3 |
| 865 | Evidence-Based Approach to Dyspepsia: From <i>Helicobacter pylori</i> to Functional Disease. <i>Postgraduate Medicine</i> , 2013, 125, 169-180. | 0.9 | 6 |
| 866 | Proton Pump Inhibitors: Key Ingredients in <i>Helicobacter pylori</i> Eradication Treatment. <i>Frontiers of Gastrointestinal Research</i> , 2013, , 59-67. | 0.1 | 3 |
| 867 | Catechins and Sialic Acid Attenuate <i>Helicobacter pylori</i> -Triggered Epithelial Caspase-1 Activity and Eradicate <i>Helicobacter pylori</i> Infection. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-13. | 0.5 | 23 |
| 869 | Effect of GutGard in the Management of <i>Helicobacter pylori</i> : A Randomized Double Blind Placebo Controlled Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-8. | 0.5 | 20 |
| 870 | Do probiotics improve eradication response to <i>Helicobacter pylori</i> on standard triple or sequential therapy?. <i>Saudi Journal of Gastroenterology</i> , 2013, 19, 113. | 0.5 | 38 |
| 871 | <i>Helicobacter pylori</i> Infection and Upper Gastrointestinal Disorders. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-3. | 0.7 | 3 |
| 872 | <i>Helicobacter pylori</i> Infection and Anemia in Taiwanese Adults. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-4. | 0.7 | 10 |
| 873 | Is <i>Helicobacter pylori</i> Infection the Primary Cause of Duodenal Ulceration or a Secondary Factor? A Review of the Evidence. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8. | 0.7 | 16 |
| 874 | In vivo Evaluation of Amoxicillin Trihydrate and Clarithromycin-Loaded Mucoadhesive Microspheres for <i>H. pylori</i> Eradication. <i>Tropical Journal of Pharmaceutical Research</i> , 2013, 12, . | 0.2 | 0 |
| 875 | <i>Helicobacter pylori</i> Infection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma. <i>Mediators of Inflammation</i> , 2013, 2013, 1-8. | 1.4 | 26 |
| 876 | The role of <i>Helicobacter pylori</i> eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. <i>Current Opinion in Oncology</i> , 2013, 25, 470-479. | 1.1 | 32 |
| 877 | Case-control study of association of eosinophilic gastrointestinal disorders with <i>Helicobacter pylori</i> infection in Japan. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2013, 53, 60-62. | 0.6 | 60 |
| 878 | The benefit of mass eradication of <i>Helicobacter pylori</i> infection: a community-based study of gastric cancer prevention. <i>Gut</i> , 2013, 62, 676-682. | 6.1 | 301 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 879 | Increased incidence of herpes zoster in adult patients with peptic ulcer disease: a population-based cohort study. <i>International Journal of Epidemiology</i> , 2013, 42, 1873-1881. | 0.9 | 19 |
| 880 | Performance of Routine <i>Helicobacter pylori</i> Invasive Tests in Patients with Dyspepsia. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-5. | 0.7 | 14 |
| 881 | Relationship Between Drug Resistance and <i>cagA</i> Gene in <i>Helicobacter pylori</i> . <i>Jundishapur Journal of Microbiology</i> , 2013, 6, . | 0.2 | 8 |
| 882 | <i>Helicobacter pylori</i> Susceptible/Resistant to Antibiotic Eradication Therapy Differ in the Maturation and Activation of Dendritic Cells. <i>Helicobacter</i> , 2013, 18, 444-453. | 1.6 | 1 |
| 883 | Changing pattern of antibiotic resistance of <i>Helicobacter pylori</i> in children during 20 years in <i>Jinju</i> , <i>Southeast Korea</i> . <i>Pediatrics International</i> , 2013, 55, 332-336. | 0.2 | 34 |
| 884 | Indications and safety of proton pump inhibitor drug use in patients with cancer. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 659-672. | 1.0 | 15 |
| 885 | Evolution of <i>Helicobacter pylori</i> susceptibility to antibiotics during a 10-year period in <i>Lithuania</i> . <i>Apmis</i> , 2013, 121, 431-436. | 0.9 | 21 |
| 886 | The Role of <i>ExbD</i> in Periplasmic <i>pH</i> Homeostasis in <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2013, 18, 363-372. | 1.6 | 15 |
| 888 | Chest pain, dyspnea, petechiae, and melena in a 58-year-old woman – What is it?. <i>Platelets</i> , 2013, 24, 415-418. | 1.1 | 0 |
| 889 | Preferences for the screen and treat Strategy of <i>Helicobacter pylori</i> to Prevent Gastric Cancer in Healthy Korean Populations. <i>Helicobacter</i> , 2013, 18, 262-269. | 1.6 | 16 |
| 890 | Randomised clinical trial: the effects of <i>Helicobacter pylori</i> eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 477-489. | 1.9 | 35 |
| 891 | Effect of <i>Helicobacter pylori</i> infection on esophagogastric variceal bleeding in patients with liver cirrhosis and portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1444-1449. | 1.4 | 16 |
| 892 | Current recommendations for <i>Helicobacter pylori</i> therapies in a world of evolving resistance. <i>Gut Microbes</i> , 2013, 4, 541-548. | 4.3 | 41 |
| 893 | The Antimicrobial Activities of Phenylbutyrates against <i>Helicobacter pylori</i> . <i>Chemical and Pharmaceutical Bulletin</i> , 2013, 61, 604-610. | 0.6 | 4 |
| 895 | Association between <i>Helicobacter pylori</i> and asthma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 460-468. | 0.8 | 53 |
| 896 | Proton pump inhibitor-based triple therapies versus dual therapies for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 0, , . | 1.5 | 0 |
| 897 | Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013, , CD008337. | 1.5 | 120 |
| 898 | Nonbismuth Quadruple Concomitant Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line <i>H. Pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 228-232. | 1.1 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|----------|-----------|
| 899 | Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 130-135. | 1.1 | 60 |
| 900 | Comparative Study of <i>Helicobacter pylori</i> Eradication Rates With 5-day Quadruple Concomitant Therapy and 7-day Standard Triple Therapy. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 21-24. | 1.1 | 60 |
| 901 | <i>Helicobacter pylori</i> is not the predominant etiology for liver cirrhosis patients with peptic ulcer disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 159-165. | 0.8 | 14 |
| 902 | Meta-Analysis of the Efficacy and Safety of Lactobacillus-containing and Bifidobacterium-containing Probiotic Compound Preparation in <i>Helicobacter pylori</i> Eradication Therapy. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 25-32. | 1.1 | 148 |
| 903 | The Incidence of Primary Antibiotic Resistance of <i>Helicobacter pylori</i> in Vietnam. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 233-238. | 1.1 | 60 |
| 904 | Increasing gastric juice pH level prior to anti- <i>Helicobacter pylori</i> therapy may be beneficial to the healing of duodenal ulcers. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 912-916. | 0.8 | 12 |
| 905 | Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients – focus on esomeprazole. <i>Clinical Interventions in Aging</i> , 2013, 8, 1433. | 1.3 | 13 |
| 906 | NMR Study on Small Proteins from <i>Helicobacter pylori</i> for Antibiotic Target Discovery: A Review. <i>Molecules</i> , 2013, 18, 13410-13424. | 1.7 | 2 |
| 907 | The role of biofilm formation in pathogenesis of <i>Helicobacter pylori</i> infections. <i>Przegląd Gastroenterologiczny</i> , 2013, 1, 27-30. | 0.3 | 3 |
| 908 | The Relationship between Bioactive Compounds with Diastase Activity and Antibacterial Synergy of Honey and Potato Starch Combinations against <i>Klebsiella pneumoniae</i> . <i>Clinical Microbiology (Los Angeles)</i> , 2013, 1, 1-14. | 0.784614 | 0 |
| 909 | 3rd BRAZILIAN CONSENSUS ON <i>Helicobacter pylori</i> . <i>Arquivos De Gastroenterologia</i> , 2013, 50, 81-96. | 0.3 | 27 |
| 910 | Predictive findings for <i>Helicobacter pylori</i> -uninfected, -infected and -eradicated gastric mucosa: Validation study. <i>World Journal of Gastroenterology</i> , 2013, 19, 4374. | 1.4 | 67 |
| 911 | Evaluation of a Newly Developed Rapid Stool Antigen Test Using an Immunochromatographic Assay To Detect <i>Helicobacter pylori</i> . <i>Japanese Journal of Infectious Diseases</i> , 2013, 66, 60-64. | 0.5 | 10 |
| 912 | A Case of Persistent <i>Helicobacter pylori</i> Infection Occurring with Anti-IgE Immunosuppression. <i>ACG Case Reports Journal</i> , 2013, 1, 16-18. | 0.2 | 1 |
| 913 | The efficacy of moxifloxacin-based triple therapy in treatment of <i>Helicobacter pylori</i> infection: a systematic review and meta-analysis of randomized clinical trials. <i>Brazilian Journal of Medical and Biological Research</i> , 2013, 46, 607-613. | 0.7 | 14 |
| 914 | In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against <i>Helicobacter pylori</i> . <i>PLoS ONE</i> , 2013, 8, e68917. | 1.1 | 32 |
| 915 | The effect of eradicating <i>Helicobacter pylori</i> on idiopathic central serous chorioretinopathy patients. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 355. | 0.9 | 37 |
| 917 | Antibiotic Resistance in <i>Helicobacter pylori</i> Strains and its Effect on <i>H. pylori</i> Eradication Rates in a Single Center in Korea. <i>Annals of Laboratory Medicine</i> , 2013, 33, 415-419. | 1.2 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 918 | Effectiveness of sequential v. standard triple therapy for treatment of <i>Helicobacter pylori</i> infection in children in Nairobi, Kenya. <i>South African Medical Journal</i> , 2013, 103, 921. | 0.2 | 17 |
| 919 | Anti- <i>Helicobacter pylori</i> actions of CV-6209, a platelet-activating factor receptor antagonist. <i>Journal of General and Applied Microbiology</i> , 2013, 59, 147-152. | 0.4 | 2 |
| 920 | Análise qualitativa das alterações anatopatológicas na mucosa gástrica decorrentes da terapêutica prolongada com inibidores da bomba de prótons: estudos experimentais x estudos clínicos. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2013, 26, 328-334. | 0.5 | 1 |
| 921 | <i>Helicobacter pylori</i> Associated Dyspepsia in Paediatrics. , 0, , . | | 0 |
| 922 | Capsaicin-Sensitive Afferentation Represents a New Mucosal Defensive Neural Pathway System in the Gastric Mucosa in Patients with Chronic Gastritis. , 2013, , . | | 2 |
| 923 | Determinación de mutaciones de un solo nucleótido en el gen 23S rRNA de <i>Helicobacter pylori</i> relacionadas con resistencia a claritromicina en una población del departamento del Cauca, Colombia. <i>Biomedica</i> , 2013, 34, 156. | 0.3 | 10 |
| 924 | Using Stool Antigen to Screen for <i>Helicobacter pylori</i> in Immigrants and Refugees from High Prevalence Countries Is Relatively Cost Effective in Reducing the Burden of Gastric Cancer and Peptic Ulceration. <i>PLoS ONE</i> , 2014, 9, e108610. | 1.1 | 21 |
| 925 | The Effect of <i>Helicobacter pylori</i> Eradication on the Levels of Essential Trace Elements. <i>BioMed Research International</i> , 2014, 2014, 1-5. | 0.9 | 5 |
| 926 | <i>Helicobacter Pylori</i> Eradication Therapy in both Erosive and Non-erosive Gastritis – A Prospective Study. <i>Journal of Enam Medical College</i> , 2014, 4, 15-20. | 0.1 | 2 |
| 927 | A review of <i>Helicobacter pylori</i> diagnosis, treatment, and methods to detect eradication. <i>World Journal of Gastroenterology</i> , 2014, 20, 1438. | 1.4 | 165 |
| 928 | Clarithromycin-Based Standard Triple Therapy Can Still Be Effective for <i>Helicobacter pylori</i> Eradication in Some Parts of the Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 1240. | 1.1 | 27 |
| 929 | Antimicrobial susceptibility of <i>Helicobacter pylori</i> isolates from Lower Silesia, Poland. <i>Archives of Medical Science</i> , 2014, 3, 505-509. | 0.4 | 25 |
| 930 | Gastric cancer: Prevention, screening and early diagnosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 13842. | 1.4 | 312 |
| 931 | Optimizing clarithromycin-containing therapy for <i>Helicobacter pylori</i> in the era of antibiotic resistance. <i>World Journal of Gastroenterology</i> , 2014, 20, 10338. | 1.4 | 59 |
| 932 | Long-term pretreatment with proton pump inhibitor and <i>Helicobacter pylori</i> eradication rates. <i>World Journal of Gastroenterology</i> , 2014, 20, 1061. | 1.4 | 16 |
| 933 | Meta-Analysis of First-Line Triple Therapy for <i>Helicobacter pylori</i> Eradication in Korea: Is It Time to Change?. <i>Journal of Korean Medical Science</i> , 2014, 29, 704. | 1.1 | 83 |
| 934 | <i>Helicobacter pylori</i> Infection, Gastric Physiology and Micronutrient deficiency (Iron and Vitamin C) in Children in Developing Countries. , 0, , . | | 0 |
| 935 | Role of <i>Helicobacter pylori</i> infection on nutrition and metabolism. <i>World Journal of Gastroenterology</i> , 2014, 20, 12809. | 1.4 | 90 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 936 | <i>Helicobacter pylori</i> and pregnancy-related disorders. World Journal of Gastroenterology, 2014, 20, 654. | 1.4 | 61 |
| 937 | Capsaicin-Sensitive Afferent Nerves and the Human Gastrointestinal Tract. , 2014, , . | | 2 |
| 938 | Antibacterial Activities of Oxyprenylated Chalcones and Napthoquinone against <i>Helicobacter pylori</i> . Natural Product Communications, 2014, 9, 1934578X1400900. | 0.2 | 5 |
| 941 | Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. The Cochrane Library, 2014, 2014, CD010623. | 1.5 | 76 |
| 942 | Perioperative management of bariatric surgery patients. American Journal of Health-System Pharmacy, 2014, 71, 1253-1264. | 0.5 | 13 |
| 943 | <i>Helicobacter pylori</i> infection in pregnant women in four districts of Uganda: role of geographic location, education and water sources. BMC Public Health, 2014, 14, 915. | 1.2 | 29 |
| 944 | <i>Helicobacter pylori</i> infection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia. BMC Infectious Diseases, 2014, 14, 656. | 1.3 | 37 |
| 945 | Association between abnormal gastric function risk and <i>Helicobacter pylori</i> infection assessed by ELISA and 14C-urea breath test. Diagnostic Microbiology and Infectious Disease, 2014, 80, 316-320. | 0.8 | 6 |
| 946 | Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for <i>Helicobacter pylori</i> after Failures of First- and Second-Line Therapies. International Scholarly Research Notices, 2014, 2014, 1-6. | 0.9 | 7 |
| 947 | Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of <i>Helicobacter pylori</i> Infection. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 16 |
| 948 | Does Long-Term Use of Silver Nanoparticles Have Persistent Inhibitory Effect on <i>H. pylori</i> Based on Mongolian Gerbil's Model?. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 4 |
| 949 | Diagnosis, Treatment, and Outcome in Patients with Bleeding Peptic Ulcers and <i>Helicobacter pylori</i> Infections. BioMed Research International, 2014, 2014, 1-10. | 0.9 | 19 |
| 950 | Therapy of <i>Helicobacter pylori</i> : Present Medley and Future Prospective. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 35 |
| 951 | Differences in the Antigens of <i>Helicobacter pylori</i> Strains Influence on the Innate Immune Response in the In Vitro Experiments. Mediators of Inflammation, 2014, 2014, 1-6. | 1.4 | 4 |
| 952 | Segmental-Dependent Drug Absorption and Delivery: The Stomach. Advances in Delivery Science and Technology, 2014, , 329-341. | 0.4 | 0 |
| 953 | Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for <i>Helicobacter pylori</i> Eradication: A Systematic Review and Meta-Analysis. Helicobacter, 2014, 19, 372-381. | 1.6 | 8 |
| 954 | Comparison of Encapsulated Versus Nonencapsulated ¹⁴ C-urea Breath Test for the Detection of <i>Helicobacter pylori</i> Infection: A Scintigraphy Study. Helicobacter, 2014, 19, 116-123. | 1.6 | 5 |
| 955 | Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate for <i>Helicobacter pylori</i> Infection after Failure of Sequential Therapy. Helicobacter, 2014, 19, 74-79. | 1.6 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 956 | Effect of <i>Helicobacter pylori</i> Eradication on Metachronous Gastric Cancer after Endoscopic Resection of Gastric Tumors: A Meta-Analysis. <i>Helicobacter</i> , 2014, 19, 243-248. | 1.6 | 128 |
| 957 | Use of selected lactic acid bacteria in the eradication of <i>Helicobacter pylori</i> infection. <i>Journal of Microbiology</i> , 2014, 52, 955-962. | 1.3 | 37 |
| 958 | Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 443-455. | 0.9 | 17 |
| 959 | Eradication of <i>Helicobacter pylori</i> infection: Which regimen first?. <i>World Journal of Gastroenterology</i> , 2014, 20, 665. | 1.4 | 36 |
| 960 | Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study. <i>Arthritis Research and Therapy</i> , 2014, 16, 421. | 1.6 | 16 |
| 961 | Association between cirrhosis and <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1309-1319. | 0.8 | 37 |
| 962 | Sequential therapy versus standard triple therapy for <i>Helicobacter pylori</i> eradication in children. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1202-1208. | 0.8 | 24 |
| 963 | Urea. <i>Sub-Cellular Biochemistry</i> , 2014, 73, 7-29. | 1.0 | 23 |
| 964 | Proton pump inhibitors: Are we still prescribing them without valid indications?. <i>Australasian Medical Journal</i> , 2014, 7, 465-470. | 0.1 | 25 |
| 965 | <i>Helicobacter pylori</i> ; Infection - Management from a European Perspective. <i>Digestive Diseases</i> , 2014, 32, 275-280. | 0.8 | 5 |
| 966 | Community-driven research on environmental sources of <i>H. pylori</i> infection in arctic Canada. <i>Gut Microbes</i> , 2014, 5, 606-617. | 4.3 | 15 |
| 967 | Capsaicin as New Orally Applicable Gastroprotective and Therapeutic Drug Alone or in Combination with Nonsteroidal Anti-Inflammatory Drugs in Healthy Human Subjects and in Patients. , 2014, 68, 209-258. | | 35 |
| 968 | Dietary Factors in Relation to <i>Helicobacter pylori</i> Infection. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-5. | 0.7 | 32 |
| 969 | Does <i>Helicobacter pylori</i> eradication effect body composition, dietary intake, serum leptin and ghrelin levels of infected patients?. <i>Turkish Journal of Biochemistry</i> , 2014, 39, 196-200. | 0.3 | 0 |
| 970 | Su1179 A Comparative Study of Sequential Therapy and Standard Triple Therapy for <i>Helicobacter pylori</i> Infection: A Randomized Multicenter Trial. <i>Gastroenterology</i> , 2014, 146, S-396. | 0.6 | 0 |
| 971 | <i>Helicobacter pylori</i> 's cholesterol uptake impacts resistance to docosahexaenoic acid. <i>International Journal of Medical Microbiology</i> , 2014, 304, 314-320. | 1.5 | 24 |
| 972 | Preparation and characterisation of gastroretentive alginate beads for targeting <i>H. pylori</i> . <i>Journal of Microencapsulation</i> , 2014, 31, 58-67. | 1.2 | 18 |
| 973 | <i>Helicobacter pylori</i> infection is positively associated with gallstones: a large-scale cross-sectional study in Japan. <i>Journal of Gastroenterology</i> , 2014, 49, 882-889. | 2.3 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 974 | Is levofloxacin-based triple therapy an alternative for first-line eradication of <i>Helicobacter pylori</i> ? A systematic review and meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 528-538. | 0.6 | 33 |
| 975 | Évolution des stratégies thérapeutiques pour <i>Helicobacter pylori</i> . <i>Actualites Pharmaceutiques</i> , 2014, 53, 25-30. | 0.0 | 0 |
| 976 | The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. <i>Digestive and Liver Disease</i> , 2014, 46, 125-130. | 0.4 | 15 |
| 977 | A Comparative Study of Sequential Therapy and Standard Triple Therapy for <i>Helicobacter pylori</i> Infection: A Randomized Multicenter Trial. <i>American Journal of Gastroenterology</i> , 2014, 109, 535-541. | 0.2 | 75 |
| 978 | Combating <i>Helicobacter pylori</i> infections with mucoadhesive nanoparticles loaded with <i>Garcinia mangostana</i> extract. <i>Nanomedicine</i> , 2014, 9, 457-468. | 1.7 | 19 |
| 979 | Comparison of <i>Helicobacter pylori</i> eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments. <i>European Journal of Internal Medicine</i> , 2014, 25, 224-229. | 1.0 | 8 |
| 980 | How I treat unexplained refractory iron deficiency anemia. <i>Blood</i> , 2014, 123, 326-333. | 0.6 | 127 |
| 981 | Graves' disease shows a significant increase in the <i>Helicobacter pylori</i> recurrence. <i>Clinical Endocrinology</i> , 2014, 81, 784-785. | 1.2 | 4 |
| 982 | A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1164-1172. | 0.6 | 24 |
| 984 | Whole-genome sequencing of clarithromycin resistant <i>Helicobacter pylori</i> characterizes unidentified variants of multidrug resistant efflux pump genes. <i>Gut Pathogens</i> , 2014, 6, 27. | 1.6 | 41 |
| 985 | A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2014, 46, 980-984. | 0.4 | 29 |
| 986 | Nickel Free-Diet Enhances the <i>Helicobacter pylori</i> Eradication Rate: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1851-1855. | 1.1 | 30 |
| 987 | Heteroresistance of <i>Helicobacter pylori</i> from the same patient prior to antibiotic treatment. <i>Infection, Genetics and Evolution</i> , 2014, 23, 196-202. | 1.0 | 38 |
| 988 | An Evidence-Based Algorithm for the Management of Marginal Ulcers following Roux-en-Y Gastric Bypass. <i>Obesity Surgery</i> , 2014, 24, 1520-1527. | 1.1 | 40 |
| 989 | Nontraditional therapies to treat <i>Helicobacter pylori</i> infection. <i>Journal of Microbiology</i> , 2014, 52, 259-272. | 1.3 | 20 |
| 990 | Resistotype of <i>Helicobacter pylori</i> isolates: the impact on eradication outcome. <i>Journal of Medical Microbiology</i> , 2014, 63, 703-709. | 0.7 | 29 |
| 991 | Role of Reactive Oxygen Species and Apoptosis in <i>Helicobacter pylori</i> Infection. , 2014, , 1849-1870. | | 0 |
| 992 | Isolation and gut microbiota modulation of antibiotic-resistant probiotics from human feces. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 405-412. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 993 | Expressions of P-glycoprotein in treatment - Resistant <i>Helicobacter pylori</i> patients. <i>Journal of Applied Biomedicine</i> , 2014, 12, 263-269. | 0.6 | 3 |
| 994 | Association of Neutrophil to Lymphocyte Ratio With Presence and Severity of Gastritis Due to <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Laboratory Analysis</i> , 2014, 28, 219-223. | 0.9 | 51 |
| 996 | Lower <i>Helicobacter pylori</i> infection rate in chronic kidney disease and end-stage renal disease patients with peptic ulcer disease. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 354-359. | 0.6 | 18 |
| 997 | Exploring alternative treatments for <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 1450. | 1.4 | 111 |
| 998 | Hematologic manifestations of <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 12818. | 1.4 | 62 |
| 999 | Probiotics for the treatment of <i>Helicobacter pylori</i> infection in children. <i>World Journal of Gastroenterology</i> , 2014, 20, 673. | 1.4 | 43 |
| 1000 | Treatment of <i>Helicobacter pylori</i> infection: Past, present and future. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 392. | 0.5 | 67 |
| 1001 | Antimicrobial susceptibility testing for <i>Helicobacter pylori</i> in times of increasing antibiotic resistance. <i>World Journal of Gastroenterology</i> , 2014, 20, 9912. | 1.4 | 112 |
| 1002 | Standard triple therapy for <i>Helicobacter pylori</i> infection in China: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 14973. | 1.4 | 39 |
| 1003 | Empirical Versus Targeted Treatment of <i>Helicobacter pylori</i> Infections in Southern Poland According to the Results of Local Antimicrobial Resistance Monitoring. , 0, , . | | 0 |
| 1004 | Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in <i>Helicobacter pylori</i> and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. <i>Medicine (United States)</i> , 2015, 94, e2056. | 0.4 | 25 |
| 1005 | Letter: clarithromycin dose for <i>H. pylori</i> therapy remains unresolved - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 632-633. | 1.9 | 2 |
| 1007 | Evaluation of antimicrobial resistance of <i>Helicobacter pylori</i> in the last 15 years in West Poland. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2015, 62, 287-293. | 0.4 | 13 |
| 1008 | Fluoroquinolone Sequential Therapy for <i>Helicobacter pylori</i> : A Meta-analysis. <i>Pharmacotherapy</i> , 2015, 35, 719-730. | 1.2 | 12 |
| 1009 | Relevance of Undetectably Rare Resistant Malaria Parasites in Treatment Failure: Experimental Evidence from <i>Plasmodium chabaudi</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1214-1221. | 0.6 | 3 |
| 1010 | A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of <i>Helicobacter pylori</i> Infection: A Pilot Study. <i>Helicobacter</i> , 2015, 20, 390-396. | 1.6 | 20 |
| 1011 | Prevalence of <i>Helicobacter pylori</i> and parasites in symptomatic children examined for <i>Helicobacter pylori</i> antibodies, antigens, and parasites in Yemen. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 126-127. | 0.5 | 10 |
| 1012 | Prevalence of antibiotic resistance in <i>Helicobacter pylori</i> : A recent literature review. <i>World Journal of Methodology</i> , 2015, 5, 164. | 1.1 | 153 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1013 | Efficacy of the antimicrobial peptide TP4 against <i>Helicobacter pylori</i> infection: <i>in vitro</i> membrane perturbation <i>via</i> micellization and <i>in vivo</i> suppression of host immune responses in a mouse model. <i>Oncotarget</i> , 2015, 6, 12936-12954. | 0.8 | 55 |
| 1014 | HIV- <i>Helicobacter pylori</i> Co-Infection: Antibiotic Resistance, Prevalence, and Risk Factors. <i>PLoS ONE</i> , 2015, 10, e0145119. | 1.1 | 9 |
| 1015 | The Effects of Broccoli Sprout Extract Containing Sulforaphane on Lipid Peroxidation and <i>Helicobacter pylori</i> Infection in the Gastric Mucosa. <i>Gut and Liver</i> , 2015, 9, 486. | 1.4 | 36 |
| 1016 | Meta-analysis: Is combination of tetracycline and amoxicillin suitable for <i>Helicobacter pylori</i> infection?. <i>World Journal of Gastroenterology</i> , 2015, 21, 2522. | 1.4 | 22 |
| 1017 | Effect of posture on ¹³ C-urea breath test in partial gastrectomy patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 12888. | 1.4 | 5 |
| 1018 | A highly acid-resistant novel strain of <i>Lactobacillus johnsonii</i> No. 1088 has antibacterial activity, including that against <i>Helicobacter pylori</i> , and inhibits gastrin-mediated acid production in mice. <i>MicrobiologyOpen</i> , 2015, 4, 465-474. | 1.2 | 43 |
| 1019 | Current Status of Five Different Regimens for Empiric First-Line <i>Helicobacter pylori</i> Eradication in Turkey. <i>Digestion</i> , 2015, 92, 55-59. | 1.2 | 14 |
| 1021 | Can Antibiotics Cure Autoimmune Diseases?. , 2015, , 279-298. | | 1 |
| 1022 | Ten-day triple therapy <i>versus</i> sequential therapy <i>versus</i> concomitant therapy as first-line treatment for <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1134-1139. | 1.4 | 38 |
| 1023 | Search for Novel Candidate Mutations for Metronidazole Resistance in <i>Helicobacter pylori</i> Using Next-Generation Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2343-2348. | 1.4 | 45 |
| 1024 | A Creative <i>Helicobacter pylori</i> Diagnosis Scheme Based on Multiple Genetic Analysis System: Qualification and Quantitation. <i>Helicobacter</i> , 2015, 20, 343-352. | 1.6 | 10 |
| 1025 | Optimised empiric triple and concomitant therapy for <i>Helicobacter pylori</i> eradication in clinical practice: the OPRICON study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 581-589. | 1.9 | 70 |
| 1026 | Low Antibiotic Resistance of <i>Helicobacter pylori</i> in The Netherlands. <i>Helicobacter</i> , 2015, 20, 69-70. | 1.6 | 6 |
| 1027 | Reverse Sequential Therapy Achieves a Similar Eradication Rate as Standard Sequential Therapy for <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial. <i>Helicobacter</i> , 2015, 20, 71-77. | 1.6 | 15 |
| 1028 | Impact of Microscopic Duodenitis on Symptomatic Response to <i>Helicobacter pylori</i> Eradication in Functional Dyspepsia. <i>Digestive Diseases and Sciences</i> , 2015, 60, 163-167. | 1.1 | 23 |
| 1029 | Beyond Maastricht IV: are standard empiric triple therapies for <i>Helicobacter pylori</i> still useful in a South-European country?. <i>BMC Gastroenterology</i> , 2015, 15, 23. | 0.8 | 11 |
| 1030 | The presence of <i>Helicobacter pylori</i> is not associated with long-term anastomotic complications in gastric bypass patients. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 2885-2890. | 1.3 | 30 |
| 1031 | Predictors of Chronic Abdominal Pain Affecting the Well-Being of Children in Primary Care. <i>Annals of Family Medicine</i> , 2015, 13, 158-163. | 0.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1032 | Management of Patients with Rebleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2015, 25, 569-581. | 0.6 | 4 |
| 1033 | Probiotic and technological properties of <i>Lactobacillus</i> spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. <i>Frontiers in Microbiology</i> , 2015, 5, 766. | 1.5 | 59 |
| 1034 | Reviewing clinical studies of probiotics as dietary supplements: probiotics for gastrointestinal disorders, <i>Helicobacter</i> eradication, lactose malabsorption and inflammatory bowel disease (IBD). , 2015, , 171-197. | | 0 |
| 1035 | Dysbiosis and <i>Staphylococcus aureus</i> Colonization Drives Inflammation in Atopic Dermatitis. <i>Immunity</i> , 2015, 42, 756-766. | 6.6 | 428 |
| 1036 | Appropriate First-Line Regimens to Combat <i>Helicobacter pylori</i> Antibiotic Resistance: An Asian Perspective. <i>Molecules</i> , 2015, 20, 6068-6092. | 1.7 | 35 |
| 1037 | Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of <i>Helicobacter pylori</i> . <i>Turkish Journal of Gastroenterology</i> , 2015, 25, 75-80. | 0.4 | 6 |
| 1038 | The aetiology of anaemia during pregnancy: a study to evaluate the contribution of iron deficiency and common infections in pregnant Ugandan women. <i>Public Health Nutrition</i> , 2015, 18, 1423-1435. | 1.1 | 24 |
| 1039 | Identifying Murl uncompetitive inhibitors by correlating decomposed binding energies with bioactivity. <i>RSC Advances</i> , 2015, 5, 40536-40545. | 1.7 | 3 |
| 1040 | Treating Gastritis, Peptic Ulcer Disease, and Dyspepsia in the Emergency Department: The Feasibility and Patient-Reported Outcomes of Testing and Treating for <i>Helicobacter pylori</i> Infection. <i>Annals of Emergency Medicine</i> , 2015, 66, 131-139. | 0.3 | 8 |
| 1041 | Association between HLA-â...;gene polymorphism and <i>Helicobacter pylori</i> infection in Asian and European population: A meta-analysis. <i>Microbial Pathogenesis</i> , 2015, 82, 15-26. | 1.3 | 9 |
| 1042 | The Effect of <i>Helicobacter pylori</i> Eradication Therapy on the Development of Gastroesophageal Reflux Disease. <i>American Journal of the Medical Sciences</i> , 2015, 349, 364-371. | 0.4 | 16 |
| 1043 | Formulation and evaluation of floating mucoadhesive alginate beads for targeting <i>Helicobacter pylori</i> . <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 511-524. | 1.2 | 38 |
| 1044 | Complete Genome Sequence of a Metronidazole-Resistant <i>Helicobacter pylori</i> Strain. <i>Genome Announcements</i> , 2015, 3, . | 0.8 | 5 |
| 1045 | Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. <i>Clinical Drug Investigation</i> , 2015, 35, 665-673. | 1.1 | 14 |
| 1046 | Prevalence of Primary Resistance of <i>Helicobacter pylori</i> to Clarithromycin and Levofloxacin in Southern Spain. <i>Digestion</i> , 2015, 92, 78-82. | 1.2 | 34 |
| 1047 | Consensus of gastroesophageal reflux disease in Taiwan with endoscopy-based approach covered by National Health Insurance. <i>Advances in Digestive Medicine</i> , 2015, 2, 85-94. | 0.1 | 3 |
| 1048 | Changing prevalence of <i>Helicobacter pylori</i> infection and peptic ulcer among dyspeptic patients. <i>Internal and Emergency Medicine</i> , 2015, 10, 763-764. | 1.0 | 1 |
| 1049 | Predicting postoperative complications of head and neck squamous cell carcinoma in elderly patients using random forest algorithm model. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 44. | 1.5 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1050 | Comparative effectiveness and tolerance of treatments for <i>Helicobacter pylori</i> : systematic review and network meta-analysis. <i>BMJ, The</i> , 2015, 351, h4052. | 3.0 | 137 |
| 1051 | To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 244-255. | 1.2 | 15 |
| 1052 | An overview on the potential of natural products as ureases inhibitors: A review. <i>Journal of Advanced Research</i> , 2015, 6, 35-44. | 4.4 | 170 |
| 1053 | Medicinal plants in the treatment of <i>Helicobacter pylori</i> infections. <i>Pharmaceutical Biology</i> , 2015, 53, 939-960. | 1.3 | 32 |
| 1054 | Review: Efficacy and Safety of Hybrid Therapy for <i>Helicobacter pylori</i> Infection: A Systematic Review and Meta-analysis. <i>Helicobacter</i> , 2015, 20, 79-88. | 1.6 | 38 |
| 1055 | Gastroduodenal ulcers on CT: forgotten, but not gone. <i>Abdominal Imaging</i> , 2015, 40, 19-25. | 2.0 | 16 |
| 1056 | Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant <i>Helicobacter pylori</i> . <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 168-174. | 1.5 | 30 |
| 1057 | Probiotics, Prebiotics, and Biogenics for the Stomach. , 0, , . | | 2 |
| 1058 | <i>Helicobacter pylori</i> and Hematologic Diseases. , 0, , . | | 1 |
| 1059 | The study of risk factors associated with dyspepsia. <i>International Journal of Biomedical and Advance Research</i> , 2016, 7, 468. | 0.1 | 0 |
| 1060 | MOLECULAR DETECTION OF CLARITHROMYCIN AND FLUOROQUINOLONES RESISTANCE IN <i>HELICOBACTER PYLORI</i> INFECTION, DIRECTLY APPLIED TO GASTRIC BIOPSIES, IN AN URBAN BRAZILIAN POPULATION. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 113-117. | 0.3 | 9 |
| 1061 | <i>Helicobacter pylori</i> Association with Acid Peptic Disease: It's Incidence in Population Having Increase Junk Food Intake. <i>Translational Biomedicine</i> , 2016, 07, . | 0.1 | 1 |
| 1062 | Current views of the relationship between <i>Helicobacter pylori</i> and Henoch-Schonlein purpura in children. <i>World Journal of Clinical Pediatrics</i> , 2016, 5, 82. | 0.6 | 16 |
| 1063 | In vitro and In vivo Anti- <i>Helicobacter pylori</i> Activities of <i>Centella asiatica</i> Leaf Extract. <i>Preventive Nutrition and Food Science</i> , 2016, 21, 197-201. | 0.7 | 8 |
| 1064 | Diagnostic Methods of <i>Helicobacter pylori</i> Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. <i>BioMed Research International</i> , 2016, 2016, 1-14. | 0.9 | 96 |
| 1065 | Dyspepsia: When and How to Test for <i>Helicobacter pylori</i> Infection. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9. | 0.7 | 19 |
| 1066 | Detection of <i>Helicobacter pylori</i> resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. <i>World Journal of Gastroenterology</i> , 2016, 22, 7587. | 1.4 | 30 |
| 1067 | <i>Helicobacter pylori</i> infection: past, present and future. <i>Pan African Medical Journal</i> , 2016, 23, . | 0.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1068 | Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant <i>Helicobacter pylori</i> . <i>Frontiers in Microbiology</i> , 2016, 7, 2015. | 1.5 | 19 |
| 1069 | Efficacy of Probiotic Supplementation Therapy for <i>Helicobacter pylori</i> Eradication: A Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2016, 11, e0163743. | 1.1 | 114 |
| 1070 | Sequential Therapy or Standard Triple Therapy for <i>Helicobacter pylori</i> Infection. <i>American Journal of Therapeutics</i> , 2016, 23, e880-e893. | 0.5 | 39 |
| 1071 | Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for <i>Helicobacter pylori</i> Eradication in Chinese Patients. <i>American Journal of Therapeutics</i> , 2016, 23, e1436-e1441. | 0.5 | 4 |
| 1072 | Bibliometric analysis of the top-cited gastroenterology and hepatology articles. <i>BMJ Open</i> , 2016, 6, e009889. | 0.8 | 42 |
| 1073 | IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 697-721. | 0.0 | 27 |
| 1075 | Efficacy and safety of high-dose dual therapy for <i>Helicobacter pylori</i> rescue therapy: A systematic review and meta-analysis. <i>Journal of Digestive Diseases</i> , 2016, 17, 811-819. | 0.7 | 33 |
| 1076 | Antimicrobial Activity of the Essential Oil Isolated from <i>Pistacia lentiscus</i> Leaves Against <i>Helicobacter pylori</i> Algerian Clinical Isolates. <i>Journal of Essential Oil-bearing Plants: JEOP</i> , 2016, 19, 466-474. | 0.7 | 9 |
| 1077 | <i>Helicobacter pylori</i> : past, current and future treatment strategies with gastroretentive drug delivery systems. <i>Journal of Drug Targeting</i> , 2016, 24, 897-915. | 2.1 | 22 |
| 1078 | <i>Helicobacter pylori</i> and cardiovascular complications: a mechanism based review on role of <i>Helicobacter pylori</i> in cardiovascular diseases. <i>Integrative Medicine Research</i> , 2016, 5, 244-249. | 0.7 | 33 |
| 1079 | Population-Based Strategies for <i>Helicobacter pylori</i> -Associated Disease Management: Asian Perspective. , 2016, , 519-542. | | 2 |
| 1080 | The diagnosis and treatment of <i>Helicobacter pylori</i> infection in Arctic regions with a high prevalence of infection: Expert Commentary. <i>Epidemiology and Infection</i> , 2016, 144, 225-233. | 1.0 | 42 |
| 1081 | The Toronto Consensus for the Treatment of <i>Helicobacter pylori</i> Infection in Adults. <i>Gastroenterology</i> , 2016, 151, 51-69.e14. | 0.6 | 671 |
| 1082 | Comparison of endoscopic based diagnosis with <i>Helicobacter urease</i> test for <i>Helicobacter pylori</i> infection. <i>BMC Research Notes</i> , 2016, 9, 421. | 0.6 | 8 |
| 1083 | IV Conferencia Española de Consenso sobre el tratamiento de la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología Y Hepatología</i> , 2016, 39, 697-721. | 0.2 | 97 |
| 1084 | Standard triple therapy versus sequential therapy for eradication of <i>Helicobacter pylori</i> in treatment naïve and retreat patients. <i>Arab Journal of Gastroenterology</i> , 2016, 17, 131-136. | 0.4 | 13 |
| 1085 | <i>Helicobacter pylori</i> resistance to clarithromycin in Reunion Island. <i>Médecine Et Maladies Infectieuses</i> , 2016, 46, 385-389. | 5.1 | 1 |
| 1086 | Early eradication has a lower risk of peptic ulcer bleeding in <i>Helicobacter pylori</i> -infected chronic kidney disease patients. <i>European Journal of Internal Medicine</i> , 2016, 33, 112-117. | 1.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-------|-----------|
| 1087 | Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 152-171. | 157.7 | 177 |
| 1088 | Phosphorylation-dependent and Phosphorylation-independent Regulation of <i>Helicobacter pylori</i> Acid Acclimation by the ArsRS Two-component System. <i>Helicobacter</i> , 2016, 21, 69-81. | 1.6 | 22 |
| 1089 | Iron Homeostasis and the Pathophysiology and Management of Iron Deficiency. , 2016, , 13-22. | | 0 |
| 1090 | 1,2-Benziselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8125-8133. | 2.9 | 82 |
| 1092 | Review article: the global emergence of <i>Helicobacter pylori</i> antibiotic resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 514-533. | 1.9 | 546 |
| 1093 | Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034. | 1.5 | 35 |
| 1094 | Emerging <i>Helicobacter pylori</i> levofloxacin resistance and novel genetic mutation in Nepal. <i>BMC Microbiology</i> , 2016, 16, 256. | 1.3 | 39 |
| 1095 | Eradication of <i>Helicobacter pylori</i> Infection Restores Ki67, p53, and Cyclin D1 Immunoreactivity in the Human Gastric Epithelium. <i>Clinical Medicine Insights Gastroenterology</i> , 2016, 9, CGast.S38330. | 1.0 | 8 |
| 1096 | Anti-inflammatory Effects of Capsaicin and Piperine on <i>Helicobacter pylori</i> -induced Chronic Gastritis in Mongolian Gerbils. <i>Helicobacter</i> , 2016, 21, 131-142. | 1.6 | 49 |
| 1097 | Novel class of Bi(III) hydroxamate complexes: synthesis, urease inhibitory activity and activity against <i>H. pylori</i> . <i>Dalton Transactions</i> , 2016, 45, 11008-11014. | 1.6 | 12 |
| 1098 | Systematic review of time trends in the prevalence of <i>Helicobacter pylori</i> infection in China and the USA. <i>Gut Pathogens</i> , 2016, 8, 8. | 1.6 | 154 |
| 1099 | Auranofin and <i>N</i> -heterocyclic carbene gold-analogs are potent inhibitors of the bacteria <i>Helicobacter pylori</i> . <i>FEMS Microbiology Letters</i> , 2016, 363, fnw148. | 0.7 | 43 |
| 1100 | A Comparison of Five Different Treatment Regimens as the First-Line Treatment of <i>Helicobacter pylori</i> in Turkey. <i>Helicobacter</i> , 2016, 21, 279-285. | 1.6 | 4 |
| 1101 | Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of <i>Helicobacter pylori</i> Infection: Two Pilot Studies. <i>Helicobacter</i> , 2016, 21, 375-381. | 1.6 | 31 |
| 1102 | How Effective Is the Quadruple Concomitant <i>Helicobacter Pylori</i> Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?. <i>Obesity Surgery</i> , 2016, 26, 1163-1166. | 1.1 | 8 |
| 1103 | Simultaneous Quantitative Detection of <i>Helicobacter Pylori</i> Based on a Rapid and Sensitive Testing Platform using Quantum Dots-Labeled Immunochromatographic Test Strips. <i>Nanoscale Research Letters</i> , 2016, 11, 62. | 3.1 | 18 |
| 1105 | Gastrointestinal Infections. , 2016, , 707-734. | | 0 |
| 1106 | Appropriateness of Proton Pump Inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy. <i>European Journal of Internal Medicine</i> , 2016, 30, 31-36. | 1.0 | 23 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1107 | Risk and mortality of gastrointestinal hemorrhage in patients with thrombocytopenia: Two nationwide retrospective cohort studies. <i>European Journal of Internal Medicine</i> , 2016, 27, 86-90. | 1.0 | 5 |
| 1108 | Amelioration of <i>Helicobacter pylori</i> -Induced PUD by Probiotic Lactic Acid Bacteria. , 2016, , 865-895. | | 1 |
| 1109 | <i>Helicobacter pylori</i> infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. <i>Platelets</i> , 2016, 27, 223-229. | 1.1 | 7 |
| 1110 | <i>Helicobacter pylori</i> infection in dyspeptic patients in an industrial belt of India. <i>Tropical Doctor</i> , 2017, 47, 2-6. | 0.2 | 8 |
| 1111 | The internalization of <i>Helicobacter pylori</i> plays a role in the failure of <i>H. pylori</i> eradication. <i>Helicobacter</i> , 2017, 22, e12324. | 1.6 | 31 |
| 1112 | <i>Helicobacter pylori</i> infection is associated with an altered gastric microbiota in children. <i>Mucosal Immunology</i> , 2017, 10, 1169-1177. | 2.7 | 80 |
| 1113 | The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of <i>Helicobacter pylori</i> by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 17 |
| 1114 | Realâ€world practice and Expectation of Asiaâ€Pacific physicians and patients in <i>Helicobacter Pylori</i> eradication (REAPâ€HP Survey). <i>Helicobacter</i> , 2017, 22, e12380. | 1.6 | 16 |
| 1115 | Clarithromycin-Based Triple Therapy Is Still Useful as an Initial Treatment for <i>Helicobacter pylori</i> Infection in the Dominican Republic. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 16-0729. | 0.6 | 18 |
| 1116 | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of <i>Helicobacter pylori</i> infection. <i>Medicine (United States)</i> , 2017, 96, e5859. | 0.4 | 15 |
| 1117 | Primary <i>Helicobacter pylori</i> resistance in elderly patients over 20 years: A Bulgarian study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 264-267. | 0.8 | 10 |
| 1118 | Global Prevalence of <i>Helicobacter pylori</i> Infection: Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 153, 420-429. | 0.6 | 1,983 |
| 1119 | Therapeutic success with bismuth-containing sequential and quadruple regimens in <i>Helicobacter pylori</i> eradication. <i>Arab Journal of Gastroenterology</i> , 2017, 18, 62-67. | 0.4 | 15 |
| 1120 | Anti- <i>Helicobacter pylori</i> activity of non-living, heat-killed form of lactobacilli including <i>Lactobacillus johnsonii</i> No.1088. <i>FEMS Microbiology Letters</i> , 2017, 364, . | 0.7 | 32 |
| 1121 | Validity of Salivary Polymerase Chain Reaction in Diagnosis of <i>Helicobacter pylori</i> Among Egyptian Patients. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 76-81. | 0.1 | 1 |
| 1122 | Proton Pump Inhibitors. , 2017, , 995-1013. | | 1 |
| 1123 | Advances in diagnosis and treatment of <i>Helicobacter pylori</i> infection. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2017, 64, 273-292. | 0.4 | 31 |
| 1124 | <i>Helicobacter pylori</i> eradication rates of concomitant and sequential therapies in Korea. <i>Helicobacter</i> , 2017, 22, e12441. | 1.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1125 | High primary antibiotic resistance of <i>Helicobacter Pylori</i> strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. <i>Helicobacter</i> , 2017, 22, e12440. | 1.6 | 36 |
| 1126 | Antibiotic susceptibility of <i>Helicobacter pylori</i> strains isolated from Iranian children: High frequency of A2143G point mutation associated with clarithromycin resistance. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 10, 131-135. | 0.9 | 21 |
| 1127 | A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343. | 0.9 | 39 |
| 1128 | Impact of health insurance coverage for <i>Helicobacter pylori</i> gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. <i>BMJ Open</i> , 2017, 7, e015855. | 0.8 | 54 |
| 1129 | Progresses about the Interplay among Clarithromycin, Immune and Central Nervous Systems. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 566-567. | 2.1 | 1 |
| 1130 | Probiotics for cure of <i>Helicobacter pylori</i> infection: A review. <i>International Journal of Food Properties</i> , 2017, 20, 2215-2222. | 1.3 | 6 |
| 1131 | Rapid identification of <i>Helicobacter pylori</i> and assessment of clarithromycin susceptibility from clinical specimens using FISH. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 29-37. | 1.3 | 14 |
| 1132 | The Role of <i>Helicobacter pylori</i> in Laryngopharyngeal Reflux: A Systematic Review and Meta-analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 255-262. | 1.1 | 13 |
| 1133 | Gastritis, Peptic Ulceration and Related Conditions. , 2017, , 321-327.e1. | | 0 |
| 1134 | Measuring and estimating the interaction between exposures on a dichotomous outcome for observational studies. <i>Journal of Applied Statistics</i> , 2017, 44, 2483-2498. | 0.6 | 0 |
| 1135 | High antibiotic resistance of <i>Helicobacter pylori</i> and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. <i>Helicobacter</i> , 2017, 22, e12365. | 1.6 | 20 |
| 1136 | CYP2C19 polymorphism has no influence on rabeprazole-based sequential therapy. <i>Advances in Digestive Medicine</i> , 2017, 4, 134-139. | 0.1 | 0 |
| 1137 | Strategies used by <i>Helicobacter pylori</i> to establish persistent infection. <i>World Journal of Gastroenterology</i> , 2017, 23, 2870. | 1.4 | 83 |
| 1138 | <i>Helicobacter pylori</i> cytotoxin-associated gene A protein among adult dyspeptic patients in South-western Nigeria. <i>African Journal of Microbiology Research</i> , 2017, 11, 681-686. | 0.4 | 1 |
| 1139 | Efficient production of nanobodies against urease activity of <i>Helicobacter pylori</i> in <i>Pichia pastoris</i> . <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 695-701. | 0.4 | 8 |
| 1140 | Antibiotics for secondary prevention of coronary heart disease. <i>The Cochrane Library</i> , 0, , . | 1.5 | 11 |
| 1141 | Association between Gastric Cancer Risk and Serum <i>Helicobacter pylori</i> Antibody Titers. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-6. | 0.7 | 11 |
| 1142 | Natural Products as a Potential Enzyme Inhibitors from Medicinal Plants. , 0, , . | | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1143 | Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infectionâ€”A randomized controlled trial. PLoS ONE, 2017, 12, e0183302. | 1.1 | 13 |
| 1144 | Phenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones. Gut Pathogens, 2017, 9, . | 1.6 | 7 |
| 1146 | Prevalence of Helicobacter pylori among patients with different gastrointestinal disorders in Saudi Arabia. Medical Journal of Indonesia, 2017, 25, 214-20. | 0.2 | 9 |
| 1147 | Changes with aging in gastric biomarkers levels and in biochemical factors associated with<i>Helicobacter pylori</i> infection in asymptomatic Chinese population. World Journal of Gastroenterology, 2017, 23, 5945. | 1.4 | 26 |
| 1149 | Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for<i>Helicobacter pylori</i>Eradication Failure. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2017, 69, 109. | 0.2 | 11 |
| 1150 | Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease. Gut and Liver, 2017, 11, 226-231. | 1.4 | 18 |
| 1151 | Fifth Chinese National Consensus Report on the management of <i>Helicobacter pylori</i> infection. Helicobacter, 2018, 23, e12475. | 1.6 | 304 |
| 1152 | Biological properties and pharmacological potential of plant exudates. Food Research International, 2018, 105, 1039-1053. | 2.9 | 44 |
| 1153 | Hepcidin correlates with interleukin-1 β and interleukin-6 but not iron deficiency in children with Helicobacter pylori infection. Pediatrics and Neonatology, 2018, 59, 611-617. | 0.3 | 8 |
| 1154 | Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Applied Microbiology and Biotechnology, 2018, 102, 4817-4827. | 1.7 | 16 |
| 1155 | Family history of gastric mucosal abnormality and the risk of gastric cancer: a population-based observational study. International Journal of Epidemiology, 2018, 47, 440-449. | 0.9 | 19 |
| 1156 | Gastric cancer in India: epidemiology and standard of treatment. Updates in Surgery, 2018, 70, 233-239. | 0.9 | 29 |
| 1158 | Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising protonâ€pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter, 2018, 23, e12466. | 1.6 | 29 |
| 1159 | A review on the development of urease inhibitors as antimicrobial agents against pathogenic bacteria. Journal of Advanced Research, 2018, 13, 69-100. | 4.4 | 79 |
| 1160 | Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clinical Gastroenterology and Hepatology, 2018, 16, 992-1002.e6. | 2.4 | 189 |
| 1161 | Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance, 2018, 14, 111-117. | 0.9 | 23 |
| 1162 | Gastritis Can Cause and Trigger Chronic Spontaneous Urticaria Independent of the Presence of <i>Helicobacter pylori</i>. International Archives of Allergy and Immunology, 2018, 175, 246-251. | 0.9 | 15 |
| 1163 | Helicobacter pylori and Risk of Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2018, 52, 386-391. | 1.1 | 44 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1164 | A link between platelet to lymphocyte ratio and <i>Helicobacter pylori</i> infection. Journal of Clinical Laboratory Analysis, 2018, 32, . | 0.9 | 15 |
| 1165 | Antimicrobial susceptibility of <i>Helicobacter pylori</i> strains isolated from children in Israel. Journal of Global Antimicrobial Resistance, 2018, 12, 175-178. | 0.9 | 13 |
| 1166 | <i>Helicobacter pylori</i> treatment: antibiotics or probiotics. Applied Microbiology and Biotechnology, 2018, 102, 1-7. | 1.7 | 219 |
| 1167 | Cumulative <i>Helicobacter Pylori</i> Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. Obesity Surgery, 2018, 28, 743-747. | 1.1 | 4 |
| 1168 | Inappropriate treatment in <i>Helicobacter pylori</i> eradication failure: a retrospective study. Scandinavian Journal of Gastroenterology, 2018, 53, 130-133. | 0.6 | 30 |
| 1169 | The prevalence and sociodemographic determinants of uninvestigated dyspepsia in the Czech Republic: a multicentre prospective study accomplished 10 years after the first study from the same geographical areas. European Journal of Gastroenterology and Hepatology, 2018, 30, 76-82. | 0.8 | 5 |
| 1170 | New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis. European Journal of Epidemiology, 2018, 33, 263-274. | 2.5 | 36 |
| 1171 | Propolis: The future therapy against <i>Helicobacter pylori</i> -mediated gastrointestinal diseases. Journal of Applied Biomedicine, 2018, 16, 81-99. | 0.6 | 18 |
| 1172 | <i>Helicobacter pylori</i> management in ASEAN: The Bangkok consensus report. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 37-56. | 1.4 | 100 |
| 1173 | Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for <i>Helicobacter pylori</i> eradication: A prospective randomized study. Turkish Journal of Gastroenterology, 2018, 29, 549-554. | 0.4 | 7 |
| 1174 | CLINICAL EVALUATION OF TRIPLE AND QUADRUPLE <i>HELICOBACTER PYLORI</i> ERADICATION THERAPY IN PEPTIC ULCER PATIENTS WITH DIFFERENT ABO BLOOD GROUP PHENOTYPES. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 460. | 0.3 | 1 |
| 1175 | Fourth-generation quinolones in the treatment of <i>Helicobacter pylori</i> infection: A meta-analysis. World Journal of Gastroenterology, 2018, 24, 3302-3312. | 1.4 | 5 |
| 1176 | Effective antimicrobial activity of rifabutin against multidrug-resistant <i>Helicobacter pylori</i> . Helicobacter, 2018, 23, e12531. | 1.6 | 11 |
| 1177 | Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for <i>Helicobacter pylori</i> eradication. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1822-1828. | 1.4 | 11 |
| 1178 | A review of gastrointestinal protocols for primary care medical service trips (MSTs) in Latin America and the Caribbean. International Health, 2018, 10, 125-132. | 0.8 | 2 |
| 1179 | Diagnosis of <i>Helicobacter pylori</i> Using Invasive and Noninvasive Approaches. Journal of Pathogens, 2018, 2018, 1-13. | 0.9 | 60 |
| 1180 | Prevalence and Risk Factors of Functional Dyspepsia in Health Check-up Population: A Nationwide Multicenter Prospective Study. Journal of Neurogastroenterology and Motility, 2018, 24, 603-613. | 0.8 | 39 |
| 1181 | Stool antigen detection versus 13 C-urea breath test for non-invasive diagnosis of pediatric <i>Helicobacter pylori</i> infection in a limited resource setting. Archives of Medical Science, 2018, 1, 69-73. | 0.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1182 | Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. <i>Cancer Management and Research</i> , 2018, Volume 10, 615-624. | 0.9 | 24 |
| 1183 | Gastric cancer: epidemiology, prevention, classification, and treatment. <i>Cancer Management and Research</i> , 2018, Volume 10, 239-248. | 0.9 | 745 |
| 1184 | Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders. <i>Chinese Medicine</i> , 2018, 13, 39. | 1.6 | 39 |
| 1185 | Marginal Zone Lymphomas (Extranodal/Malt, Splenic, and Nodal). , 2018, , 1277-1287.e6. | | 0 |
| 1186 | Comparison between different first-line therapy protocols in eradicating <i>Helicobacter pylori</i> in a region with high clarithromycin resistance. <i>Przegląd Gastroenterologiczny</i> , 2018, 13, 150-156. | 0.3 | 2 |
| 1187 | Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible <i>Helicobacter pylori</i> strains with A2143G of 23S rRNA gene. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2018, 17, 10. | 1.7 | 32 |
| 1188 | Understanding treatment guidelines with bismuth and non-bismuth quadruple <i>Helicobacter pylori</i> eradication therapies. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 679-687. | 2.0 | 55 |
| 1189 | Molecular Basis of Diseases of the Gastrointestinal Tract. , 2018, , 387-415. | | 1 |
| 1190 | <i>Saccharomyces boulardii</i> as an adjuvant therapy for <i>Helicobacter pylori</i> eradication: A systematic review and meta-analysis with trial sequential analysis. <i>Helicobacter</i> , 2019, 24, e12651. | 1.6 | 39 |
| 1191 | Online registry for nationwide database of <i>Helicobacter pylori</i> eradication in Korea: Correlation of antibiotic use density with eradication success. <i>Helicobacter</i> , 2019, 24, e12646. | 1.6 | 20 |
| 1192 | Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in <i>Helicobacter pylori</i> Eradication Therapy. <i>Chemical and Pharmaceutical Bulletin</i> , 2019, 67, 810-815. | 0.6 | 5 |
| 1193 | Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (HpEuReg). <i>Helicobacter</i> , 2019, 24, e12630. | 1.6 | 46 |
| 1194 | Efficacy and Safety of AlbiD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 403-412. | 0.8 | 1 |
| 1195 | Potential Health-Promoting Effects of Probiotics in Dairy Beverages. , 2019, , 173-204. | | 9 |
| 1196 | Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 639-656. | 0.9 | 12 |
| 1197 | <i>Helicobacter pylori</i> and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. <i>Frontiers in Microbiology</i> , 2019, 10, 1796. | 1.5 | 27 |
| 1198 | Evaluation of the Epidemiologic Efficacy of Eradicating <i>Helicobacter pylori</i> on Development of Gastric Cancer. <i>Epidemiologic Reviews</i> , 2019, 41, 97-108. | 1.3 | 13 |
| 1199 | In vitro anti- <i>Helicobacter pylori</i> activity of aqueous extract from Persian Oak testa. <i>Chinese Herbal Medicines</i> , 2019, 11, 394-399. | 1.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1200 | Probiotics and Herbal Therapies. , 2019, , 103-113. | | 0 |
| 1201 | Influence of serum vitamin D level on Helicobacter pylori eradication: A multi-center, observational, prospective and cohort study. Journal of Digestive Diseases, 2019, 20, 421-426. | 0.7 | 24 |
| 1202 | Risk Factor Modification in Patients with Peptic Ulcer Disease. , 2019, , 643-652. | | 1 |
| 1203 | Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. Helicobacter, 2019, 24, e12593. | 1.6 | 18 |
| 1204 | Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infectious Diseases, 2019, 19, 447. | 1.3 | 20 |
| 1205 | Pathological Diagnosis and Classification of Gastric Epithelial Tumours. Current Clinical Pathology, 2019, , 53-82. | 0.0 | 2 |
| 1206 | A Comprehensive Review on the Screening Models for the Pharmacological Assessment of Antiulcer Drugs. Current Clinical Pharmacology, 2019, 14, 175-196. | 0.2 | 16 |
| 1207 | Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study. Drug Safety, 2019, 42, 993-1003. | 1.4 | 12 |
| 1208 | Synergistic effect of anti-Helicobacter pylori urease immunoglobulin Y from egg yolk of immunized hens and Lactobacillus johnsonii No.1088 to inhibit the growth of Helicobacter pylori in vitro and in vivo. Vaccine, 2019, 37, 3106-3112. | 1.7 | 21 |
| 1209 | Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?. Frontiers in Pharmacology, 2019, 10, 316. | 1.6 | 23 |
| 1210 | Comparison of high and low molecular weight chitosan as in-vitro boosting agent for photodynamic therapy against Helicobacter pylori using methylene blue and endoscopic light. Photodiagnosis and Photodynamic Therapy, 2019, 26, 111-115. | 1.3 | 7 |
| 1211 | Herbal medicine as an auspicious therapeutic approach for the eradication of <i>Helicobacter pylori</i> infection: A concise review. Journal of Cellular Physiology, 2019, 234, 16847-16860. | 2.0 | 18 |
| 1212 | GastroPanel® Biomarker Assay: The Most Comprehensive Test for <i>Helicobacter pylori</i> Infection and Its Clinical Sequelae. A Critical Review. Anticancer Research, 2019, 39, 1091-1104. | 0.5 | 24 |
| 1214 | Strengthening strategic management approaches to address antimicrobial resistance in global human health: a scoping review. BMJ Global Health, 2019, 4, e001730. | 2.0 | 19 |
| 1215 | BIOMEDICINAL AND GASTROPROTECTIVE ASPECTS OF ORGANOBISMUTH COMPOUNDS: RECENT APPROACHES AND FUTURE PERSPECTIVES. Asian Journal of Pharmaceutical and Clinical Research, 0, , 172-181. | 0.3 | 0 |
| 1216 | A historical review of classic Helicobacter pylori publications in science citation index expanded. Collnet Journal of Scientometrics and Information Management, 2019, 13, 313-330. | 0.4 | 1 |
| 1217 | Helicobacter Pylori Classification based on Deep Neural Network. , 2019, , . | | 2 |
| 1218 | Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study. PLoS ONE, 2019, 14, e0225585. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1219 | Efficacy and safety of acupuncture therapy for chronic atrophic gastritis. <i>Medicine (United States)</i> , 2019, 98, e17003. | 0.4 | 11 |
| 1220 | Association between <i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 735-742. | 0.8 | 28 |
| 1221 | Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for <i>Helicobacter pylori</i> : a prospective, open-label, comparative study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1206-1210. | 0.8 | 8 |
| 1222 | <p></p> <i>Helicobacter pylori</i> And Duodenal Ulcer: Systematic Review Of Controversies In Causation</p>. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 441-447. | 1.0 | 10 |
| 1223 | Diagnostic methods for <i>Helicobacter pylori</i> infection: ideals, options, and limitations. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 55-66. | 1.3 | 102 |
| 1224 | Heineke&eMikulicz pyloroplasty for the treatment of pyloric stenosis secondary to gastro&eododenal ulcer disease in three foals. <i>Equine Veterinary Education</i> , 2020, 32, 540-544. | 0.3 | 1 |
| 1225 | Accuracy of Different Rapid Urease Tests in Comparison with Histopathology in Patients with Endoscopic Signs of Gastritis. <i>Digestion</i> , 2020, 101, 184-190. | 1.2 | 26 |
| 1226 | What Would the Screen-and-Treat Strategy for <i>Helicobacter pylori</i> Mean in Terms of Antibiotic Consumption?. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1632-1642. | 1.1 | 9 |
| 1227 | Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of <i>Helicobacter pylori</i> infection. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 212-225. | 1.2 | 11 |
| 1228 | Transitioning of <i>Helicobacter pylori</i> Therapy from Trial and Error to Antimicrobial Stewardship. <i>Antibiotics</i> , 2020, 9, 671. | 1.5 | 47 |
| 1229 | Clinical characterization of <i>Helicobacter pylori</i> infected patients 15 years after unsuccessful eradication. <i>PLoS ONE</i> , 2020, 15, e0238944. | 1.1 | 4 |
| 1230 | The updated JSPGHAN guidelines for the management of <i>Helicobacter pylori</i> infection in childhood. <i>Pediatrics International</i> , 2020, 62, 1315-1331. | 0.2 | 42 |
| 1231 | Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. <i>pylori</i> infection in a treatment-na&ve cohort of junior high school students in Japan. <i>Journal of Gastroenterology</i> , 2020, 55, 969-976. | 2.3 | 41 |
| 1232 | <i>Helicobacter pylori</i> (Hp) IgG ELISA of the New-Generation GastroPanel& Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients. <i>Anticancer Research</i> , 2020, 40, 6387-6398. | 0.5 | 11 |
| 1233 | High Effectiveness of a 14-Day Concomitant Therapy for <i>Helicobacter pylori</i> Treatment in Primary Care. An Observational Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2410. | 1.0 | 6 |
| 1234 | Diagnostic accuracy of &esweeping&method compared to conventional sampling in rapid urease test for <i>Helicobacter pylori</i> detection in atrophic mucosa. <i>Scientific Reports</i> , 2020, 10, 18483. | 1.6 | 7 |
| 1235 | Using next-generation sequencing to analyze <i>Helicobacter pylori</i> clones with different levofloxacin resistances from a patient with eradication failure. <i>Medicine (United States)</i> , 2020, 99, e20761. | 0.4 | 7 |
| 1236 | Analysis of serum gastrin&17 and <i>Helicobacter pylori</i> antibody in healthy Chinese population. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23518. | 0.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1237 | Helicobacter pylori Prevalence in Laparoscopic Sleeve Gastrectomy Specimen. Gastroenterology Research and Practice, 2020, 2020, 1-5. | 0.7 | 6 |
| 1238 | Accuracy of Endoscopic Diagnosis of Helicobacter pylori Based on the Kyoto Classification of Gastritis: A Multicenter Study. Frontiers in Oncology, 2020, 10, 599218. | 1.3 | 19 |
| 1239 | Helicobacter pylori prevalence in the Southwest of China. Medicine (United States), 2020, 99, e19369. | 0.4 | 4 |
| 1240 | Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clinical and Experimental Gastroenterology, 2020, Volume 13, 25-33. | 1.0 | 8 |
| 1241 | Bismuth drugs as antimicrobial agents. Advances in Inorganic Chemistry, 2020, 75, 183-205. | 0.4 | 19 |
| 1242 | Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter, 2020, 25, e12679. | 1.6 | 20 |
| 1243 | Association of Genetic Polymorphisms in FOXA1 with the Progression of Genetic Susceptibility to Gastric Cancer. Gastroenterology Research and Practice, 2020, 2020, 1-8. | 0.7 | 5 |
| 1244 | Effects of Helicobacter pylori on the glutathione-related pathway in gastric epithelial cells. Biochemical and Biophysical Research Communications, 2020, 526, 1118-1124. | 1.0 | 9 |
| 1245 | Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori. Helicobacter, 2021, 26, e12758. | 1.6 | 13 |
| 1246 | Bi(MOFs): syntheses, structures and applications. Inorganic Chemistry Frontiers, 2021, 8, 572-589. | 3.0 | 32 |
| 1247 | Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microbial Pathogenesis, 2021, 152, 104661. | 1.3 | 15 |
| 1248 | Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter, 2021, 26, e12767. | 1.6 | 15 |
| 1249 | European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. Gut, 2021, 70, 40-54. | 6.1 | 139 |
| 1250 | Recurrent Iron Deficiency Anemia Revealing Chronic Gastritis with Helicobacter pylori. Open Journal of Gastroenterology, 2021, 11, 47-51. | 0.1 | 0 |
| 1251 | Room for Improvement in the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology, 2022, 56, e98-e108. | 1.1 | 36 |
| 1252 | Indigenous Probiotic Lactobacillus Strains to Combat Gastric Pathogen Helicobacter pylori: Microbial Interference Therapy. , 2021, , 215-230. | | 1 |
| 1253 | The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482198917. | 1.4 | 15 |
| 1254 | Serological Biomarker Test (GastroPanel [®]) in the Diagnosis of Functional Gastric Disorders, Helicobacter pylori and Atrophic Gastritis in Patients Examined for Dyspeptic Symptoms. Anticancer Research, 2021, 41, 811-819. | 0.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1255 | Helicobacter pylori in Childhood. , 2021, , 275-292.e12. | | 0 |
| 1256 | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma). Hematologic Malignancies, 2021, , 93-115. | 0.2 | 1 |
| 1257 | Gastric Acid Powered Nanomotors Release Antibiotics for In Vivo Treatment of <i>Helicobacter pylori</i> Infection. Small, 2021, 17, e2006877. | 5.2 | 44 |
| 1258 | Antibiotics for secondary prevention of coronary heart disease. The Cochrane Library, 2021, 2021, CD003610. | 1.5 | 11 |
| 1259 | Complete symptom resolution as predictor of Helicobacter pylori eradication and factors affecting symptom resolution: Prospective follow up study. PLoS ONE, 2021, 16, e0246624. | 1.1 | 2 |
| 1260 | MAIN CAUSES OF THE STOMACH CANCER ORIGIN, PRETUMOR NEOPLASM CONDITIONS AND PREVENTION DIRECTIONS. Clinical & Experimental Pathology, 2021, 19, . | 0.0 | 0 |
| 1261 | EVALUATION OF EFFECTIVENESS OF COMPREHENSIVE TREATMENT OF DUODENAL ULCER IN CHILDREN. Clinical & Experimental Pathology, 2021, 19, . | 0.0 | 0 |
| 1262 | Comparison of intestinal metaplasia and Helicobacter pylori positivity in patients from different age groups with antral gastritis. Journal of Surgery and Medicine, 2021, 5, 226-229. | 0.0 | 1 |
| 1263 | VARIABILITY OF NEUTROPHIL-ACTIVATING PROTEIN AMONG HELICOBACTER PYLORI STRAINS. Roumanian Archives of Microbiology and Immunology, 2021, 80, 43-50. | 0.1 | 0 |
| 1264 | Efficacy of bismuth added to standard triple therapy as the firstâ€line eradication regimen for <i>Helicobacter pylori</i> infection. Helicobacter, 2021, 26, e12792. | 1.6 | 8 |
| 1265 | Design and Optimization of a Novel Strategy for the Local Treatment of Helicobacter pylori Infections. Journal of Pharmaceutical Sciences, 2021, 110, 1302-1309. | 1.6 | 1 |
| 1266 | Vegetable Extracts and Nutrients Useful in the Recovery from Helicobacter pylori Infection: A Systematic Review on Clinical Trials. Molecules, 2021, 26, 2272. | 1.7 | 9 |
| 1267 | Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study. Cancers, 2021, 13, 1657. | 1.7 | 7 |
| 1269 | OBSERVATIONS IN CONTROLLING HELICOBACTER PYLORI BETWEEN TRIPLE REGIME AND SEQUENTIAL REGIME.. Pakistan Postgraduate Medical Journal, 2021, 31, 155-158. | 0.0 | 0 |
| 1270 | What Is New in Helicobacter pylori Diagnosis. An Overview. Journal of Clinical Medicine, 2021, 10, 2091. | 1.0 | 33 |
| 1271 | Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. Turkish Journal of Gastroenterology, 2021, 32, 269-275. | 0.4 | 2 |
| 1272 | Impact of <i>Helicobacter pylori</i> on hematological parameters among Saudi population. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 643-648. | 0.5 | 3 |
| 1273 | â€œPREVALENCE OF H.PYLORI INFECTION IN PEPTIC ULCER DISEASE PATIENTS IN A TERTIARY CARE HOSPITAL, KURNOOL, ANDHRA PRADESH.â€¸, 2021, , 26-29. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1274 | Dyspepsia Challenge in Primary Care Gastroenterology. <i>Digestive Diseases</i> , 2022, 40, 270-275. | 0.8 | 2 |
| 1275 | Management of <i>Helicobacter pylori</i> infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 420-444. | 0.7 | 13 |
| 1276 | Research Trends on Clinical <i>Helicobacter pylori</i> Eradication: A Bibliometric Analysis from 1983 to 2020. <i>Helicobacter</i> , 2021, 26, e12835. | 1.6 | 8 |
| 1277 | Diagnosis of <i>Helicobacter pylori</i> Infection and Recent Advances. <i>Diagnostics</i> , 2021, 11, 1305. | 1.3 | 17 |
| 1278 | <i>Helicobacter pylori</i> eradication with a clarithromycin-based triple therapy in elderly patients. <i>Panminerva Medica</i> , 2021, 63, 332-335. | 0.2 | 7 |
| 1279 | Trends in iron deficiency anemia research 2001-2020: A bibliometric analysis. <i>World Journal of Meta-analysis</i> , 2021, 9, 389-404. | 0.1 | 1 |
| 1280 | An evaluation of gastrointestinal endoscopic examination outcomes in patients with iron deficiency through guidelines. <i>Journal of Contemporary Medicine</i> , 0, , . | 0.1 | 0 |
| 1281 | <i>Helicobacter pylori</i> infection: from standard to alternative treatment strategies. <i>Critical Reviews in Microbiology</i> , 2022, 48, 376-396. | 2.7 | 31 |
| 1282 | Influence of adding vitamin D3 to standard clarithromycin-based triple therapy on the eradication rates of <i>Helicobacter pylori</i> infection. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 209-214. | 0.4 | 9 |
| 1283 | Endoscopic Diagnosis for <i>H. pylori</i> Infection: White Light Imaging (WLI) vs. Image-Enhanced Endoscopy (IEE). <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3031-3038. | 0.5 | 6 |
| 1284 | Breath Biomarkers in Diagnostic Applications. <i>Molecules</i> , 2021, 26, 5514. | 1.7 | 29 |
| 1285 | Effect of Statins on <i>Helicobacter pylori</i> Eradication Rate: A Systematic Review and Meta-Analysis. <i>GE Portuguese Journal of Gastroenterology</i> , 0, , 1-9. | 0.3 | 2 |
| 1286 | Long-term risk of upper gastrointestinal bleeding after <i>Helicobacter pylori</i> eradication: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1162-1169. | 1.9 | 14 |
| 1287 | Effects of cranberry beverages on oxidative stress and gut microbiota in subjects with <i>Helicobacter pylori</i> infection: a randomized, double-blind, placebo-controlled trial. <i>Food and Function</i> , 2021, 12, 6878-6888. | 2.1 | 7 |
| 1288 | Genetic Instability and Chronic Inflammation in Gastrointestinal Cancers. , 2010, , 351-397. | | 1 |
| 1289 | Magen-Darm-Mittel und Laxantien. , 2009, , 653-681. | | 1 |
| 1290 | Magen-Darm-Mittel und Laxantien. , 2011, , 699-728. | | 1 |
| 1291 | Magen-Darm-Mittel und Laxantien. , 2013, , 703-732. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1292 | Magen-Darm-Mittel und Lebertherapeutika. , 2017, , 539-561. | | 2 |
| 1293 | Synopsis of Antibiotic Treatment. , 2016, , 417-426. | | 3 |
| 1294 | Molecular Basis of Diseases of the Gastrointestinal Tract. , 2009, , 365-393. | | 2 |
| 1295 | Dyspepsia. , 2010, , 183-195.e3. | | 6 |
| 1298 | Effect of Helicobacter pylori on insulin resistance in nonobese, nondiabetic, and normolipidemic Egyptian patients. Egyptian Liver Journal, 2018, 8, 23-28. | 0.3 | 2 |
| 1299 | Validation of a Monoclonal Stool Antigen Test for Diagnosing <i>Helicobacter pylori</i> Infection in Young Children. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 400-403. | 0.9 | 33 |
| 1300 | Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract—evidence from next-generation sequencing studies. Alimentary Pharmacology and Therapeutics, 2020, 51, 505-526. | 1.9 | 51 |
| 1301 | Comparative Evaluation of 29 Commercial <i>Helicobacter pylori</i> Serological Kits. Helicobacter, 2013, 18, 169-179. | 1.6 | 97 |
| 1303 | Investigating dyspepsia. BMJ: British Medical Journal, 2008, 337, a1400-a1400. | 2.4 | 16 |
| 1304 | Kucers' The Use of Antibiotics. , 0, , . | | 51 |
| 1305 | Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication. Medical Science Monitor, 2011, 17, CR235-CR240. | 0.5 | 6 |
| 1306 | Trace gas sensing using diode-pumped collinearly detected spontaneous Raman scattering enhanced by a multipass cell. Optics Letters, 2020, 45, 133. | 1.7 | 29 |
| 1307 | Docosahexaenoic Acid Inhibits Helicobacter pylori Growth In Vitro and Mice Gastric Mucosa Colonization. PLoS ONE, 2012, 7, e35072. | 1.1 | 90 |
| 1308 | Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials. PLoS ONE, 2013, 8, e62162. | 1.1 | 82 |
| 1309 | Gastrointestinal Symptoms are Still Prevalent and Negatively Impact Health-Related Quality of Life: A Large Cross-Sectional Population Based Study in The Netherlands. PLoS ONE, 2013, 8, e69876. | 1.1 | 39 |
| 1310 | Immunization with Heat Shock Protein A and β -Glutamyl Transpeptidase Induces Reduction on the Helicobacter pylori Colonization in Mice. PLoS ONE, 2015, 10, e0130391. | 1.1 | 16 |
| 1311 | Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS ONE, 2016, 11, e0166199. | 1.1 | 55 |
| 1312 | Gastric mucosal status in populations with a low prevalence of Helicobacter pylori in Indonesia. PLoS ONE, 2017, 12, e0176203. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1313 | Effectiveness of <i>Helicobacter pylori</i> eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference. <i>PLoS ONE</i> , 2017, 12, e0183321. | 1.1 | 34 |
| 1318 | Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of : a randomized, double-blind clinical trial. <i>EXCLI Journal</i> , 2019, 18, 644-652. | 0.5 | 14 |
| 1319 | A real life study of <i>Helicobacter pylori</i> eradication with bismuth quadruple therapy in naïve and previously treated patients. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 552-558. | 0.1 | 15 |
| 1320 | Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera [®] 1/2) to eradicate <i>Helicobacter pylori</i> infection in 200 patients. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 467-470. | 0.1 | 8 |
| 1321 | Comparison of three different regimens against <i>Helicobacter pylori</i> as a first-line treatment: A randomized clinical trial. <i>Bosnian Journal of Basic Medical Sciences</i> , 2016, 16, 52-7. | 0.6 | 13 |
| 1322 | Role of <i>Helicobacter Pylori</i> in Chronic Urticaria among Egyptian Patients with Dyspepsia: A caseâ€“control study. <i>International Journal of Dermatology and Clinical Research</i> , 0, , 026-031. | 0.4 | 1 |
| 1323 | THE RELATION BETWEEN HELICOBACTER PYLORI SEROPOSITIVITY AND IRON DEFICIENCY ANEMIA IN IRAQ-KURDISTAN-SULAIMANI CITY. <i>Journal of Sulaimani Medical College</i> , 2018, 8, 17-21. | 0.0 | 1 |
| 1324 | Long-term management of patients taking proton pump inhibitors. <i>Australian Prescriber</i> , 2008, 31, 5-7. | 0.5 | 4 |
| 1325 | <i>Helicobacter pylori</i> and Migraine: Is Eradication of <i>Helicobacter pylori</i> Effective in Relief of Migraine Headache?. <i>Caspian Journal of Neurological Sciences</i> , 2016, 2, 29-35. | 0.1 | 7 |
| 1326 | Clinical aspects of <i>Helicobacter pylori</i> infection. <i>Polish Archives of Internal Medicine</i> , 2008, 118, 426-430. | 0.3 | 8 |
| 1327 | <i>Helicobacter pylori</i> vacuolating cytotoxin and gastric cancer risk: reconsidered. <i>Translational Cancer Research</i> , 2016, 5, S557-S560. | 0.4 | 3 |
| 1328 | Linking Antimicrobial Potential of Natural Products Derived from Aquatic Organisms and Microbes Involved in Alzheimerâ€™s Disease - A Review. <i>Current Medicinal Chemistry</i> , 2020, 27, 4372-4391. | 1.2 | 7 |
| 1329 | Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in <i>Helicobacter pylori</i> . <i>Current Drug Therapy</i> , 2008, 3, 190-203. | 0.2 | 31 |
| 1330 | Impact of a two-bacterial-strain formula, containing <i>Bifidobacterium animalis lactis</i> BB-12 and <i>Enterococcus faecium</i> L3, administered before and after therapy for <i>Helicobacter pylori</i> eradication. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 117-123. | 2.2 | 10 |
| 1331 | Improvement of reflux symptom related quality of life after <i>Helicobacter pylori</i> eradication therapy. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2013, 52, 172-178. | 0.6 | 23 |
| 1332 | Absence of bacteria in intracranial aneurysms. <i>Journal of Neurosurgery</i> , 2020, 132, 1197-1201. | 0.9 | 3 |
| 1333 | <i>Helicobacter Pylori</i> and Gastroduodenal Ulcer Disease. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 801-8. | 0.6 | 21 |
| 1334 | HELICOBACTER PYLORI (HP) INFECTION IN OBESE PATIENTS UNDERGOING ROLIXEN- Y GASTRIC BYPASS; EFFICACY OF TWO DIFFERENT TREATMENT REGIMENS IN HP ERADICATION. <i>Nutricion Hospitalaria</i> , 2015, 32, 600-5. | 0.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1335 | Efficacy of Different Laboratory Tests to Diagnose <i>Helicobacter pylori</i> Infection. Faridpur Medical College Journal, 2013, 8, 11-14. | 0.0 | 3 |
| 1336 | Management of <i>Helicobacter pylori</i> . F1000 Medicine Reports, 2010, 2, . | 2.9 | 5 |
| 1337 | Anti- <i>Helicobacter pylori</i> Properties of GutGard TM . Preventive Nutrition and Food Science, 2013, 18, 104-110. | 0.7 | 11 |
| 1338 | Is a 7-day <i>Helicobacter pylori</i> treatment enough for eradication and inactivation of gastric inflammatory activity?. World Journal of Gastroenterology, 2008, 14, 2838. | 1.4 | 5 |
| 1339 | Treatment of <i>Helicobacter pylori</i> in surgical practice: A randomised trial of triple versus quadruple therapy in a rural district general hospital. World Journal of Gastroenterology, 2008, 14, 3855. | 1.4 | 23 |
| 1340 | Efflux pump gene <i>hefA</i> of <i>Helicobacter pylori</i> plays an important role in multidrug resistance. World Journal of Gastroenterology, 2008, 14, 5217. | 1.4 | 74 |
| 1341 | “Rescue” regimens after <i>Helicobacter pylori</i> treatment failure. World Journal of Gastroenterology, 2008, 14, 5385. | 1.4 | 98 |
| 1342 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World Journal of Gastroenterology, 2008, 14, 6224. | 1.4 | 18 |
| 1343 | <i>H. pylori</i> eradication: A randomized prospective study of triple therapy with or without ecabet sodium. World Journal of Gastroenterology, 2008, 14, 908. | 1.4 | 24 |
| 1344 | Dietary and socio-economic factors in relation to <i>Helicobacter pylori</i> re-infection. World Journal of Gastroenterology, 2009, 15, 1119. | 1.4 | 27 |
| 1345 | Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World Journal of Gastroenterology, 2009, 15, 853. | 1.4 | 78 |
| 1346 | Therapy of gastric mucosa associated lymphoid tissue lymphoma. World Journal of Gastroenterology, 2007, 13, 3554. | 1.4 | 41 |
| 1347 | Diagnostic accuracy of a rapid fecal test to confirm <i>H. pylori</i> eradication after therapy: Prospective comparison with a laboratory stool test. World Journal of Gastroenterology, 2007, 13, 4484. | 1.4 | 6 |
| 1348 | An optimized ¹³ C-urea breath test for the diagnosis of <i>H. pylori</i> infection. World Journal of Gastroenterology, 2007, 13, 5454. | 1.4 | 15 |
| 1349 | Association of autoimmune type atrophic corpus gastritis with <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology, 2010, 16, 83-8. | 1.4 | 40 |
| 1350 | Distribution of <i>gyrA</i> mutations in fluoroquinolone-resistant <i>Helicobacter pylori</i> strains. World Journal of Gastroenterology, 2010, 16, 2272. | 1.4 | 52 |
| 1351 | First-line eradication of <i>Helicobacter pylori</i> : Are the standard triple therapies obsolete? A different perspective. World Journal of Gastroenterology, 2010, 16, 3865. | 1.4 | 24 |
| 1352 | Age-dependent eradication of <i>Helicobacter pylori</i> in Japanese patients. World Journal of Gastroenterology, 2010, 16, 4176. | 1.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1353 | Resistance of <i>Helicobacter pylori</i> to antibiotics from 2000 to 2009 in Shanghai. World Journal of Gastroenterology, 2010, 16, 5118. | 1.4 | 65 |
| 1354 | Consequences of <i>Helicobacter pylori</i> infection in children. World Journal of Gastroenterology, 2010, 16, 5181. | 1.4 | 97 |
| 1355 | Antimicrobial susceptibility of <i>Helicobacter pylori</i> strains isolated from patients in Shiraz, Southern Iran. World Journal of Gastroenterology, 2010, 16, 5746. | 1.4 | 37 |
| 1356 | Does <i>Helicobacter pylori</i> infection play a role in iron deficiency anemia? A meta-analysis. World Journal of Gastroenterology, 2010, 16, 886-96. | 1.4 | 146 |
| 1357 | Cure of alopecia areata after eradication of <i>Helicobacter pylori</i> : a new association?. World Journal of Gastroenterology, 2011, 17, 3165-70. | 1.4 | 26 |
| 1358 | A new look at anti- <i>Helicobacter pylori</i> therapy. World Journal of Gastroenterology, 2011, 17, 3971. | 1.4 | 139 |
| 1359 | Influence of proton pump inhibitor treatment on <i>Helicobacter pylori</i> stool antigen test. World Journal of Gastroenterology, 2012, 18, 44. | 1.4 | 39 |
| 1360 | Autoimmune thyroid diseases and <i>Helicobacter pylori</i> : The correlation is present only in Graves's disease. World Journal of Gastroenterology, 2012, 18, 1093. | 1.4 | 39 |
| 1361 | Antibiotic resistance and <i>cagA</i> gene correlation: A looming crisis of <i>Helicobacter pylori</i> . World Journal of Gastroenterology, 2012, 18, 2245. | 1.4 | 32 |
| 1362 | Quadruple therapy with moxifloxacin and bismuth for first-line treatment of <i>Helicobacter pylori</i> . World Journal of Gastroenterology, 2012, 18, 4386. | 1.4 | 18 |
| 1363 | Levofloxacin/amoxicillin-based schemes vs quadruple therapy for <i>Helicobacter pylori</i> eradication in second-line. World Journal of Gastroenterology, 2012, 18, 5669. | 1.4 | 53 |
| 1364 | Trends in the eradication rates of <i>Helicobacter pylori</i> infection for eleven years. World Journal of Gastroenterology, 2012, 18, 6628. | 1.4 | 29 |
| 1365 | Increased expression of matrix metalloproteinase-9 associated with gastric ulcer recurrence. World Journal of Gastroenterology, 2013, 19, 4590. | 1.4 | 32 |
| 1366 | Antibiotics resistance rate of <i>Helicobacter pylori</i> in Bhutan. World Journal of Gastroenterology, 2013, 19, 5508. | 1.4 | 17 |
| 1367 | Ethnicity association of <i>Helicobacter pylori</i> virulence genotype and metronidazole susceptibility. World Journal of Gastroenterology, 2013, 19, 1283. | 1.4 | 7 |
| 1368 | Rabeprazole, clarithromycin, and amoxicillin <i>Helicobacter pylori</i> eradication therapy: Report of an efficacy study. World Journal of Gastroenterology, 2014, 20, 3615. | 1.4 | 14 |
| 1369 | Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. World Journal of Gastroenterology, 2014, 20, 5205. | 1.4 | 38 |
| 1370 | Management of <i>Helicobacter pylori</i> infection after gastric surgery. World Journal of Gastroenterology, 2014, 20, 5274. | 1.4 | 27 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1371 | Helicobacter pylori: Management in 2013. World Journal of Gastroenterology, 2014, 20, 5302. | 1.4 | 10 |
| 1372 | Optimal treatment strategy for <i>Helicobacter pylori</i> : Era of antibiotic resistance. World Journal of Gastroenterology, 2014, 20, 5654. | 1.4 | 21 |
| 1373 | <i>Helicobacter pylori</i> infection in older people. World Journal of Gastroenterology, 2014, 20, 6364. | 1.4 | 56 |
| 1374 | Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology, 2014, 20, 6547. | 1.4 | 26 |
| 1375 | Fluoroquinolone-based protocols for eradication of <i>Helicobacter pylori</i> . World Journal of Gastroenterology, 2014, 20, 8947-56. | 1.4 | 4 |
| 1376 | Treatment of <i>Helicobacter pylori</i> infection: Meeting the challenge of antimicrobial resistance. World Journal of Gastroenterology, 2014, 20, 9898. | 1.4 | 95 |
| 1377 | Pharmacological therapy used in the elimination of <i>Helicobacter pylori</i> infection: A Review. World Journal of Gastroenterology, 2015, 21, 139. | 1.4 | 21 |
| 1378 | Seven-day quintuple regimen as a rescue therapy for <i>Helicobacter pylori</i> eradication. World Journal of Gastroenterology, 2015, 21, 661. | 1.4 | 15 |
| 1379 | Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for <i>Helicobacter pylori</i> eradication in Italy. World Journal of Gastroenterology, 2015, 21, 6698. | 1.4 | 19 |
| 1380 | Centralized isolation of <i>Helicobacter pylori</i> from multiple centers and transport condition influences. World Journal of Gastroenterology, 2015, 21, 944. | 1.4 | 12 |
| 1381 | Hybrid vs sequential therapy for eradication of <i>Helicobacter pylori</i> in Taiwan: A prospective randomized trial. World Journal of Gastroenterology, 2015, 21, 10435. | 1.4 | 27 |
| 1382 | Geographical distribution of the incidence of gastric cancer in Bhutan. World Journal of Gastroenterology, 2015, 21, 10883. | 1.4 | 12 |
| 1383 | Optimal initiation of <i>Helicobacter pylori</i> eradication in patients with peptic ulcer bleeding. World Journal of Gastroenterology, 2015, 21, 2497. | 1.4 | 8 |
| 1384 | Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for <i>Helicobacter pylori</i> as high priority pathogen by World Health Organization. World Journal of Gastroenterology, 2017, 23, 6379-6384. | 1.4 | 28 |
| 1385 | Development of <i>Helicobacter pylori</i> treatment: How do we manage antimicrobial resistance?. World Journal of Gastroenterology, 2019, 25, 1907-1912. | 1.4 | 72 |
| 1386 | <i>Helicobacter pylori</i> and gastric cancer: current status of the Austrain Czech German gastric cancer prevention trial (PRISMA-Study). World Journal of Gastroenterology, 2001, 7, 243. | 1.4 | 48 |
| 1387 | <i>Helicobacter pylori</i> antibiotic susceptibility patterns in Bangladesh: Emerging levofloxacin resistance. Journal of Infection in Developing Countries, 2016, 10, 245-253. | 0.5 | 27 |
| 1388 | Clarithromycin-based triple therapy for <i>Helicobacter pylori</i> treatment in peptic ulcer patients. Journal of Infection in Developing Countries, 2010, 4, 712-716. | 0.5 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1389 | Serum Prohepcidin Levels in <i>Helicobacter Pylori</i> Infected Patients with Iron Deficiency Anemia. Korean Journal of Internal Medicine, 2010, 25, 195. | 0.7 | 19 |
| 1390 | The effects of sequential treatment as a first-line therapy for <i>Helicobacter pylori</i> eradication. Turkish Journal of Medical Sciences, 0, , . | 0.4 | 3 |
| 1391 | A clinician's guide to managing <i>Helicobacter pylori</i> infection.. Cleveland Clinic Journal of Medicine, 2005, 72, 109-110. | 0.6 | 13 |
| 1392 | Evaluation of methods for <i>H. pylori</i> detection in PPI consumption using culture, rapid urease test and smear examination. Annals of Translational Medicine, 2015, 3, 11. | 0.7 | 16 |
| 1393 | Two-week triple therapy has a higher <i>Helicobacter pylori</i> eradication rate than 1-week therapy: A single-center randomized study. Saudi Journal of Gastroenterology, 2015, 21, 355. | 0.5 | 7 |
| 1394 | Prevalence of <i>Helicobacter pylori</i> infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in Kerala, India. Annals of Medical and Health Sciences Research, 2013, 3, 559. | 0.8 | 39 |
| 1395 | N-acetyl cysteine as an adjunct to standard anti- <i>Helicobacter pylori</i> eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial. Advanced Biomedical Research, 2014, 3, 189. | 0.2 | 6 |
| 1396 | A comparison between standard triple therapy and sequential therapy on eradication of <i>Helicobacter pylori</i> in uremic patients: A randomized clinical trial. Advanced Biomedical Research, 2014, 3, 248. | 0.2 | 4 |
| 1397 | Medical Use of Bismuth: the Two Sides of the Coin. , 2011, s3, . | | 10 |
| 1398 | Which Treatment in <i>Helicobacter pylori</i> Infection?. Clinical & Experimental Pharmacology, 2013, 03, . | 0.3 | 1 |
| 1399 | The <i>Helicobacter pylori</i> Eradication Rate in a High Prevalence Area (West Africa): Three Triple Therapy Comparative Study. Open Journal of Gastroenterology, 2015, 05, 200-206. | 0.1 | 5 |
| 1400 | Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: <i>Helicobacter pylori</i> and beyond. World Journal of Gastrointestinal Oncology, 2010, 2, 181. | 0.8 | 42 |
| 1401 | Gender-associated differences in urea breath test for <i>Helicobacter pylori</i> infection referrals and results among dyspeptic patients. World Journal of Gastrointestinal Pathophysiology, 2012, 3, 80. | 0.5 | 15 |
| 1402 | Capsaicin-sensitive afferentation represents an indifferent defensive pathway from eradication in patients with <i>H. pylori</i> gastritis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2011, 2, 36. | 0.6 | 3 |
| 1403 | Non-bismuth quadruple therapy for first-line <i>Helicobacter pylori</i> eradication: A randomized study in Japan. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 1. | 0.6 | 29 |
| 1404 | <i>Helicobacter pylori</i> : Effect of coexisting diseases and update on treatment regimens. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6, 127. | 0.6 | 6 |
| 1405 | Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with <i>Helicobacter pylori</i> positive non-ulcer dyspepsia. Turkish Journal of Gastroenterology, 2010, 21, 12-16. | 0.4 | 23 |
| 1406 | Sequential therapy for <i>Helicobacter pylori</i> eradication. Turkish Journal of Gastroenterology, 2010, 21, 206-211. | 0.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1407 | Efficacy of probiotics in <i>Helicobacter pylori</i> eradication therapy. Turkish Journal of Gastroenterology, 2010, 21, 212-217. | 0.4 | 33 |
| 1408 | Effectiveness of different treatment regimens in <i>Helicobacter pylori</i> eradication: Ten-year experience of a single institution. Turkish Journal of Gastroenterology, 2010, 21, 218-223. | 0.4 | 6 |
| 1409 | Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for <i>Helicobacter pylori</i> . Turkish Journal of Gastroenterology, 2012, 23, 8-13. | 0.4 | 20 |
| 1410 | A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of <i>Helicobacter pylori</i> in dyspeptic patients. Turkish Journal of Gastroenterology, 2013, 24, 316-321. | 0.4 | 7 |
| 1411 | <i>Helicobacter pylori</i> : its discovery and relevance for medicine. Revista Espanola De Enfermedades Digestivas, 2006, 98, 770-85. | 0.1 | 28 |
| 1414 | The Influence of CYP2C19 Polymorphism on Eradication of <i>Helicobacter pylori</i> : A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut and Liver, 2010, 4, 201-206. | 1.4 | 37 |
| 1415 | Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of <i>H. pylori</i> Eradication in <i>H. pylori</i> -Infected Patients with Functional Dyspepsia. Gut and Liver, 2011, 5, 468-471. | 1.4 | 12 |
| 1416 | Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of <i>Helicobacter pylori</i> . Gut and Liver, 2012, 6, 452-456. | 1.4 | 16 |
| 1417 | Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of <i>Helicobacter pylori</i> Infection in Korea. Gut and Liver, 2013, 7, 406-410. | 1.4 | 25 |
| 1418 | Sequential Therapy for <i>Helicobacter pylori</i> Infection in Korea: Systematic Review and Meta-Analysis. Gut and Liver, 2013, 7, 546-551. | 1.4 | 37 |
| 1419 | Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for <i>Helicobacter pylori</i> Infection. Gut and Liver, 2015, 9, 478. | 1.4 | 18 |
| 1420 | Management of Antibiotic-Resistant <i>Helicobacter pylori</i> Infection: Perspectives from Vietnam. Gut and Liver, 2019, 13, 483-497. | 1.4 | 31 |
| 1421 | Korean Red Ginseng: Qualitative and Quantitative Benefits on <i>Helicobacter pylori</i> Infection. Journal of Ginseng Research, 2010, 34, 77-88. | 3.0 | 4 |
| 1422 | Efficacy of Korean Red Ginseng Supplementation on Eradication Rate and Gastric Volatile Sulfur Compound Levels after <i>Helicobacter pylori</i> Eradication Therapy. Journal of Ginseng Research, 2010, 34, 122-131. | 3.0 | 13 |
| 1423 | Comparison of standard and standard plus vitamin E therapy for <i>Helicobacter pylori</i> eradications in children. Turkish Journal of Gastroenterology, 2015, 25, 99-103. | 0.4 | 4 |
| 1424 | Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for <i>Helicobacter pylori</i> infection. Turkish Journal of Gastroenterology, 2015, 26, 456-460. | 0.4 | 17 |
| 1425 | Does <i>Helicobacter pylori</i> infection influence the major postoperative complication rate after sleeve gastrectomy? A retrospective cohort study in an endemic region. Turkish Journal of Gastroenterology, 2018, 29, 379-383. | 0.4 | 9 |
| 1426 | Standard triple therapy in <i>Helicobacter pylori</i> eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turkish Journal of Gastroenterology, 2019, 30, 420-435. | 0.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1427 | Advances in gastric cancer prevention. World Journal of Clinical Oncology, 2012, 3, 128. | 0.9 | 18 |
| 1428 | Helicobacter pylori vs immune system or antibiotics. World Journal of Immunology, 2015, 5, 142. | 0.5 | 2 |
| 1429 | The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2013, 67, 348. | 0.4 | 8 |
| 1430 | Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. African Health Sciences, 2007, 7, 143-7. | 0.3 | 35 |
| 1431 | Resistance Rate and Minimum Inhibitory Concentration of Metronidazole Among Helicobacter pylori Strains in Tehran, Iran. Archives of Clinical Infectious Diseases, 2016, 11, . | 0.1 | 7 |
| 1432 | The Association Between Helicobacter pylori Infection and Rosacea. Archives of Clinical Infectious Diseases, 2018, 13, . | 0.1 | 2 |
| 1433 | Eradication of Helicobacter pylori in Children by Triple Therapy Regimens of Amoxicillin, Omeprazole, and Clarithromycin or Azithromycin. Iranian Journal of Pediatrics, 2015, 25, e2360. | 0.1 | 7 |
| 1434 | Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection. Clinical Endoscopy, 2011, 44, 33. | 0.6 | 5 |
| 1435 | Real-Time PCR Detection of 16S rRNA Novel Mutations Associated with Helicobacter pylori Tetracycline Resistance in Iran. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8883-8886. | 0.5 | 24 |
| 1436 | Reliability of Stool Antigen Tests: Investigation of the Diagnostic Value of a New Immunochromatographic Helicobacter pylori Approach in Dyspeptic Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 657-660. | 0.5 | 15 |
| 1437 | Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. Asian Pacific Journal of Cancer Prevention, 2016, 17, 285-287. | 0.5 | 6 |
| 1438 | Sequential Therapy of Helicobacter pylori Infection. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2011, 11, 103. | 0.1 | 2 |
| 1439 | Future of Helicobacter pylori Eradication-New Trials. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2012, 12, 232. | 0.1 | 2 |
| 1440 | Endoscopic Findings in Patients With Uninvestigated Dyspepsia: A Retrospective Study From Qatar. Cureus, 2020, 12, e11166. | 0.2 | 2 |
| 1441 | A Retrospective Study to Assess the Effect of Proton Pump Inhibitors on Renal Profile in a South Indian Hospital. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, FC09-FC12. | 0.8 | 2 |
| 1442 | Superiority of non-capsulated 14C-urea breath test over capsule based method for detection of Helicobacter pylori infection – a preliminary report. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2012, 33, 123-128. | 0.0 | 3 |
| 1443 | Helicobacter pylori and recurrent abdominal pain in children: Is there any relation?. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2012, 33, 55-61. | 0.0 | 17 |
| 1445 | The Seroprevalence and Eradication Success of Helicobacter pylori in Indigenous People of Seletar in Southern Malaysia. British Journal of Medicine and Medical Research, 2014, 4, 1854-1863. | 0.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1446 | Helicobacter pylori infection a risk for upper gastrointestinal diseases among patients in North Central Nigeria. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2021, 30, 607. | 0.0 | 0 |
| 1447 | Long-Term Clinical Outcomes of Gastric MALT Lymphoma: A Nationwide Multicenter Study in Korea. Frontiers in Oncology, 2021, 11, 681689. | 1.3 | 6 |
| 1448 | V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterologÿ Hepatologÿ (English Edition), 2021, , . | 0.0 | 0 |
| 1450 | Helicobacter pylori Seromarkers in a University Students Population in Central Nigeria. , 0, , . | | 0 |
| 1451 | Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterology, 2021, 21, 388. | 0.8 | 35 |
| 1452 | Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Review of Anti-Infective Therapy, 2022, 20, 407-424. | 2.0 | 11 |
| 1453 | The Serological Gastric Biopsy: A Non-endoscopical/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients. American Journal of Immunology, 2006, 2, 88-96. | 0.1 | 2 |
| 1454 | Helicobacter Pylori en ferriprive anemie bij premenopauzale vrouwen. Tijdschrift Voor Geneeskunde, 2007, 63, 1228-1235. | 0.0 | 0 |
| 1455 | Ethical Considerations of Comparing Sequential and Traditional Anti-Helicobacter pylori Therapy. Annals of Internal Medicine, 2007, 147, 435. | 2.0 | 0 |
| 1456 | ÿ-sophagus und Magen. , 2008, , 411-428. | | 0 |
| 1457 | Magen-Darm-Mittel und Laxantien. , 2008, , 661-690. | | 0 |
| 1458 | Eradication of Helicobacter pylori Infection in Outpatient Care. Hungarian Medical Journal, 2008, 2, 161-172. | 0.0 | 0 |
| 1459 | Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First- and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen. American Journal of Gastroenterology, 2008, , . | 0.2 | 0 |
| 1460 | Role of Probiotics in the Management of Helicobacter pylori Infection. , 2009, , 231-240. | | 0 |
| 1461 | How to prevent gastric cancer in East and West. , 2009, , 51-62. | | 0 |
| 1462 | Erkrankungen des Gastrointestinalsystems. , 2009, , 841-1057. | | 0 |
| 1463 | ACID REFLUX AND ULCER DISEASE. , 2009, , 457-473. | | 0 |
| 1464 | Future Prospects for Helicobacter pylori Vaccination. , 2009, , 601-620. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1465 | Epidemiology of Gastric Cancer and Helicobacter pylori. , 2009, , 25-57. | | 0 |
| 1469 | Gastritis, peptic ulceration and related conditions. , 2010, , 366-372. | | 0 |
| 1470 | Magen-Darm-Mittel und Laxantien. , 2010, , 681-709. | | 0 |
| 1473 | Erkrankungen der Leber. , 2010, , 416-449. | | 0 |
| 1474 | Treatment of Helicobacter pylori. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2011, 11, 21. | 0.1 | 0 |
| 1475 | Dyspepsia in the Elderly. , 2011, , 239-252. | | 0 |
| 1476 | Therapeutic Approach in Functional (Nonulcer) Dyspepsia. , 2011, , 143-151. | | 0 |
| 1477 | Quality of Life Issues. , 2011, , 161-173. | | 1 |
| 1478 | Organic Upper Digestive Diseases in Children with Chronic Abdominal Pain. Korean Journal of Pediatric Gastroenterology and Nutrition, 2011, 14, 232. | 0.2 | 0 |
| 1479 | Treatment and Prognosis of Gastric MALT Lymphoma. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2011, 11, 165. | 0.1 | 1 |
| 1480 | Erkrankungen von Mund, Speiseröhre und Magen. , 2011, , 273-357. | | 0 |
| 1484 | Helicobacter. , 2011, , 1141-1151. | | 0 |
| 1485 | How to Discover a New World Without Being in Danger of Wreck. , 0, , . | | 0 |
| 1486 | NSAIDs and Peptic Ulcer Disease. , 0, , . | | 2 |
| 1487 | Helicobacter pylori Infection in Elderly Patients. , 0, , . | | 4 |
| 1489 | Oesophago-Gastric Cancer. , 2012, , 221-244. | | 9 |
| 1490 | Successful isolation of Helicobacter pylori after prolonged incubation: A case report of prolonged incubation for H. pylori. Archives of Biological Sciences, 2012, 64, 1297-1299. | 0.2 | 0 |
| 1491 | Acute Gastrointestinal Hemorrhage. , 2012, , 1160-1181. | | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1492 | Indications for Helicobacter pylori Eradication Therapy. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2012, 12, 213. | 0.1 | 1 |
| 1493 | Gastric, Pancreatic, and Intestinal Function. , 2012, , 1695-1732. | | 1 |
| 1494 | Magen-Darm-Mittel und Laxantien. , 2012, , 713-743. | | 0 |
| 1495 | Helicobacter pylori Infection and Undiagnosed Dyspepsia in Dyspeptic Populations Under 45 of Age Tested by ELISA, Urease Breath Test and Helicotest. , 0, , . | | 0 |
| 1497 | Serological Diagnosis of Certain Human, Animal and Plant Diseases. , 2012, , . | | 2 |
| 1498 | Chronic NSAIDs Therapy and Upper Gastrointestinal Tract " Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management. , 0, , . | | 0 |
| 1500 | Efficiency of Helicobacter pylori Infection Treatment Protocol: Clarithromycin, Amoxicillin and Omeprazole. Archives of Clinical Infectious Diseases, 2012, 8, 14-7. | 0.1 | 4 |
| 1501 | Molecular Mechanisms and Pathology of Gastric Carcinogenesis: Sporadic Cancers. Molecular Pathology Library, 2013, , 67-81. | 0.1 | 0 |
| 1502 | Gastrointestinal Lymphomas. , 2013, , 1035-1045. | | 0 |
| 1503 | MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma). , 2013, , 111-126. | | 0 |
| 1505 | Gastrointestinal Disease. , 2013, , 169-184. | | 0 |
| 1506 | The Patients'™ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 462-6. | 0.8 | 11 |
| 1507 | The frequency of "Helicobacter pylori" in patients diagnosed with peptic ulcer and gastritis. The Journal of Kartal Training and Research Hospital, 2013, 24, 87-92. | 0.0 | 2 |
| 1508 | Hydroxamic Acids as Inhibitors of Urease in the Treatment of Helicobacter pylori Infections. , 2013, , 241-253. | | 0 |
| 1509 | Clinical features and prognosis in patients examined in medical and social expertise bureaus due to peptic ulcer disease. Kazan Medical Journal, 2013, 94, 124-127. | 0.1 | 1 |
| 1510 | Esomeprazole-based sequential therapy and probiotic for Helicobacter pylori eradication. Scripta Scientifica Medica, 2014, 45, 61. | 0.1 | 0 |
| 1511 | Effects of Xiang Sha Yang Wei Wan on Ethanol-Induced Gastric Ulcer in Sprague Dawley Rats: a Histological Study. IIUM Medical Journal Malaysia, 2013, 12, . | 0.1 | 0 |
| 1512 | Suppression of Helicobacter Pylori in Mice Intestine by Ingestion of Lactic Acid Bacteria in Yoghurt. IOSR Journal of Dental and Medical Sciences, 2014, 13, 09-12. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1513 | Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12. | | 1 |
| 1514 | Sequential Therapy vs Quadruple Therapy for Helicobacter pylori Eradication in South West of Iran. Euroasian Journal of Hepato-gastroenterology, 2014, 4, 63-66. | 0.1 | 4 |
| 1515 | Helicobacter Pylori in the Pathogenesis of Gastric Cancer. , 2014, , 1-5. | | 0 |
| 1516 | The Study of Association between Helicobacter pylori (H. pylori) and Chronic Obstructive Pulmonary Disease (COPD). Journal of Pulmonary & Respiratory Medicine, 2014, 04, . | 0.1 | 0 |
| 1517 | Magen-Darm-Mittel und Lebertherapeutika. , 2014, , 747-780. | | 0 |
| 1518 | Evaluation of the Equivalence in Dissolution Profiles of Brands of Metronidazole Tablet in Nigeria. IOSR Journal of Pharmacy and Biological Sciences, 2014, 9, 41-44. | 0.1 | 3 |
| 1519 | Efficacy of Bismuth-Containing Quadruple Therapy as First-line Treatment for Helicobacter pylori Infection. Euroasian Journal of Hepato-gastroenterology, 2012, 2, 90-93. | 0.1 | 1 |
| 1520 | Surgical treatment of peptic ulcer disease: current indications and techniques. Research, 0, 1, . | 0.0 | 0 |
| 1521 | Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, 1, . | 0.0 | 0 |
| 1522 | The Presence of H. Pylori in Cases of Chronic Idiopathic Urticaria. World Family Medicine Journal/Middle East Journal of Family Medicine, 2014, 12, 21-28. | 0.1 | 0 |
| 1523 | Analgetika. , 2015, , 417-651. | | 0 |
| 1524 | The iron deficiency and helicobacter pylori infection in children. Siberian Medical Review, 2015, , 24-29. | 0.1 | 0 |
| 1525 | Chapter 25. Gastrointestinal Diseases. , 2015, , . | | 0 |
| 1526 | Ulcus-ventriculi- und Uicus-duodeni-Krankheit. , 2015, , 1-10. | | 0 |
| 1527 | Triple and Quadruple Eradication Therapy for H. pylori in Iraqi Patients with Peptic Ulcer Disease a Comparative Study. British Journal of Medicine and Medical Research, 2015, 7, 231-240. | 0.2 | 2 |
| 1528 | Gastroduodenal Changes Two Years After Eradication of Helicobacter pylori in a Population-Based Cohort. Gastroenterology Research, 2015, 8, 171-177. | 0.4 | 0 |
| 1529 | Upper Gastrointestinal System Bleeding in Children: The Role of Helicobacter Pylori Infection and Non-Steroid Anti-Inflammatory Drug Use. West Indian Medical Journal, 2015, 64, 113-6. | 0.4 | 6 |
| 1530 | The Genus Helicobacter. , 2015, , 709-738. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1532 | Magen-Darm-Mittel und Lebertherapeutika. , 2016, , 531-552. | | 0 |
| 1533 | Blutmanagement in der Orthopädie und Unfallchirurgie. , 2016, , 157-172. | | 1 |
| 1534 | Rapid Urease Test and Faecal Antigen Detection for Rapid Diagnosis of <i>Helicobacter pylori</i>; Infection in Dyspepsia. Open Journal of Gastroenterology, 2016, 06, 5-10. | 0.1 | 0 |
| 1535 | Treatment Guidelines. , 2016, , 487-493. | | 1 |
| 1536 | Addition of Rifaximin and N-Acetyl Cysteine to the Standard Helicobacter pylori Treatment Regimens: Is it Possible to Improve Outcomes?. Journal of Gastric Disorders and Therapy, 2016, 2, . | 0.1 | 0 |
| 1537 | Caveats in Diagnosis of Helicobacter Pylori Infection can be Avoided by a Panel of Serum Biomarkers (GastroPanel®). Journal of Carcinogenesis & Mutagenesis, 2016, 07, . | 0.3 | 2 |
| 1538 | Quadruple Regimens for Helicobacter pylori Infection. , 2016, , 237-252. | | 0 |
| 1539 | Dispepsi ÅžikÃcyeti ile BaÅyvuran Hastalarda Helikobakter Pilon PozitifliÅyi AÅsÃ±sÃ±ndan C-14 Åœere Nefes Testi ile Endoskopinin KarÅyÃ±laÅytÃ±rÃ±lmasÃ±. Family Practice and Palliative Care, 2016, 1, 9-9. | 0.2 | 1 |
| 1540 | The influence of Helicobacter pylori eradication therapy on the presence of H. pylori antigens in dental plaque and saliva. Progress in Health Sciences, 2016, 6, 19-24. | 0.1 | 0 |
| 1541 | Les Perforations Dâ€™ulcère Gastro-Duodenal Au Centre National Hospitalier Et Universitaire (Cnhu) De Cotonou (Benin). European Scientific Journal, 2016, 12, 117. | 0.0 | 1 |
| 1542 | Helicobacter Pylori in the Pathogenesis of Gastric Cancer. , 2017, , 2004-2008. | | 0 |
| 1543 | Diagnostic Criteria in Peptic Ulcer Disease. , 2017, , 27-38. | | 0 |
| 1544 | Endoscopia preoperatoria en cirurgia bariÃtrica: Es realmente necesaria.. Ars Medica, 2017, 42, . | 0.1 | 0 |
| 1545 | Global Challenges in the Treatment of Gastroenterology and Hepatology Diseases. Advanced Research in Gastroenterology & Hepatology, 2017, 5, . | 0.1 | 0 |
| 1546 | Isolated gastric sarcoidosis: a rare entity. BMJ Case Reports, 2017, 2017, bcr-2017-219682. | 0.2 | 2 |
| 1547 | Analgetika. , 2018, , 447-696. | | 0 |
| 1548 | Endoscopists and Surgeons Playing in the Same Team: The Multidisciplinary Approach in Screening and Preoperative Workup. , 2018, , 221-260. | | 0 |
| 1549 | Magen-Darm-Mittel und Lebertherapeutika. , 2018, , 587-609. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1550 | Prevalence of Helicobacter pylori infection in upper gastrointestinal tract disorders (dyspepsia) patients visiting outpatient department of a hospital of North India. Journal of Family Medicine and Primary Care, 2018, 7, 577. | 0.3 | 9 |
| 1551 | COMPARISON OF 14C-UREA BREATH TEST WITH GASTRIC HISTOLOGY FOR DIAGNOSIS OF HELICOBACTER PYLORI INFECTION AMONG PATIENTS WITH PEPTIC ULCER DISEASE. Journal of Sulaimani Medical College, 2018, 8, 1-8. | 0.0 | 0 |
| 1552 | Retrospective Examination of the Results of Gastroscopy in Bandirma State Hospital in Terms of Helicobacter Pylori and Sydney Classification. Clinical and Experimental Health Sciences, 0, , . | 0.1 | 0 |
| 1553 | A Two-Week Nitazoxanide-Based Quadruple Treatment as a Rescue Therapy for Helicobacter Pylori Eradication. The Egyptian Journal of Hospital Medicine, 2018, 72, 4509-4514. | 0.0 | 1 |
| 1555 | Magen-Darm-Mittel und Lebertherapeutika. , 2019, , 761-788. | | 0 |
| 1556 | Comparative Study between Two Triple-therapy Regimens in Treating Helicobacter pylori: Related Peptic Ulcer Disease. SBV Journal of Basic Clinical and Applied Health Science, 2019, 2, 108-111. | 0.2 | 0 |
| 1557 | Duodenal darlÄ±k Helicobacter pylori eradikasyonu ile gerileyebilir mi?. Akademik Gastroenteroloji Dergisi, 0, , . | 0.0 | 0 |
| 1559 | PÄ±rupura trombocitopÄ±nica idiopÄ±tica en adultos: experiencia en un hospital de tercer nivel, La Paz, Bolivia. Ciencia Medica, 2019, 22, 7-14. | 0.0 | 1 |
| 1560 | The incidence of infection, diagnosis and treatment of H. pylori in developing countries on the example of Kenya. Journal of Education, Health and Sport, 2020, 10, 11. | 0.0 | 0 |
| 1561 | Helicobacter pylori incidence of patients with gastritis in endoscopic biopsies. Journal of Surgery and Medicine, 0, , . | 0.0 | 1 |
| 1562 | Birinci Basamakta Dispepsi Ä±zikayeti Olan EriÄ±kin Hastaya Klinik YaklaÄ±m. Sakarya Medical Journal, 0, , . | 0.1 | 0 |
| 1563 | Prevalence of Helicobacter pylori in Vinnytsia region and the effectiveness of the eradication schemes according to 13C-urease breath tests (2006â€”2019). Modern Gastroenterology, 2020, . | 0.1 | 0 |
| 1564 | Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects. Translational and Clinical Pharmacology, 2020, 28, 136. | 0.3 | 4 |
| 1565 | ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3. | | 0 |
| 1566 | Helicobacter pylori and gastric cancer. Hospital Pharmacology, 2020, 7, 954-965. | 0.1 | 1 |
| 1567 | Magen-Darm-Mittel und Lebertherapeutika. , 2020, , 615-642. | | 0 |
| 1568 | Formulation and evaluation of lansoprazole sublingual tablet. Journal of Research in Pharmacy, 2020, 24, 264-276. | 0.1 | 0 |
| 1569 | Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and Helicobacter pylori Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel [®] Test. Anticancer Research, 2021, 41, 5527-5537. | 0.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1570 | Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 23-35. | 1.1 | 22 |
| 1571 | Comparison of Immunohistochemistry and Conventional Stains for Helicobacter Pylori Detection in Gastric Biopsies of Patients Receiving Proton Pump Inhibitors. <i>Journal of Health Science and Medical Research</i> , 0, , . | 0.4 | 4 |
| 1572 | Helicobacter pylori infection: diagnosis, treatment and risks of untreated infection. , 2008, , 33-40. | | 0 |
| 1573 | Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2020, 20, 218-224. | 0.1 | 1 |
| 1574 | Does hyperhomocysteinaemia contribute to gastric carcinogenesis in Helicobacter pylori infected patients?. <i>Gut</i> , 2007, 56, 1480; author reply 1480-1. | 6.1 | 0 |
| 1577 | Prevalence of Helicobacter pylori among Nigerian patients with dyspepsia in Ibadan. <i>Pan African Medical Journal</i> , 2010, 6, 18. | 0.3 | 25 |
| 1579 | Sequential therapy boosts H pylori eradication rates. <i>Journal of Family Practice</i> , 2008, 57, 651-4. | 0.2 | 1 |
| 1580 | Is quadruple therapy the new triple therapy for H pylori?. <i>Canadian Family Physician</i> , 2012, 58, 58. | 0.1 | 2 |
| 1581 | Helicobacter pylori infection in India from a western perspective. <i>Indian Journal of Medical Research</i> , 2012, 136, 549-62. | 0.4 | 23 |
| 1582 | Prevalence of helicobacter pylori infection in children, a population-based cross-sectional study in west iran. <i>Iranian Journal of Pediatrics</i> , 2013, 23, 13-8. | 0.1 | 36 |
| 1583 | Current Consensus and Remaining Questions Regarding the Diagnosis and Treatment of Helicobacter pylori Infection. <i>Gastroenterology and Hepatology</i> , 2012, 8, 623-5. | 0.2 | 4 |
| 1584 | Helicobacter pylori Infection: Options for Testing and Treatment. <i>Gastroenterology and Hepatology</i> , 2012, 8, 621-3. | 0.2 | 1 |
| 1585 | Functional dyspepsia today. <i>MÃ dica</i> , 2013, 8, 68-74. | 0.4 | 8 |
| 1586 | Low Prevalence of Helicobacter pylori infection evaluated by stool antigen test in preschool and school children. <i>Brazilian Journal of Microbiology</i> , 2008, 39, 664-7. | 0.8 | 1 |
| 1587 | The role of infection in functional dyspepsia. <i>Annals of Gastroenterology</i> , 2012, 25, 176-177. | 0.4 | 2 |
| 1588 | Eradication Rate of Helicobacter pylori using a Two-week Quadruple Therapy: A Report from Southern Iran. <i>Middle East Journal of Digestive Diseases</i> , 2013, 5, 81-5. | 0.2 | 7 |
| 1589 | The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trial. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, S99-S104. | 0.6 | 23 |
| 1590 | Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. <i>Revista Espanola De Quimioterapia</i> , 2011, 24, 32-6. | 0.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1609 | Current development of <i>Helicobacter pylori</i>; eradication protocols. Russian Journal of Infection and Immunity, 2022, 11, 1037-1049. | 0.2 | 2 |
| 1610 | Zinc carnosine-based modified bismuth quadruple therapy <i>vs</i> standard triple therapy for <i>Helicobacter pylori</i> eradication: A randomized controlled study. World Journal of Clinical Cases, 2022, 10, 227-235. | 0.3 | 8 |
| 1611 | Helicobacter pylori eradication in renal transplant candidates. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022, , . | 0.4 | 0 |
| 1612 | Helicobacter pylori and gastric cancer: a lysosomal protease perspective. Gastric Cancer, 2022, 25, 306-324. | 2.7 | 5 |
| 1613 | Analgetika. , 2022, , 511-774. | | 0 |
| 1614 | Helicobacter pylori culture: from bench to bedside. Annals of Gastroenterology, 2022, , . | 0.4 | 2 |
| 1615 | Standard Triple Therapy as a Remedy for Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Current Reviews in Clinical and Experimental Pharmacology, 2022, 17, . | 0.4 | 0 |
| 1616 | Gastric metastasis from small bowel adenocarcinoma in a Lynch syndrome patient. Clinical Journal of Gastroenterology, 2022, , 1. | 0.4 | 0 |
| 1617 | Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (United States), 2021, 100, e28323. | 0.4 | 5 |
| 1618 | A Link Between Platelet-to-Lymphocyte Ratio and <i>Helicobacter pylori</i> Infection. Journal of Interdisciplinary Medicine, 2021, 6, 182-184. | 0.1 | 0 |
| 1619 | Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population. Journal of Applied Microbiology, 2022, 132, 2694-2704. | 1.4 | 1 |
| 1620 | Age of eradication and failure rates of clarithromycin-containing triple therapy for <i>Helicobacter pylori</i>: A 15-year population-based study. Helicobacter, 2022, 27, e12893. | 1.6 | 6 |
| 1621 | Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS ONE, 2022, 17, e0265322. | 1.1 | 8 |
| 1628 | Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2022, 117, 1221-1230. | 0.2 | 49 |
| 1629 | Helicobacter pylori Enfeksiyonu Tanımasında Gaitada Antijen Arama Test Sonuçlarının Değerlendirilmesi. , 0, , 246-249. | | 0 |
| 1630 | CLINICAL MORPHOLOGICAL FEATURES OF UPPER DIGESTIVE TRACT SEGMENTS IN CHILDREN OF GOMEL REGION. Problemy Zdorov'ia i Ākologii, 2013, , 88-92. | 0.0 | 0 |
| 1631 | ĐıĐ¼Đ²ÑĐµĐ¼ĐµĐ½Đ½ÑĐµ ĐıĐ¼ĐÑ...Đ¼ĐÑĐ Đº ĐıÑĐ¼Ñ,Đ,Đ»ĐºÑ,Đ,ĐºĐµ Đ, Đ»ĐµÑ±ĐµĐ½Đ,Ñž ĐºĐºĐºÑ,ÑĐ | | |
| 1632 | Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010-2019. Antibiotics, 2022, 11, 698. | 1.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1633 | The Challenges of Eradicating Pediatric <i>Helicobacter pylori</i> Infection in the Era of Probiotics. <i>Children</i> , 2022, 9, 795. | 0.6 | 7 |
| 1634 | Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives. <i>Cancers</i> , 2022, 14, 3019. | 1.7 | 7 |
| 1635 | Are pro- and/or synbiotics beneficial in <i>Helicobacter pylori</i> eradication therapy in children? A narrative review. <i>European Journal of Pediatrics</i> , 0, , . | 1.3 | 6 |
| 1636 | Phytochemical Investigation of <i>Cordia africana</i> Lam. Stem Bark: Molecular Simulation Approach. <i>Molecules</i> , 2022, 27, 4039. | 1.7 | 2 |
| 1637 | SYNERGETIC BIO-PSYCHO-SOCIO-SPIRITUAL CONCEPTION OF PEPTIC ULCER SOCIAL EPIDEMIC. <i>Ekologiya Cheloveka (Human Ecology)</i> , 2015, 22, 43-51. | 0.2 | 0 |
| 1638 | Electrodeposition of bismuth at a graphene modified carbon electrode and its application as an easily regenerated sensor for the electrochemical determination of the antimicrobial drug metronidazole. <i>Talanta</i> , 2023, 251, 123758. | 2.9 | 9 |
| 1639 | <i>Helicobacter pylori</i> and unignorable extragastric diseases: Mechanism and implications. <i>Frontiers in Microbiology</i> , 0, 13, . | 1.5 | 14 |
| 1640 | COMPARISON OF MOLECULAR-GENETIC TECHNIQUES, HISTOLOGICAL AND IMMUNOHISTOCHEMICAL METHODS OF ANALYSIS FOR CONTROL OF ERADICATION OF <i>HELICOBACTER PYLORI</i> -INFECTION. <i>Problemy Zdorov'Ā i Ākologii</i> , 2010, , 29-33. | 0.0 | 0 |
| 1641 | Analytical Approaches for Disease Detection. , 2022, , 284-322. | | 1 |
| 1642 | Development of Probiotics for <i>Helicobacter pylori</i> Infection Management. , 2022, , 499-523. | | 0 |
| 1643 | Specific Diagnoses and Management Principles of the Upper Digestive Canal. , 2022, , 51-105. | | 0 |
| 1644 | Jinghua Weikang capsule for <i>helicobacter pylori</i> eradication: A systematic review and meta-analysis with trial sequential analysis. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 1 |
| 1645 | Probiotics for Otolaryngologic Disorders. <i>Otolaryngologic Clinics of North America</i> , 2022, 55, 939-946. | 0.5 | 2 |
| 1646 | Mucoadhesive carriers for oral drug delivery. <i>Journal of Controlled Release</i> , 2022, 351, 504-559. | 4.8 | 36 |
| 1647 | Alpha-Glutamyl-Tryptophan in the Treatment of Chronic Atrophic Gastritis, Associated with <i>Helicobacter pylori</i> . , 0, , . | | 0 |
| 1648 | Efficacy of <i>Helicobacter pylori</i> Eradication Based on Rabeprazoleâ€Bismuthâ€Tetracyclineâ€Tinidazole Regimen in Vietnamese Patients with Duodenal Ulcers. <i>Gastroenterology Insights</i> , 2022, 13, 365-376. | 0.7 | 2 |
| 1649 | Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. <i>Gastroenterology</i> , 2023, 164, 61-71. | 0.6 | 32 |
| 1650 | Chemical and pharmacological difference between honey-fried licorice and fried licorice. <i>Journal of Ethnopharmacology</i> , 2023, 302, 115841. | 2.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1651 | Letter to the editor:<i>Helicobacter pylori</i> eradication “ the proof is not in the symptoms. Gut, 2023, 72, 2387-2388. | 6.1 | 5 |
| 1653 | Tratamento Das Infecções Por Helicobacter Pylori: Revisão De Ensaio Clínicos. , 2022, 1, e021. | | 0 |
| 1654 | Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Frontiers in Cellular and Infection Microbiology, 0, 12, . | 1.8 | 18 |
| 1655 | Antibiotic Resistance of Helicobacter pylori in Patients with Peptic Ulcer. Medicina (Lithuania), 2023, 59, 6. | 0.8 | 2 |
| 1656 | Vitamin D3 eradicates Helicobacter pylori by inducing VDR-CAMP signaling. Frontiers in Microbiology, 0, 13, . | 1.5 | 6 |
| 1657 | The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter pylori Eradication: A Randomized, Double-Blind Clinical Trial. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-7. | 0.5 | 1 |
| 1658 | Effect of H. pylori eradication on gastric preneoplastic lesions and gastritis progression. , 2022, 1, 89-94. | | 0 |
| 1659 | Microbiota in the stomach and application of probiotics to gastroduodenal diseases. World Journal of Gastroenterology, 0, 28, 6702-6715. | 1.4 | 9 |
| 1660 | Dolor abdominal agudo: Enfoque para el médico de atención primaria. Medunab, 2012, 15, 113-122. | 0.0 | 1 |
| 1661 | Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics, 2023, 12, 191. | 1.5 | 20 |
| 1663 | Magen/Darm- und Lebererkrankungen. , 2022, , 303-328. | | 0 |
| 1664 | Current Worldwide Trends in Pediatric Helicobacter pylori Antimicrobial Resistance. Children, 2023, 10, 403. | 0.6 | 2 |
| 1665 | Diets. , 2023, , 291-306. | | 1 |
| 1666 | Application of biomaterials in the eradication of Helicobacter pylori: A bibliometric analysis and overview. Frontiers in Microbiology, 0, 14, . | 1.5 | 2 |
| 1667 | Synthesis and Pharmacological Evaluation of the derivatives of 1,4-dihydropyridine: A Pleiotropic Molecule with Antiulcer activity. Research Journal of Pharmacy and Technology, 2023, , 561-565. | 0.2 | 0 |
| 1668 | Gastric mucosal swab as an alternative to biopsy for <i>Helicobacter pylori</i> detection. Helicobacter, 2023, 28, . | 1.6 | 0 |
| 1669 | Helicobacter pylori eradication and aspirin: a puzzle yet to be solved “ Author's reply. Lancet, The, 2023, 401, 1266. | 6.3 | 0 |
| 1670 | Helicobacter pylori infection. Nature Reviews Disease Primers, 2023, 9, . | 18.1 | 93 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1679 | The possible role of Helicobacter pylori in liver diseases. Archives of Microbiology, 2023, 205, . | 1.0 | 2 |
| 1680 | Bioinformatics Approaches for Structural and Functional Annotation of an Uncharacterized Protein of Helicobacter pylori. , 0, , . | | 0 |
| 1694 | Extranodales Marginalzonenlymphom des mukosaassoziierten lymphatischen Gewebes (MALT-Lymphom). , 2023, , 103-128. | | 0 |
| 1697 | Can Antibiotics Cure Autoimmune Diseases?. , 2024, , 407-430. | | 0 |
| 1702 | Magen/Darm- und Lebererkrankungen. , 2023, , 329-358. | | 0 |